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ABSTRACT 
Anti-apoptotic BCL-XL is frequently overexpressed in non-small cell lung cancer, 
leading to inhibition of apoptosis and poor prognosis. MicroRNAs play a role in 
regulating apoptosis and cell survival during tumourigenesis, with cancer cells showing 
perturbed expression of miRNAs. The aim of this study was to determine the biological 
effects of miRNA dysregulation on non-small cell lung cancer, and the molecular 
mechanisms by which apoptosis is regulated. Overexpression and knockdown studies 
were performed via transfection of miRNA mimics and inhibitors and cell death was 
detected using the annexin V-FITC detection kit and caspase 3/7 activity assay. Cell 
cycle analysis was also performed to determine the role candidate miRNAs play in cell 
growth. Results indicated that overexpression of miR-608 and down-regulation of miR-
361-5p induced cell death in A549 and SK-LU-1 cells. Gene target prediction analysis 
implicated various signaling pathways as targets of BCL-XL induced miRNA 
alterations. Luciferase reporter assay identified AKT2 and SMAD2 as direct targets of 
miR-608 and miR-361-5p, respectively, and suppression of its protein levels were 
validated using Western blot. To elucidate the role and importance of these miRNAs in 
vivo, labeled tumour cells were injected into the yolk sac of zebrafish embryos and 
immunostained using monoclonal antibodies to detect the cleaved, active form of 
caspase 3. In conclusion, BCL-XL silencing in A549 and SK-LU-1 cells leads to the 
occurrence of apoptosis through the dysregulation of miR-608 and miR-361-5p, thus 
providing a platform for anti-sense gene therapy whereby miRNA expression can be 
exploited to increase the apoptotic properties in lung adenocarcinoma cells. 
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ABSTRAK 
BCL-XL merupakan protein anti-apoptotik yang kerap dijumpai dalam kanser paru-
paru yang menyebabkan perencatan apoptosis serta prognosis yang kurang baik. 
MicroRNAs (miRNAs) memainkan peranan dalam mengawal selia apoptosis dan 
kehidupan sel semasa tumorigenesis, dimana sel-sel kanser menunjukkan ungkapan 
miRNA terganggu. Tujuan kajian ini adalah untuk menentukan perubahan dalam 
ungkapan miRNA dalam sel-sel paru-paru adenokarsinoma, dan menentukan 
mekanisme molekul yang meregulasikan apoptosis. Kajian peningkatan dan perencatan 
ekspresi miRNA dilaksanakan melalui transfeksi miRNA mimik dan perencat, dan 
kematian sel dibuktikan menggunakan kit pengesanan annexin V-FITC dan cerakin 
aktiviti “caspase” 3/7. Analisis kitaran sel juga dilakukan untuk menentu peranan yang 
dimainkan oleh calon miRNA ini dalam dalam pertumbuhan sel. Keputusan 
menunjukkan bahawa peningkatan miR-608 dan perencatan miR-361-5p menyebabkan 
kematian sel-sel A549 dan SK-LU-1. Analisis ramalan sasaran gen membabitkan 
pelbagai laluan isyarat sebagai sasaran dari penginduksian perubahan miRNA oleh 
BCL-XL. Assay pelapor luciferase menunjukkan bahawa AKT2 dan SMAD2 adalah 
sasaran langsung untuk miR-608 dan miR-361-5p, masing-masing, dimana penindasan 
tahap protin AKT dan SMAD2 disahkan dengan menggunakan pemendapan Western. 
Untuk menjelaskan peranan miRNAs ini in vivo, sel-sel tumor berlabel telah disuntik ke 
dalam kantung kuning telur embrio zebrafish dan telah di “immunostain” menggunakan 
antibodi monoklonal untuk mengesahkan pembentukan “caspase” 3 aktif yang tersisih. 
Kesimpulannya, pelenyapan BCL-XL dalam sel-sel A549 dan SK-LU-1 menyebabkan 
apoptosis melalui perubahan ekspresi miR-608 dan miR-361-5p. Keputusan ini 
menyediakan platform untuk terapi gen “anti-sense” di mana ekspresi miRNA boleh 
dieksploitasi untuk meningkatkan ciri-ciri apoptosis dalam sel-sel paru-paru 
adenokarsinoma. 
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CHAPTER 1: INTRODUCTION 
The most common cancer worldwide, remains to be lung cancer (Ferlay et al., 2013). 
In Malaysia, lung cancer led to the most cancer deaths in the country in 2012, making 
up 19.1% of total cancer deaths, with adenocarcinoma being the most common cell type 
(Ferlay et al., 2012). When possible, the most effective option for treatment of lung 
cancer is surgical resection (Molina et al., 2008). As a majority of lung cancer patients 
are diagnosed at an advanced or metastatic stage of disease, the most favorable form of 
treatment is chemotherapy and/or simultaneous administration of radiation and 
chemotherapy (Pfister et al., 2004). However, even with treatment, the 5-year survival 
rate in lung cancer remains to be very low at only 17.7% (Howlader, 2017a), with late 
stage diagnosis and high incidence of drug resistance being the main contributors to low 
survival rates. 
Apoptosis plays a crucial role in the development and maintenance of multicellular 
organisms through the elimination of cells that are damaged, aged or autoimmune 
(Sorenson, 2004). Cancer cells have the ability to disrupt the balance between pro- and 
anti-apoptotic factors, thereby making evasion of apoptosis an important hallmark of 
tumour progression. The B-cell lymphocyte 2 (BCL-2) family of proteins are the central 
regulators of apoptosis (Daniel & Smythe, 2004). Studies have demonstrated that 
anomalous patterns of BCL-2 expression was found in a wide variety of human cancers 
(Hockenbery et al., 1991). However, studies conducted on non-small cell lung cancer 
(NSCLC), which accounts for the majority of lung cancer cases (Liam et al., 2006), 
have shown that the expression of BCL-2 is either very low or even absent (Daniel & 
Smythe, 2004). Instead, the expression of B-cell lymphocyte xL (BCL-XL), the other 
major prototype of the anti-apoptotic BCL-2 gene, is shown to be overexpressed in 
NSCLC (Soini et al., 1999). BCL-XL over-expression counteracts the pro-apoptotic 
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functions of Bcl-2 associated X protein (BAX) and Bcl-2 associated death promoter 
(BAD) through the inhibition of their translocation from the cytosol to the 
mitochondria. Apoptosis is thereby obstructed through the maintenance of the 
permeability status or stabilization of the outer mitochondrial membrane, which in turn 
prevents the release of cytochrome c and pro-caspase 9 activation (Gottlieb et al., 2000). 
MicroRNAs (miRNAs) are a subset of non-coding RNAs of about 19 to 23 
nucleotides long which regulate gene expression post-transcriptionally via inhibition of 
mRNA translation through the direct binding of particular targets sites in the 3’-
untranslated region (3’UTR), or by stimulation of target mRNA degradation through 
cleavage (Bartel, 2004). Individual miRNAs are able to regulate the expression of 
multiple genes; correspondingly a single target can be modulated my many miRNAs 
(Lewis et al., 2005). These regulatory elements play a role in a wide range of biological 
processes including apoptosis (Mott et al., 2007). A disturbed miRNA function or 
altered miRNA expression has been reported to disorganize cellular processions and 
may eventually contribute to human diseases, including cancer (Calin et al., 2004a). 
MiRNAs have the ability to influence the development of cancer through the 
manipulation of the apoptotic process (Jovanovic & Hengartner, 2006; Lima et al., 
2011). The expression of miRNAs can be either up-regulated or down-regulated, and 
studies have demonstrated that dysregulated miRNAs can act as oncogenes or tumour 
suppressor genes in lung cancers (Volinia et al., 2006; Son, 2009).  
In my Masters project, miRNA microarrays were utilized to determine the expression 
of miRNA dysregulated in response to BCL-XL silencing in A549 cells and to determine 
their involvement in regulation of apoptosis. A total of ten miRNAs were found to be 
significantly differentially expressed when compared between siRNA-transfected and 
non-transfected cells. These miRNAs were found to have putative gene targets in 
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various signal transduction pathways including the PI3K/AKT, WNT, TGF-β and ERK 
pathways. 
The expression of miRNAs has frequently been identified to be dysregulated in 
cancers, however, due to non-specific binding properties of each individual miRNAs, 
their specific functions remain to be unclear. This study is an extension of my Masters 
project, with validation of the expression of the dysregulated miRNAs in a second lung 
adenocarcinoma cell line, SK-LU-1. As the characteristics of A549 and SK-LU-1 cells 
are similar, it is hypothesized that the biological effects, as well as regulation of miRNA 
expression, in response to anti-apoptotic BCL-XL, in these two cell lines, will be 
comparable. As miRNA studies continue to be developed, it is crucial to obtain an in-
depth understanding of miRNA biogenesis and function, as it will certainly affect the 
improvement of miRNA-based therapies. Therefore, further analysis will be performed 
on the candidate miRNAs to determine their biological functions. Animal studies using 
zebrafish embryos will then be performed to determine the in vivo effects of miRNA 
regulation on apoptosis. 
Objectives 
1) To determine the change in expression of miRNAs in lung adenocarcinoma 
cancer cells regulated by the anti-apoptotic protein BCL-XL 
2) To predict and identify the targets of selected candidate miRNAs dysregulated in 
lung adenocarcinoma cells.  
3) To identify experimentally validated miRNA gene targets through 
overexpression or silencing studies on candidate miRNA. 
4) To investigate and determine the effects of miRNA regulation on downstream 
mRNA and protein expression.  
5) To observe the effects of candidate miRNA on in vivo regulation of apoptosis. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Cancer 
Cancer is a genetic disease that is characterized by the transformation of normal cells 
to a neoplastic state. This progression is enabled through the acquisition of various 
hallmark capabilities that allows cells to become tumourigenic and ultimately 
malignant, as illustrated in Figure 2.1 (Hanahan & Weinberg, 2011). These distinctive 
and complementary capabilities that facilitate tumour growth and metastatic 
dissemination include sustaining proliferative signaling, evasion of growth suppressors, 
avoidance of immune destruction, enabling replicative immortality, tumour-promoting 
inflammation, activation of invasion and metastasis, inducing angiogenesis, resistance 
to cell death, deregulation of cellular energetics, and genome instability and mutation 
(Hanahan & Weinberg, 2011). 
 
Figure 2.1: The hallmarks of cancer (Reproduced from Cell, Vol. 144, Hanahan & 
Weinberg, Hallmarks of Cancer: The Next Generation, 646-674, 2011, with permission 
from Elsevier). 
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2.1.1 Cancer statistics 
According to GLOCOBAN, a Windows based software which provides access to 
global cancer incidence and mortality rates, there are about 14.1 million new cancer 
cases (within 5 years of diagnosis), 8.2 million cancer deaths and 32.6 million people 
living with cancer in 2012 worldwide (Ferlay et al., 2013). Lung cancer remains to be 
the most common cancer worldwide, in both sexes combined, with an estimated 1.8 
million new cases in 2012 (12.9% of the total cancer cases), followed by breast cancer 
(1.67 million new cases in 2012) and colorectum cancer (746,000 new cases in men and 
614,000 new cases in females) (Ferlay et al., 2013). As highlighted in Figure 2.2, the 
most common cancer site for males, in Malaysia, in the year 2012, was lung (17.9% 
incidence) followed by colorectum (14.1% incidence) and prostate (6.5). In females, the 
most common cancer site was breast (28.0% incidence), with cervix uteri (11.1% 
incidence) and colorectum (10.2% incidence) followed by lung (6.0% incidence) 
(Ferlay et al., 2012). 
 Lung cancer led to the most cancer deaths worldwide with 1,098,606 deaths in 
males and females combined, accounting for 23.6% of the total deaths caused by cancer 
(Ferlay et al., 2012). Similarly, in Malaysia, lung cancer led to the most cancer deaths in 
the country in 2012, making up 19.1% of total cancer deaths, followed by breast cancer 
(11.9% of total cancer deaths) and colorectum cancer (10.6% of total cancer deaths) 
(Ferlay et al., 2012). 
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Figure 2.2: Malaysian population’s incidence and mortality of cancers in males and 
females combined, in 2012 (Reproduced with permission from Ferlay et al. 
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC 
CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on 
Cancer; 2013. Available from: http://globocan.iarc.fr, accessed May 26, 2017). 
2.2 Lung cancer 
Lung cancer is characterized by uncontrolled cell growth in the tissues of the lungs 
(Howlader, 2017a), and can be categorized into two main groups: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for about 15% of 
lung cancer cases and is a highly malignant tumour, while NSCLC makes up the 
remaining 85% of cases and can be further grouped into 3 major pathologic subtypes: 
adenocarcinoma, squamous cell carcinoma and large cell carcinoma (Dela Cruz et al., 
2011). Adenocarcinoma is the most common NSCLC subtype accounting for 38.5% of 
all lung cancer cases, while squamous cell carcinoma accounts for 20.0% and large cell 
carcinoma 2.9% (Howlader, 2017b). 
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2.2.1 Etiology of lung cancer 
There are various factors that may increase the risk of lung cancer, and they can be 
grouped into two broad categories: factors inherent to the individual (intrinsic factors) 
and factors extraneous to the individual (extrinsic or environmental factors) (Ruano-
Ravina et al., 2003). Intrinsic factors include genetic susceptibility, family history of 
cancer, gender, race, age, and previous respiratory diseases, whereas the extrinsic 
factors include use of tobacco, diet and obesity, occupational and environmental air 
pollution (Ruano-Ravina et al., 2003; Dela Cruz et al., 2011). 
 The use of tobacco remains to be the principal risk factor for lung cancer. 
Tobacco smoke was suspected to be linked to lung cancer as early as the 1920’s, and a 
case-control study was published in 1940 in Germany that reported for the first time that 
tobacco use was the single most important source of increase in lung cancer incidence 
(Müller, 1940). Today, tobacco smoking accounts for approximately 90% of male lung 
cancer deaths and 75-80% of female lung cancer deaths in the United States (Shopland, 
1995). Due to the complexity of tobacco smoke there is still some unknowns regarding 
the mechanism by which it causes lung cancer. However, to date, among the multiple 
components of tobacco smoke, at least 50 carcinogens have been identified by the 
International Agency for Research on Cancer (IARC) (Hoffmann & Hoffmann, 1997). 
Polycyclic aromatic hydrocarbons and nicotine-derived nitroso-aminoketone are the 
most well known carcinogens found in tobacco smoke, and they have been reported to 
lead to genetic mutations through DNA adduct formation (Hecht, 1999).   
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 While all subtypes of lung cancer are associated with tobacco smoking, the 
strongest association is with SCLC and squamous cell carcinoma. In contrast 
adenocarcinoma is more common in non-smokers, which refers to those who have never 
smoked in their lifetime or those who have smoked less than 100 cigarettes in their 
lifetime (Gabrielson, 2006; Sun et al., 2007). The principal key risk factors in non-
smokers include secondhand smoke, radon exposure, environmental exposures, history 
of lung disease, and genetic factors (Samet et al., 2009). 
 Familial aggregation of lung cancer has been observed frequently in the past 60 
years. This implies a hereditary base to the development of this disease (Sellers & Yang, 
2002). For example, Bailey-Wilson and colleagues reported the first association of 
familial lung cancer to a region on chromosome 6q23-25 in 2004 (Bailey-Wilson et al., 
2004). A history of smoking in addition to this inheritance was found to be associated 
with a three-fold increase risk for lung cancer (Bailey-Wilson et al., 2004). Studies have 
also demonstrated that carriers of TP53 germline sequence variations who also smoked 
was found to be three times more likely to develop lung cancer than carriers who do not 
smoke (Hwang et al., 2003). Furthermore, T790M sequence variation in germline 
epidermal growth factor (EGF) was reported in a family with multiple cases of NSCLC 
(Li & Hemminki, 2004). Therefore, it is clear that susceptibility to lung cancer is 
determined in part by host genetic factors. These findings could thus be utilized for the 
design of early detection and treatment of lung cancers in patients with inherited cancer 
predisposition.  
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2.2.2 Pathogenesis of lung cancer 
Development of lung cancer occurs through a multi-step process that involves the 
acquisition of numerous genetic and epigenetic changes, especially the activation of 
growth promoting pathways and silencing of tumour suppressor pathways (Fong et al., 
1999). Genetic and epigenetic changes would in turn cause dysregulation of molecular 
signal transduction pathways, which can regulate cell proliferation, differentiation and 
apoptosis, directly or indirectly (Kitamura et al., 2008). The stimulation of growth 
promoting oncogenes can arise through gene amplification, point mutations or structural 
rearrangements that lead to uncontrolled signaling (Fong et al., 1999). Growth 
promoting protein such as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
(KRAS) is found to be frequently activated by point mutations in approximately 20% of 
lung adenocarcinomas but rarely exhibited in SCLCs (Rodenhuis & Slebos, 1992; Riely 
et al., 2008; Schmid et al., 2009). Constitutive activation of KRAS may result in 
inappropriate extended signaling for continued cell division (Richardson & Johnson, 
1993). 
Mutation in the activation of the epidermal growth factor receptor (EGFR) is also 
observed in NSCLC cells, most frequently in lung adenocarcinoma, although they may 
also be seen in squamous cell carcinomas (Kosaka et al., 2004; Shigematsu et al., 2005; 
Ohtsuka et al., 2007). Mutations of EGFR in NSCLC normally appear in the first four 
exons of the tyrosine kinase domain, most frequently exon 19 frame deletions (Tam et 
al., 2006). EGFR plays a role in the regulation of various oncogenic processes including 
cell proliferation, survival, differentiation, neovascularization, invasion, and metastasis 
(Yarden & Sliwkowski, 2001), and a mutant EGFR has been reported to have enhanced 
tyrosine kinase activity (Sordella et al., 2004). Other, less common, somatic mutations 
have also been reported in other EGFR pathway genes including v-Erb-B2 avian 
erythroblastic leukemia viral oncogene homolog 2 (HER2) (Shigematsu et al., 2005) 
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and homolog 4 (HER4) (Soung et al., 2006), B-Raf proto-oncogene, serine/threonine 
kinase (BRAF) (Naoki et al., 2002) and phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA) (Samuels et al., 2004; Yamamoto et al., 2008). 
Inactivation of tumour suppressor p53 is the most significant genetic abnormality in 
lung cancer occurring in approximately 90% of SCLC and 50% of NSCLC (Takahashi 
et al., 1989; Greenblatt et al., 1994; Bennett et al., 1999), usually through missense 
mutations within the DNA-binding domain (D'Amico et al., 1992). In response to DNA 
damage, p53 maintains genomic integrity through regulation of downstream genes 
including cyclin dependent kinase inhibitor 1A (p21), mouse double minute 2 homolog 
(MDM2), growth arrest and DNA damage inducible alpha (GADD45) and BCL2 
associated X, apoptosis regulator (BAX), to help regulate the G1/S cell cycle transition, 
G2/M DNA damage checkpoint and apoptosis (Fong et al., 1999). Therefore, a 
dysregulation of p53 expression in lung cancer will allow for continued survival of 
genetically damaged cells, thus leading to accumulation of numerous mutations and 
consequent evolution of cancer cells (Fong et al., 1999). 
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Other alterations that occurs in lung cancer is the inactivation of tumour suppressor 
genes, such as, retinoblastoma (Rb) (Kaye, 2002; Wikman & Kettunen, 2006), 
phosphatase and tensin homolog (PTEN) (Marsit et al., 2005; Jin et al., 2010) and 
cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1 (p16/CDKN2A) 
(Otterson et al., 1994; Brambilla et al., 1999), as well as, amplification of oncogenes, 
such as, fibroblast growth factor receptor 1 (FGFR1) (Dutt et al., 2011; Tran et al., 
2013), discoidin domain receptor 2 (DDR2) (Hammerman et al., 2011), retinoblastoma-
associated protein 1 (E2F) (Eymin et al., 2001; Cooper et al., 2006) and v-Myc avian 
myelocytomatosis viral oncogene homolog (c-MYC) (Johnson et al., 1987; Johnson et 
al., 1996). Therefore, the identification of genetic alterations in lung cancer that lead to 
stimulation or inactivation of oncogenes and tumour suppressor genes, respectively, can 
potentially offer further opportunities in development of therapeutics. 
2.2.3 Treatment of lung cancer 
When possible, the most reliable and successful option for cure of lung cancer 
patients is surgical resection (Molina et al., 2008). Lobectomy, in which the entire lobe 
that contains the tumour is removed, is the most common surgical procedure. Patients 
who cannot tolerate an extensive procedure normally undergo limited resections, such 
as, wedge resections, though they are associated with an increased risk of local 
recurrence. In cases of extensive disease, a total pneumonectomy (removal of an entire 
lung) may be required (Ginsberg et al., 1983). However, as almost 70% of patients are 
diagnosed at an advanced or metastatic stage of disease, the most beneficial form of 
treatment becomes chemotherapy and/or simultaneous administration of radiation and 
chemotherapy (Pfister et al., 2004). Even with treatment, the 5-year survival rate for 
lung cancer is very low at 17.7% (Howlader et al., 2017b), with late stage diagnosis and 
high incidence of drug resistance being the main contributors to low survival rates. 
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With an increase in comprehension of the biology of cancer, abundant potential 
therapeutic strategies has been revealed, including the targeting of signal transduction 
and angiogenesis pathways known to be dysregulated in lung cancer. Targeted therapy 
drugs are often used in combination with chemotherapy drugs. For example, EGFR is 
overexpressed in 40-80% of NSCLC patients, and its overexpression is correlated with 
poor prognosis (Mendelsohn & Baselga, 2003). The first targeted therapy for lung 
cancer to be registered and approved by the Food and Drug Administration (FDA) was 
gefitinib, an EGFR inhibitor (Kris et al., 2003). However, findings from two phase 3 
randomized trials of gefitinib comparing daily dosage of 250 mg of the drug versus 
placebo did not show a survival benefit (Thatcher et al., 2005). Another EGFR 
inhibitor, erlotinib, has been approved by FDA for patients with locally advanced or 
metastatic NSCLC who have not responded to previous rounds of therapy (Shepherd et 
al., 2004). The rate of response to erlotinib in comparison with placebo was found to be 
statistically significant at 8.9% with a average survival rate of 6.7 months (Shepherd et 
al., 2004). In another trial, bevacizumab, which targets vascular endothelial growth 
factor (VEGF) in combination with chemotherapy, was found to significantly increase 
survival rates for patients with advanced non-squamous NSCLC and was thus approved 
by FDA in 2005 (Sandler et al., 2005). 
2.3 Apoptosis 
Apoptosis is programmed cell death that plays an essential role in normal 
development and tissue homeostasis through the elimination of damaged, aged or 
autoimmune cells (Kerr et al., 1972). The process of apoptosis, regulated by 
intracellular and/or extracellular signals, is characterized by morphological hallmarks, 
which include chromatin condensation, nuclear fragmentation, cell shrinkage, 
membrane blebbing, and the formation of apoptotic bodies (Nicholson, 1999; 
Hengartner, 2000). Proper apoptotic signaling is crucial for maintaining the balance 
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between cell survival and cell death, thus dysregulation of apoptosis can contribute to 
human diseases, including cancer (Reed, 1999). Apoptosis evasion is a prominent 
hallmark of cancer and the mechanism by which this can occur includes disruption of 
the balance between pro-apoptotic and anti-apoptotic proteins, decreased caspase 
function, and compromised signaling of death receptors (Hanahan & Weinberg, 2000). 
Therefore, current cancer therapies, such as, chemotherapy, gamma-irradiation, 
immunotherapy or targeted gene therapy largely exercises their anti-tumour effect by 
stimulating apoptosis in cancer cells (Makin & Dive, 2001; Fulda & Debatin, 2004). 
2.3.1 Caspase cascade 
Apoptosis is primarily executed by a group of enzymes called caspases (cysteinyl 
aspartate-specific proteases), which belong to the cysteine protease family (Thornberry 
& Lazebnik, 1998; Li & Yuan, 2008). Caspases are sub-classified based on their 
mechanism of action and are either initiator caspases (caspase 8 and 9) or effector 
caspases (caspase 3, 6, and 7) (McIlwain et al., 2013). Upon receiving pro-apoptotic 
signals, initiator caspases, which exists as inactive pro-caspase monomers, are recruited 
to oligomeric complexes by activating adaptor proteins, which stimulates dimerization 
(Muzio et al., 1998; Degterev et al., 2003). Dimerization enables the autocatalytic 
cleavage of caspase monomers into a p20 and p10 heterotetramer, resulting in 
stabilization of the dimer (Muzio et al., 1998). In turn, the activated initiator caspases 
will activate effector caspases, to cleave downstream key proteins to induce biochemical 
and morphological changes specific to apoptotic cells (Degterev et al., 2003; Luthi & 
Martin, 2007; Pop & Salvesen, 2009). This caspase cascade can be activated by either 
the intrinsic (or mitochondrial) or the extrinsic (or death receptor) pathways of apoptosis 
(Figure 2.3). These two pathways will ultimately merge to a common pathway termed 
the execution phase of apoptosis (Orrenius et al., 2003; Elmore, 2007). 
14 
2.3.2 Intrinsic (mitochondrial) pathway 
The intrinsic pathway of apoptosis is activated by various stress stimuli including 
UV radiation, gamma radiation, growth-factor deprivation, DNA damage, and 
activation of oncogenic factors (Kroemer, 2002; Green & Kroemer, 2004). Multiple 
intracellular components will recognize these stressors and convey the message to the 
mitochondria, resulting in mitochondrial outer membrane permeability (MOMP) (Zou et 
al., 1999; Garrido et al., 2006). Disruption of the outer mitochondrial membrane will 
result in the diffusion of various proteins normally found in the mitochondrial 
intermembrane space (Grimson et al., 2007) into the cytosol, such as, cytochrome c, 
second mitochondria derived activator of caspase (SMAC)/ direct inhibitor of apoptosis 
protein (IAP)-binding protein with low PI (DIABLO), Omi/High temperature 
requirement protein A (HTRA2), apoptosis inducing factor (AIF), and endonuclease G 
(Cande et al., 2004; Saelens et al., 2004; Kroemer et al., 2007). Cytochrome c will form 
a complex with apoptosis protease-activating factor 1 (APAF-1) and dATP, to result in 
the dimerization and subsequent activation of pro-caspase 9 (Li et al., 1997; Pop et al., 
2006). Caspase 9, an initiator caspase, in turn activates effector caspases that cleave 
multiple cellular proteins (Singh, 2007). At the same time, SMAC/DIABLO and 
OMI/HTRA2 enhances the activation of caspases through the alleviation of the inhibitor 
effects of IAPs (Saelens et al., 2004; Garrido et al., 2006). The central regulators of the 
mitochondrial pathway are a group of proteins that belong to the BCL-2 family. 
Dysregulation of the intrinsic pathway has been reported in lung cancer. For 
example, decreased expression of Apaf-1 has been detected in NSCLC tumours in 
comparison to normal lung, whereas expression of pro-caspase 9 and 3 were found to be 
up-regulated in the absence of apoptosis (Yang et al., 2003; Krepela et al., 2006). There 
is mounting evidence that tumour cells also express higher levels of IAPs, signifying 
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that increased expression of IAPs thwarted the high basal caspase activity in tumour 
cells (Yang et al., 2003).  
2.3.2.1 BCL-2 family members 
B-cell lymphoma-2 (BCL-2) was the first protein of this family to be identified, and 
it is encoded by the BCL-2 gene found in human B-cell lymphomas with the t(14;18) 
chromosomal translocation (Tsujimoto et al., 1984). This family of proteins is made up 
of pro-apoptotic and anti-apoptotic members that play a crucial role in the regulation of 
apoptosis by mediating permeability of the mitochondrial membrane, and they can be 
divided into three sub-groups based on their function and the presence of shared blocks 
of sequence homology, termed BCL-2 homology (BH) (Table 2.1) (Danial, 2007; Giam 
et al., 2008). The first group is the anti-apoptotic multi-domain proteins, which 
counteract the process of apoptosis by sequestering pro-apoptotic family members (Hata 
et al., 2015). This group is made up of BCL-2, B cell lymphoma extra large (BCL-XL), 
induced myeloid leukemia cell differentiation protein (MCL-1), BCL-2-like protein 2 
(BCL-W), BCL-2 related protein A1 (BFL-1), and BCL-2-like protein 10 (BCL-B). The 
second group is the pro-apoptotic BH-3-only proteins, which share only a single block 
of sequence homology, the BH3 block. Members of this group include BCL-2-
interacting mediator of cell death (BIM), BH3-interacting domain death agonist (BID) 
(Sevilla et al., 2001), and BCL-2-associated agonist of cell death (BAD), amongst 
others (Hata et al., 2015). Members of the third group are the pro-apoptotic multi-
domain proteins, and some examples include BCL-2-associated protein X (BAX) and 
BCL-2 antagonist/killer (BAK) (Hata et al., 2015). 
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In response to cellular stress, pro-apoptotic proteins, such as, BAX and BAK are 
dephosphorylated and cleaved leading to their translocation from the cytoplasm to the 
mitochondria. Oligomerization of BAX and BAK will be induced and the oligomers 
will subsequently be inserted into the mitochondrial outer membrane for the release of 
cytochrome c and activation of caspases to induce cell death (Debatin, 2004; Green & 
Kroemer, 2004). Furthermore, BH3-proteins, such as, BIM and BID, function by 
directly or indirectly activating pro-apoptotic BAX and BAK to induce apoptosis 
(Delbridge & Strasser, 2015). The balance between pro- and anti-apoptotic BCL-2 
family members is crucial for cellular apoptotic homeostasis and abnormalities in BCL-
2 family proteins have been observed in various human cancers, including lung cancer 
(Daniel & Smythe, 2004).   
Table 2.1: Functional categories of the BCL-2 family of proteins 
Anti-apoptotic proteins Pro-apoptotic proteins BH-3 only proteins 
BCL-2 BAX BID 
BCL-XL BAK BIM 
MCL-1 BOK/MTC PUMA 
BCL-W  NOXA 
BFL-1  BAD 
BCL-B  BMF 
  HRK 
  BIK 
(Reproduced from Seminars in Thoracic and Cardiovascular Surgery, Vol. 16, Daniel & 
Smythe, The Role of Bcl-2 Family Members in Non-Small Cell Lung Cancer, 19-27, 
2004, with permission from Elsevier). 
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2.3.2.2 BCL-2 family members expression in lung cancer 
Overexpression of anti-apoptotic BCL-2 and BCL-XL is a prominent mechanism of 
apoptosis dysregulation in various cancers including acute lymphoblastic leukemia 
(ALL), acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), 
glioblastoma, melanoma, as well as prostate and lung cancers (Campana et al., 1993; 
Colombel et al., 1993; Ramsay et al., 1995; Kitagawa et al., 1996; Deininger et al., 
1999; Venditti et al., 2004; Abramson & Shipp, 2005; Reed, 2008). Increased 
expression of BCL-2 is often correlated with poor prognosis, recurrence, and resistance 
to cancer therapeutics (Granville et al., 1999; Pellecchia & Reed, 2004).  
In lung cancer, overexpression of BCL-2 is more frequently overexpressed in SCLC 
and squamous cell carcinoma than in adenocarcinoma (Pezzella et al., 1993). 
Furthermore, loss of BCL-2 expression has been reported to be associated with an 
increase in angiogenesis and cell migration (Koukourakis et al., 1997; Koukourakis et 
al., 1999), thus suggesting that BCL-2 expression may be required for survival of 
premalignant cells and some malignant cells, however as the tumour develops 
metastatic potential it may be less prone to undergo apoptosis, resulting in inhibition of 
BCL-2 (Kim et al., 1998; Koty et al., 2002).  
While BCL-2 expression is less significant in lung adenocarcinoma, the expression 
of BCL-XL is frequently overexpressed in these tumours (Reeve et al., 1996; Groeger et 
al., 2004; Sanchez-Ceja et al., 2006). BCL-XL has the ability to neutralize the pro-
apoptotic functions of BAX and BAD through prevention of its translocation from the 
cytosol to the mitochondria. This will prevent initiation of apoptosis by maintaining the 
stability of the outer mitochondrial membrane, thus preventing release of cytochrome c 
and ensuing activation of pro-caspase 9 (Gottlieb et al., 2000; Grad et al., 2000). Pro-
apoptotic BAD is normally phosphorylated at a number of serine residues allowing it to 
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be sequestered by the cytosolic scaffold protein 14-3-3. Upon receiving an apoptotic 
signal, BAD will be dephosphorylated and bind to BCL-XL leading to inactivation of 
BCL-XL’s pro-survival function (Zha et al., 1996). However, when BCL-XL is present 
in large quantities it will have a greater affinity for BAD than 14-3-3, thus sequestering 
BAD to the mitochondria, leaving excess uncomplexed BCL-XL to perform its pro-
survival functions (Cheng et al., 2001; Jeong et al., 2004).  
2.3.3 Extrinsic (death receptor) pathway 
The extrinsic pathway of apoptosis is initiated at the plasma membrane upon 
stimulation of the death receptors, which include the tumour necrosis factor (TNF) 
receptor 1 (TNFR1), FAS (APO-1, CD95), TNF-related apoptosis-inducing ligand 
(TRAIL) receptor 1 (TRAILR1, DR4), and TRAIL receptor 2 (TRAIL-R2, DR5) 
(Hengartner, 2001; Jin & El-Deiry, 2005; Guicciardi & Gores, 2009). Upon receiving 
extracellular cues, the cytoplasmic domains of the death receptors recruits death 
domain-containing adaptor proteins, such as, TNF receptor-associated death domain 
(TRADD) and Fas-associated death domain (FADD), which then interacts with pro-
caspase 8 via the death effector domain (DED), resulting in the formation of a complex 
known as the death inducing signaling complex (DISC) (Kischkel et al., 1995). The 
formation of DISC in turn initiates the assembly and activation of initiator caspase 8, 
which can transmit the apoptosis signal through direct cleavage and activation of 
downstream effector caspases, such as, caspase 3, 6 and 7 (Figure 2.3) (Scaffidi et al., 
1998; Fulda, 2009). Alternatively, activated caspase 8 can induce mitochondrial damage 
through the cleavage of the BH3-only protein BID to generate truncated BID (tBID) (Li 
et al., 1998; Garrido et al., 2006). 
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Studies have shown that TRAIL receptors, TRAIL-R1 and -R2, are located on 
chromosome 8p, a region of frequent loss of heterozygosity (LOH) in tumours, 
including lung carcinomas (LeBlanc & Ashkenazi, 2003). Somatic mutations of 
TRAIL-R2 can be found in approximately 10% of NSCLC patients, with the mutations 
reported to be located in the death domain region (Lee et al., 1999). However, whether 
these mutations influence patient response to therapy or overall survival remains to be 
examined. Furthermore, loss of pro-caspase 8, FAS-L, FAS-R and TRAIL-R have all 
been reported in SCLC (Joseph et al., 1999; Hopkins-Donaldson et al., 2003), and 
expression of decoy receptor 3 (DCR3), which competitively binds Fas ligand (FASL) 
to interfere with FAS-induced apoptosis has been found to be genetically overexpressed 
in lung carcinoma (Pitti et al., 1998; Shen et al., 2005). 
 
Figure 2.3: Extrinsic and intrinsic pathways of apoptosis (Reproduced from Trends in 
Cell Biology, Vol. 23, Fernald & Kurokawa, Evading Apoptosis in Cancer, 620-633, 
2013, with permission from Elsevier). 
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2.3.4 Transforming growth factor, beta (TGF-β) signaling pathway 
The TGF-β signaling pathway controls a critical network of signals that regulate 
cellular growth, differentiation, migration, adhesion, and cell death (Massagué, 1998). 
Signaling is initiated when the TGF-β ligand binds to the cell surface type II 
serine/threonine kinase receptor, also known as the transforming growth factor, beta-
receptor II (TGF-βRII). This will be followed by an interaction and phosphorylation of 
a glycine/serine rich domain within transforming growth factor, beta-receptor I (TGF-
βRI) to form an activated multimeric ligand-receptor complex (Massagué, 1998; Shi & 
Massagué, 2003). The activated TGF-βRI in turn propagates the signal by 
phosphorylating receptor-regulated Smad proteins (R-Smads) that consist of SMAD2 
and SMAD3 proteins. R-Smads will undergo homotrimerization and form heteromeric 
complexes with common-mediator Smad (Co-Smad), SMAD4 (Massagué, 1998). This 
complex will be translocated into the nucleus and in cooperation with other transcription 
factors, regulate the transcription of target genes (Shi & Massagué, 2003; Gatza et al., 
2010). 
TGF-β regulates the transcription of cell cycle regulators, thus functioning as a 
tumour suppressor through inhibition of cell cycle (Alexandrow & Moses, 1995). Cell 
cycle arrest is mediated by TGF-β through up-regulation of cyclin dependent kinase 
inhibitor proteins (CDKI), p15 and p21 (Hu et al., 1999; Feng et al., 2000). The p15 
protein binds to CDK4 and CDK6 subunits to inactivate their catalytic activity and 
subsequently inhibits the cyclin D-CDK4/6 complex formation, whereas p21 blocks 
both cyclin D-CDK4/6 and cyclin E/CDK2 formation during the G1-S phase of cell 
cycle (Hannon & Beach, 1994; Sherr & Roberts, 1999), thus inhibiting cell cycle 
progression. In addition to activating cell cycle inhibitors, TGF-β also suppresses 
mitogenic factors that stimulate cell growth, such as, v-MYC avian myelocytomatosis 
viral oncogene homolog (c-MYC) (Warner et al., 1999; Feng et al., 2002).  
21 
As depicted in Figure 2.4, TGF-β also has the ability to mediate the induction of 
apoptosis; however activation of apoptosis by TGF-β is variable depending on the cell 
and tissue type (Schuster & Krieglstein, 2002). For example, in human gastric SNU-620 
cell line, TGF-β induces apoptosis via the Fas death receptor pathway and can 
subsequently activate caspase 8 via Bid cleavage (Kim et al., 2004). Smad induced 
factors, such as, TGF-β early-response gene (TIEG1) and the death associated protein 
kinase (DAPK) have also been reported to be related to TGF-β mediated apoptosis 
(Tachibana et al., 1997; Jang et al., 2002). Expression of TIEG1 and DAPK are 
increased in response to TGF-β treatment, with TIEG1 inducing cell cycle arrest and 
enhancing TGF-β mediated apoptosis (Bender et al., 2004).  On the other hand, DAPK 
is directly activated by TGF-β via the SMAD2, SMAD3, and SMAD4 transcription 
factors, and in turn sensitizes cells to TGF-β dependent apoptosis (Jang et al., 2002).  
Alterations in TGF-β signaling have been associated with numerous human diseases, 
including cancer (Massague & Wotton, 2000; Jeon & Jen, 2010). TGF-β ligands along 
with downstream elements, including the receptors and SMAD proteins, are all essential 
in suppressing primary tumorigenesis in many tissues types (Markowitz & Roberts, 
1996). However, many cancers have also been reported to use the TGF-β pathway to 
their advantage. As the tumour progresses, mutations are amassed and disturbs the 
suppressive effects of TGF-β (Miyazono et al., 2003). For example, a marked increase 
in TGF-β ligand is frequently observed in lung cancer and is associated with advanced 
stages of malignancy and metastasis and with decreased survival (Jakowlew, 2008). 
Therefore, depending upon the context of the tumour microenvironment, TGF-β can 
function as either a tumour suppressor or a tumour promoter.  
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Figure 2.4: TGF-β induced apoptotic pathway (Reproduced from Cytokines in the 
Genesis and Treatment of Cancer, Bonine-Summers et al., Transforming Growth 
Factor-β and Cancer, 91-111, 2007, with permission from Humana Press). 
2.3.5 Phosphatidylinositol 3-Kinase (PI3K)/Protein kinase B (AKT) signaling 
pathway 
 
The PI3K/AKT signaling pathway affects a vast assortment of intracellular events 
that can directly or indirectly influence cell apoptosis (Duronio, 2008). PI3K 
phosphorylates phosphatidylinositol-3,4-biphosphase  (PtdIns(3,4)P2) (PIP2) to generate 
PIP3 (Vivanco & Sawyers, 2002). The PIP3 ligands will in turn mediate their cellular 
effects through the recruitment of plekstrin homology (PH) containing proteins to the 
inner surface of the cell membrane (Lemmon & Ferguson, 2000). One of the key 
kinases activated downstream of PI3K at the plasma membrane is 3-phosphoinositide-
dependent protein kinase-1 (PDK1) (Alessi et al., 1997).  
A central event for PI3K-dependent cell survival is the phosphorylation of a 
serine/threonine kinase, AKT, the cellular homologue of the retroviral oncogene v-Akt, 
also known as protein kinase B (PKB), at the threonine-308 (Thr308) region by PDK-1 
in the presence of PIP3 (Vivanco & Sawyers, 2002; Mora et al., 2004). AKT will 
relocalize from the cytoplasm to signaling complexes located at the plasma membrane. 
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Signaling of AKT plays an important role in processes critical to tumourigenesis, 
including inhibition of apoptosis, aberrant cell proliferation, promotion of angiogenesis, 
and tumour cell invasiveness (summarized in Figure 2.5) (Testa & Bellacosa, 2001).  
Activation of AKT plays a crucial role in cell survival by inhibiting apoptotic 
pathways. For example, AKT phosphorylates BAD, a pro-apoptotic member of the 
BCL-2 family of proteins, at serine-136 (Ser136) leading to inactivation of BAD 
activity by promoting its association with cytosolic 14-3-3 proteins (del Peso et al., 
1997; Blume-Jensen et al., 1998). This localizes BAD to the cytosol and inhibits its 
interaction with anti-apoptotic BCL-2 and BCL-XL, thus deactivating its pro-apoptotic 
activity (Zha et al., 1996). Another member of the BCL-2 family protein regulated by 
AKT is the pro-apoptotic BAX, which is a key regulator of mitochondrial permeability 
leading to apoptosis. AKT phosphorylates BAX at serine-184 (Ser184), suppressing 
BAX-mediated cell death (Gardai et al., 2004). 
Another set of substrates targeted by AKT is the forkhead transcription factors 
(FKHR) (Brunet et al., 1999; Tang et al., 1999). Phosphorylation by AKT will lead to 
binding of FKHR to 14-3-3 proteins, leading to sequestration and degradation in the 
cytoplasm (Brunet et al., 1999). Thus in the event of AKT loss, FKHR will be 
dephosphorylated and translocated to the nucleus where they can induce an increase in 
numerous regulators of cell death, including the FAS death receptor ligand, as well as 
the pro-apoptotic BIM, and the cell cycle inhibitor p27Kip1 (Biggs et al., 1999; Guo et 
al., 1999; Kops et al., 1999; Nakae et al., 1999; Rena et al., 1999; Tang et al., 1999). 
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NFκB (nuclear factor of light polypeptide gene enhancer in B cells), an important 
regulator of numerous anti-apoptotic and pro-apoptotic genes, is indirectly affected by 
AKT signaling (Vivanco & Sawyers, 2002). AKT regulates NFκB through the 
activation of IKK (IκB kinase) α, which together with IKKβ phosphorylates inhibitor of 
NFκB (IκB), leading to its ubiquitination and degradation (Ozes et al., 1999; 
Romashkova & Makarov, 1999; Karin & Ben-Neriah, 2000). Degradation of IκB will 
allow for the release of NFκB from the cytoplasm into the nucleus, and regulation of its 
target genes, which includes BCL-2, BCL-XL, and the inhibitor of caspase 8, FLIP 
(FLICE (FADD (Fas-associated death domain)-like IL-1β-converting enzyme)-
inhibitory protein) (Chen et al., 2000; Kreuz et al., 2001; Sevilla et al., 2001). 
Another pathway influenced by PI3K/AKT signaling is regulation of the tumour 
suppressor P53 (Vivanco & Sawyers, 2002; Duronio, 2008). p53 regulates apoptosis 
through various mechanisms including the up-regulation of pro-apoptotic proteins, such 
as, BAX and PUMA (Wu & Deng, 2002; Roos & Kaina, 2006). Negative regulation of 
p53 occurs via a molecule called murine double minute 2 (MDM2), which can move 
into the nucleus to promote the ubiquitination and consequent degradation of p53. 
Reports have shown that AKT can mediate the phosphorylation of MDM2 at serine-166 
(Ser166) and serine-186 (Ser186), which in turn allows the translocation of MDM2 
from the cytoplasm into the nucleus (Mayo & Donner, 2001). 
AKT plays a role in various components of the cell-death process, and studies have 
shown that aberrant expression of AKT can significantly influence human malignancy 
(Testa & Bellacosa, 2001). Expression of AKT has been demonstrated to be up-
regulated in various tumour types including ovarian, breast, prostate, pancreatic, gastric, 
and lung cancer (Staal, 1987; Bellacosa et al., 1995; Edlind & Hsieh, 2014; Baer et al., 
2015). In lung cancer, amplification of AKT has been associated with resistance to 
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chemotherapy, radiation, and tyrosine kinase inhibitors (Brognard et al., 2001; Hill & 
Hemmings, 2002; Janmaat et al., 2003).  
 
Figure 2.5: Target substrates of PI3K/AKT whose pro-apoptotic activities are 
suppressed by phosphorylation (Reproduced from Biochemical Journal, Vol. 415, 
Duronio, The Life of a Cell: Apoptosis Regulation by the PI3K/PKB Pathway, 333-344, 
2008, with permission from Portland Press).  
2.3.6 Mitogen-activated protein kinase (MAPK) signaling pathway 
Mitogen-activated protein kinases (MAPKs) are serine-threonine kinases that control 
numerous cellular activities including proliferation, differentiation, apoptosis, survival, 
inflammation, transformation, and innate immunity (Platanias, 2003; Torii et al., 2006; 
Turjanski et al., 2007; Arthur & Ley, 2013; Peti & Page, 2013). This signaling cascade 
is activated by various extracellular and intracellular stimuli, such as, peptide growth 
factors, cytokines, hormones, and cellular stresses including oxidative stress and 
endoplasmic reticulum stress (Kim & Choi, 2010). The MAPK family is made up of 
three subfamilies: the extracellular signal-regulated kinase (ERK; ERK1 and ERK2), c-
Jun N-terminal kinase (JNK; JNK1, JNK2, and JNK3), and the p38-MAP kinase (α, β, δ 
and γ) (Figure 2.6) (Schaeffer & Weber, 1999; Raman et al., 2007). Each MAPK 
signaling cascade consists of at least three components: a MAPK kinase kinase 
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(MAP3K), a MAPK kinase (MAP2K), and a MAPK (Chang & Karin, 2001; Plotnikov 
et al., 2011). Within each tier of the cascade, one or more kinase component will 
phosphorylate and activate components in the next tier, eventually leading to the 
phosphorylation of target regulatory molecules by the activated MAPK (Figure 2.6) 
(Raman et al., 2007).  
 
Figure 2.6: Mitogen-activated protein kinase (MAPK) signaling pathways (Reproduced 
from Biochimica et Biophysica Acta, Vol. 1802, Kim & Choi, Pathological Roles of 
MAPK Signaling Pathways in Human Diseases, 396-405, 2010, with permission from 
Elsevier). 
2.3.6.1 ERK1/2 cascade 
The best characterized MAPK pathway is the ERK cascade, and there are two ERK 
isoforms that are ubiquitously expressed, ERK1 (p42) and ERK2 (p33), that are 83% 
identical (Boulton et al., 1991).  The ERK cascade is initially activated by mitogenic 
stimuli, such as, epidermal growth factor (EGF) or platelet-derived growth factor 
(PDGF). Binding of the growth factors to its cell surface receptor tyrosine kinase, will 
induce dimerization and autophosphorylation of the receptor (Mercer & D’Armiento, 
2006). This in turn will activate guanine nucleotide exchange factors (GEFs) such as 
Son of Sevenless (SOS), which facilitates the activation of GTPase Ras (Dhillon et al., 
2007; Plotnikov et al., 2011). Ras-GTP will activate the MAP3K tier of the cascade, the 
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Raf isoforms (RAF-1, A-RAF, B-RAF), which mediates phosphorylation of the dual-
specificity MAP kinase-1 and -2 (MEKs), MEK1/2 (Malumbres & Barbacid, 2003; 
Mercer & D’Armiento, 2006). MEK1/2 will in turn phosphorylate ERK1/2 allowing the 
activated ERK to execute its function through a large number of downstream molecules.  
Activation of ERK1/2 can promote cell survival through the inhibition of apoptosis 
at stages upstream, downstream or unrelated to changes in the mitochondrial membrane 
potential and release of cytochrome c (Erhardt et al., 1999; Qiao et al., 2001). For 
example, ERK1/2 can inhibit the activation of caspase 8, cleavage of Bid and loss of 
mitochondrial membrane potential through the stimulation of FAS/CD95, TNF, and 
TRAIL receptors (Holmstrom et al., 2000; Tran et al., 2001; Shonai et al., 2002). 
ERK1/2 can also stimulate cell survival by boosting the activation of anti-apoptotic 
molecules, such as, MCL-1, an anti-apoptotic member of the BCL-2 family, which is 
phosphorylated by ERK1/2 at threonine-163 (Thr163) (Domina et al., 2004). 
Furthermore, IEX-1 (immediately early gene X-1) can be phosphorylated at threonine-
18 (Thr18) by ERK/1/2 and prevents cell death by inhibiting the release of cytochrome 
c from the mitochondria (Garcia et al., 2002). Reports have also concluded that caspase 
9 can be regulated by ERK1/2 by phosphorylation at threonine-125 (Thr125) to inhibit 
caspase 9 processing and subsequent activation of caspase 3 (Allan et al., 2003). 
ERK1/2 is also able to phosphorylate and activate various transcription factors 
including TCF-member ELK-1, c-FOS (Fos proto-oncogene, AP-1 transcription factor 
subunit), p53, ETS1/2 (avian erythroblastosis virus E26 (v-ETS) oncogene homolog) 
and c-JUN (JUN proto-oncogene, AP-1 transcription factor subunit), all of which are 
important for the initiation and regulation of cell proliferation and oncogenic 
transformation (Gille et al., 1992; Milne et al., 1994; Yang et al., 1996; Murphy et al., 
2002; Morton et al., 2003). 
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Studies have also reported an association between the dysregulation of the ERK 
pathway and tumourigenesis. The incidence of cancer has been positively correlated 
with an increased activation of RAS, increased ERK1/2 activity, or binding of DNA by 
ERK1/2 transcription factor targets in both in vitro and in vivo studies (Sebolt-Leopold 
et al., 1999; Vicent et al., 2004; Han et al., 2005; Mercer & D’Armiento, 2006).  
2.3.6.2 JNK/SAPK cascade 
The JNK-family kinases, also known as stress-activated protein kinases (SAPK), is 
initiated by numerous stimuli, including growth factors, cytokines, and cellular stresses, 
such as, genotoxic, osmotic, hypoxic, or oxidative stress (Hibi et al., 1993; Cano et al., 
1994; Westwick et al., 1994). The activated stimuli will transmit their signal to 
GTPases, such as, cell division cycle 42 (CDC42) and Ras-related C3 botulinum toxin 
substrate 1 (RAC1) which induces the activation of the MAP3K level kinases 
(Plotnikov et al., 2011), which includes members of the mitogen-activated protein 
kinase kinase kinase 1, E3 ubiquitin protein ligase group (MEKK1-4), apoptosis signal-
regulating kinase group (ASK1 and ASK2), mixed lineage kinase (MLK1, MLK2, 
MLK3, DLK, and LZK), and transforming growth factor-β activated kinase 1 (TAK1) 
(Davis, 2000). The signal will then be transmitted further by phosphorylation of the 
kinases at the MAPKK level, MEK4 (MKK4) and MEK7 (MKK7). MKK4 and MKK7 
will in turn activate the components at the MAPK level, JNK (JNK1-3) via dual 
phosphorylation of the Thr-Pro-Tyr motif (Davis, 2000; Fleming et al., 2000).  
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Activated JNK can control various transcription factors, such as, c-JUN, c-FOS, 
ATF-2 (activating transcription factor 2), p53, ELK, and NFAT (nuclear factor of 
activated T cells) (Johnson & Nakamura, 2007; Raman et al., 2007). These 
phosphorylated targets would in turn regulate transcription of many genes thus 
mediating numerous cellular processes including apoptosis, immunological effects, 
neuronal activity, and insulin signaling (Dhanasekaran & Reddy, 2008; Haeusgen et al., 
2009; Rincon & Davis, 2009). In regards to apoptosis, JNK can phosphorylate and 
inhibit the activity of cytoplasmic substrates including the anti-apoptotic proteins BCL-
2 and BCL-XL, to produce a change in mitochondrial membrane potential and 
subsequent release of cytochrome c and activation of caspase 3 (Fan et al., 2000; Basu 
& Haldar, 2003). Furthermore, the phosphorylation of c-JUN and ATF-2 resulted in 
activation of activator protein 1 (AP-1) and increased expression of pro-apoptotic genes, 
FasL and Fas, to initiate activation of caspase 8 (Fan & Chambers, 2001; Tang et al., 
2012). 
2.3.6.3 p38 cascade 
Similar to the JNK pathway, the p38 cascade is also induced by stress related stimuli 
(heat shock, changes in osmolarity, ultraviolet, oxygen radicals and hypoxic state) and 
various growth factors including granulocyte macrophage-colony stimulating factor 
(GM-CSF), colony stimulating factor 1 (CSF1), erythropoietin (EPO), insulin-like 
growth factor (IGF), VEGF, and PDGF (Foltz et al., 1997; Pyne & Pyne, 1997; 
Rousseau et al., 1997; Cheng & Feldman, 1998). Activated receptors will transmit the 
signals via adaptor proteins, small GTPases, MAP4Ks and MAP3Ks, similar to those 
functioning in the JNK cascade, such as, ASK and TAK1 (Plotnikov et al., 2011). 
Following that, MAP3Ks will phosphorylate and activate the MAP2K components, 
which are made up of the MKK3 and MKK6 (Brancho et al., 2003). Activated MKK3 
and MKK6 will in turn activate the four isoforms at the MAPK tier of the cascade, 
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p38α, p38β, p38δ, and p38γ. Upon activation, p38 proteins will translocate from the 
cytosol to the nucleus to mediate cellular responses via downstream transcription factors 
(Plotnikov et al., 2011). 
The p38 cascade plays a critical role in the control of immunological effects, cell 
cycle checkpoint, and apoptosis (Huang et al., 2009; Thornton & Rincon, 2009). 
Therefore, a dysregulation of the p38 has been implicated in tumourigenesis. Studies 
have shown that p38 functions as a tumour suppressor through the down-regulation of 
Ras-dependent and independent transformation, invasion and also by inducing apoptosis 
(Plotnikov et al., 2011). For example, activation of p38 leads to rapid 
dephosphorylation of MEK1/2 and subsequent apoptosis (Li et al., 2003). Furthermore, 
p38 can mediate TNF-induced BCL-XL phosphorylation, however the exact mechanism 
by which this occurs is still unknown (Grethe et al., 2004). p38 has also been implicated 
indirectly through increasing or decreasing BAD phosphorylation at serine-112 
(Ser112) (She et al., 2002; Grethe & Porn-Ares, 2006).  
2.3.7 Wingless-type MMTV integration site family (WNT) signaling pathway 
WNT signaling plays a crucial role in development as it acts as a regulator of 
embryonic cell patterning, proliferation, differentiation, cell survival, and apoptosis 
(Pećina-Šlaus, 2010). WNT signaling can be classified as canonical and non-canonical, 
whereby the canonical pathway is responsible for prevention of β-catenin degradation 
(Widelitz, 2005). When WNT signaling is absent, β-catenin is linked with a cytoplasmic 
complex made up of the glycogen synthase kinase 3-beta (GSK3-β), adenomatous 
polyposis coli protein (APC), and axin (Su et al., 1993; Sakanaka et al., 1998). GSK3-β 
phosphorylates β-catenin at the NH2-terminal region and induces its degradation 
through the ubiquitin-proteasome pathway (Kitagawa et al., 1999; Winston et al., 1999). 
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As depicted in Figure 2.7, when WNT signaling is activated, WNT ligands bind to 
receptors of the Frizzled (FZD) family on the cell surface. In turn, FZD receptors 
activates the intracellular protein, Disheveled, to inhibit the multiprotein GSK3-β 
/APC/AXIN complex thus allowing β-catenin to escape from phosphorylation and 
accumulate in the cytoplasm (Barth et al., 1997; Rubinfeld et al., 1997). β-catenin can 
then translocate to the nucleus to form a complex with members of the T-cell 
factor/lymphocyte enhancer factor (TCF/LEF) family of transcription factors to activate 
various target genes including c-MYC, CCND1, BIRC5, and MMP (Roose & Clevers, 
1999; Tapia et al., 2006). Therefore, a constitutively activated WNT pathway can lead 
to cancer. 
Reports have demonstrated that the WNT signaling pathway can regulate apoptosis 
through a variety of mechanisms. The tumour suppressor protein, APC, can play a role 
in regulation of apoptosis depending on whether it is present as a full length (wild type) 
or truncated (mutant) protein. Expression of the wild type APC induces apoptosis, 
whereas overexpression of the mutant truncated protein maintains an anti-apoptotic 
mode of action (Brocardo & Henderson, 2008). The mutated truncated APC protein is 
frequently found in cancers and is it has been reported that mutant APC can bind to Bcl-
2 proteins to increase their levels in the mitochondria, resulting in increased cell 
survival (Brocardo & Henderson, 2008). However, the exact mechanism by which this 
occurs is still unclear.  
Another well-researched WNT protein, WNT1, has also been associated with the 
control of apoptosis. WNT1 inhibits apoptosis through the prevention of cytochrome c 
release from the mitochondria and inhibition of the subsequent activation of caspase 9. 
WNT1 is frequently overexpressed in NSCLC, and its overexpression results in 
increased resistance to therapies that mediate apoptosis (Chen et al., 2001; Li et al., 
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2006). Other WNT-pathway components including frizzled-8 (FZD8), disheveled 
(DSH), porcupine (PORC), and transcription factor 4 (TCF-4) are also frequently 
overexpressed in NSCLC, and is associated with poor prognosis (Xu et al., 2007; Wei et 
al., 2008; Bartling et al., 2010; Bravo et al., 2013). Furthermore, down-regulation of 
WNT inhibitors, such as axin, WNT inhibitory factor 1 (WIF-1), dickkopf WNT 
signaling pathway inhibitor 1(DKK-1), runt related transcription factor 3 (RUNX3), and 
caudal type homeobox 2 (CDX2), amongst others, is also common is NSCLC cell lines 
and may be associated with high stage, dedifferentiation, and poor prognosis (Licchesi 
et al., 2008; Liu et al., 2012; Na et al., 2012). 
 
Figure 2.7: Canonical WNT/β-catenin signaling pathway (Reproduced from Journal of 
Thoracic Oncology, Vol. 2, Tennis et al., Role of the WNT Signaling Pathway and 
Lung Cancer, 889-892, 2001, with permission from Elsevier). 
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2.4 MicroRNA (miRNA) 
MiRNAs were first discovered in the Caenorhabdotis elegans (C. elegans) worm by 
Ambros and colleagues in 1993 (Lee et al., 1993). They discovered that a 22-nucleotide 
transcript of lin-4, a repressor of lin-14 that controls the timing of C. elegans larval 
development, did not code for a protein. Instead it was observed that lin-4 produces two 
small RNAs of about 22 and 62 nucleotides in length. The authors determined that the 
shorter lin-4 RNA had anti-sense complementarity to multiple sites in the 3’-
untranslated region (3’UTR) of lin-14 which led the authors to hypothesize that lin-4 
inhibits the translation of lin-14 through interaction with these 3’UTR elements (Lee et 
al., 1993; Wightman et al., 1993). Seven years later, in 2000, the evolutionarily 
conserved let-7 miRNA of C. elegans was determined to also regulate the expression of 
downstream genes through partial complementarity between the miRNA and its target 
3’UTR (Reinhart et al., 2000). These discoveries led to the characterization of 
numerous large-scale cDNA libraries enriched for small miRNAs, which in turn led to 
the identification of other miRNAs from plants, C. elegans, Drosophila, and mammals 
(Lagos-Quintana et al., 2001). 
 MiRNAs are a subset of non-coding RNAs of about 19 to 23 nucleotides long 
which regulate gene expression post-transcriptionally through the inhibition of mRNA 
translation, via direct binding to specific target sites in their 3’UTR regions, or 
inducement of target mRNA degradation through cleavage (Bartel, 2004). MiRNAs 
target approximately 60% of human protein-coding genes (Friedman et al., 2009). 
These regulatory elements play a role in a wide range of biological processes including 
cell proliferation (Hayashita et al., 2005), differentiation (Shivdasani, 2006), and 
apoptosis (Mott et al., 2007).  
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2.4.1 MiRNA biogenesis 
MiRNA genes can be found embedded within intergenic and intragenic (in introns 
and exons) regions of both protein-coding and non-coding transcripts, and are therefore 
co-transcribed with the gene in which they reside (Rodriguez et al., 2004). As 
demonstrated in Figure 2.8, miRNAs are initially transcribed by RNA polymerase II to 
form a primary miRNA (pri-miRNA) that can measure up to several thousands of 
nucleotides and contain stem-loop structures with single stranded RNA extensions at 
both ends. Pri-miRNA also contains a 5’ 7-methylguanosine cap structures and are 
polyadenylated at their 3’end (Lee et al., 2003; Cai et al., 2004; Borchert et al., 2006). 
The hairpin structures are recognized and the maturation process will begin with the 
nuclear cleavage of pri-miRNA by a 650 kDA microprocessor complex made up of 
RNase III endonuclease Drosha and the double-stranded RNA-binding protein 
DiGeorge syndrome critical region 8 (DGCR8) (Lee et al., 2003; Han et al., 2004).  
The resulting precursor miRNA (pre-miRNA), a ~65 nucleotide RNA hairpin 
intermediate with two nucleotide 3’overhang, will be bound by the nuclear export factor 
Exportin 5 and transported from the nucleus to the cytoplasm (Lee et al., 2002; Lund et 
al., 2004). In the cytoplasm, the terminal loop of the the pre-miRNA will be cleaved by 
a second RNase endonuclease Dicer, with its dsRNA binding partner, the human 
immunodeficiency virus transactivating response RNA-binding protein (TRBP), to 
generate a double stranded RNA duplex that is made up of both the mature miRNA 
strand and its complementary strand (Chendrimada et al., 2005; Haase et al., 2005). 
TBRP will then recruit the argonaute protein (AGO2), to form the RNA-induced 
silencing complex (RISC) (Chendrimada et al., 2005). The strand of the duplex that has 
the lowest thermodynamic stability at its 5’end is selected as the guide strand, which 
then functions to direct RISC to the 3’UTR of target mRNA based on sequence 
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complementarity. The passenger strand of the duplex will be degraded and removed 
from the RISC complex (Schwarz et al., 2003; Matranga et al., 2005).  
 
Figure 2.8: Biogenesis of miRNAs (Reproduced from Cell, Vol. 116, Bartel, 
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function, 281-297, 2004, with 
permission from Elsevier). 
2.4.2 MiRNA mode of action 
Mature miRNA incorporated in the RISC will target mRNA based upon Watson-
Crick base-pairing between the 3’UTR of the target and the seed region (residues 2-8 at 
the 5’ end) of the miRNA guide strand (Lee et al., 1993; Lewis et al., 2003; Brennecke 
et al., 2005). Therefore, a single miRNA is able to control the expression of hundreds of 
mRNA targets, and each mRNA may be regulated by multiple miRNAs. 
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The gene silencing mechanism that is employed depends upon the degree and nature 
of complementary sites between the target and guide miRNA (Bartel, 2004). In the case 
of multiple complementary sites with partial base-pairing in each site, translational 
inhibition of the mRNA will occur, whereas AGO2 endonuclease cleavage of target 
mRNA will occur in situations of perfect base-pairing (Bartel, 2004; Yekta et al., 2004).  
The two silencing mechanisms; mRNA cleavage and mRNA translational repression 
can be defined as slicer-dependent and slicer-independent silencing, respectively, with 
slicer activity referring to endonuclease cleavage of mRNA by AGO2 (Sheth & Parker, 
2003; Meister et al., 2004; Brengues et al., 2005). In the slicer-dependent silencing 
mechanism, mRNA can be degraded by one of two processes, both beginning with the 
removal of the poly (A) tail through deadenylation of the mRNA (Parker & Song, 2004; 
Valencia-Sanchez et al., 2006). Degradation can then occur via exosome or decapping 
by the enzymes DCP1 and DCP2, which performs 5’-to-3’ degradation through the 
exoribonuclease XRN1P (Coller & Parker, 2004; Valencia-Sanchez et al., 2006). For 
slicer-independent silencing mechanism, the multiple complementary sites of partial 
base-pairing induces the creation of bulges in the RNA duplex, thus inhibiting the slicer 
activity of AGO2 (Valencia-Sanchez et al., 2006). Furthermore, mRNA targeted by 
miRNA can be relocated and separated into P-bodies, which are small cytoplasmic 
protein spheroid domains, for temporary storage and/or decay sites (Brengues et al., 
2005; Liu et al., 2005a; Liu et al., 2005b). The reduction in the amount of target mRNA 
is the principal result of this molecular event.  
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2.4.3 MiRNA and lung cancer 
As miRNAs play a vital role in a variety of biological processes including 
differentiation, cell proliferation, development, and apoptosis, a disturbed miRNA 
function or altered miRNA expression may disorganize cellular processes and 
eventually cause or contribute to disease, including cancer (Wiemer, 2007). Studies 
have reported that miRNA genes reside in genomic regions that are involved in cancers, 
including minimal regions of loss of heterozygosity (LOH), minimal regions of 
amplification, or breakpoint cluster regions (Calin et al., 2004b). MiRNAs can be either 
up-regulated or down-regulated in human cancers, with those whose expressions are 
increased are considered oncogenic miRNAs, or oncomiRs, while miRNAs that are 
down-regulated are considered tumour suppressor genes (Zhang et al., 2007). 
Overexpression of miRNAs may result from deregulation of transcription factors, 
amplification or demethylation of CpG islands in the promoter regions of the gene 
(Croce, 2008). On the other hand, down-regulation of miRNAs may be due to deletions, 
epigenetic silencing, or loss of transcription factor expression (Ruan et al., 2009). 
In lung cancer, there are a number of miRNAs implicated in the development and 
progression of this disease (Table 2.2). For example, miR-21 is an oncomiR up-
regulated in lung cancer that functions to inhibit the expression of phosphatase and 
tensin homolog (PTEN), programmed cell death protein 4 (PDCD4) and tropomyosin 1 
(TPM1) to promote cell proliferation, migration, and inhibition of apoptosis (Zhu et al., 
2008; Zhang et al., 2010b; Bhatti et al., 2011). The miR-17-92 polycistronic cluster 
(miR-17-3p, miR-17-5p, miR-18a, miR-19a, miR-20a, miR-19b, miR-92-1) is also 
overexpressed in lung cancer, particularly in SCLC, and functions as oncomiRs to 
promote cancer progression and cell proliferation (Hayashita et al., 2005; Matsubara et 
al., 2007; Osada & Takahashi, 2011). Another well documented oncomiR is miR-
221/222, which is overexpressed in lung cancer to inhibit apoptosis and promote cell 
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migration through the down-regulation of PTEN and tissue inhibitor of 
metalloproteinases 3 (TIMP3) (Garofalo et al., 2009).  
Tumour suppressor miRNAs that are frequently down-regulated in lung cancer 
includes the let-7 family, miR-34 family, and miR-200 family. The let-7 family 
negatively regulates numerous oncogenes involved in cell proliferation and cell cycle 
regulation, including RAS, MYC, HMGA2 (high mobility group AT-hook 2), CDC25A 
(cell division cycle 25A), CDK6 and CCND2 (cyclin D2) (Johnson et al., 2005; Johnson 
et al., 2007; Kumar et al., 2007; Lee & Dutta, 2007). Meanwhile, the miR-34 family 
(miR-34a, miR-34b, miR-34c), also down-regulated in lung cancer, controls cell 
proliferation via inhibition of MET (hepatocyte growth factor receptor), BCL2, PDGFR-
α and PDGFR-β (platelet derived growth factor receptor). Another tumour suppressor 
down-regulated in lung cancer is the miR-200 family (miR-200a, miR-200b, miR-200c, 
and miR-429), which regulates the induction of epithelial-mesenchymal transition 
(EMT) via regulation of ZEB (zinc finger E-box-binding homeobox) transcription 
factors (ZEB1 and ZEB2), CDH1 (E-cadherin), and VIM (vimentin) (Ceppi et al., 2010; 
Takeyama et al., 2010). 
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Table 2.2: Principal microRNAs involved in the development or progression of lung 
cancer  
MicroRNAs Gene Targets Biological Processes 
Tumor suppressor microRNAs with down-regulation in lung cancer 
let-7 family RAS, HMGA2, CDK6, 
CCND2, MYC, DICER1 
(i) Cell proliferation (RAS, MYC, HMGA2) 
(ii) Cell cycle regulation (CDK6, CCND2) 
(iii) microRNA maturation (DICER1) 
miR‐34 family BCL2, PDGFRA, 
PDGFRB 
 
TRAIL‐induced cell death and cell 
proliferation 
miR-200 family ZEB1, ZEB2, E‐cadherin 
(CDH1), vimentin (VIM) 
Promotion of EMT and metastasis 
 
Oncogenic microRNAs with up‐regulation in lung cancer  
miR-21 PTEN, PDCD4, TPM1  Apoptosis, cell proliferation, and migration 
miR-17-92 cluster miR-17-92 cluster E2F1, 
PTEN, HIF1A  
Cell proliferation and carcinogenesis 
miR-221/222 miR-221/222 PTEN, 
TIMP3  
Apoptosis and cell migration 
(Reproduced from Journal of Clinical Medicine, Vol. 5, Inamura & Ishikawa, 
MicroRNA in Lung Cancer: Novel Biomarkers and Potential Tools for Treatment, 36, 
2016, licensed under CC BY 4.0). 
 
The expression of miRNAs has also been associated with prognosis and survival of 
lung cancer patients. Studies have reported that a lower let-7 expression and a higher 
expression of miR-155 in lung cancer in comparison to normal lung tissue were 
associated with poor prognosis in NSCLC patients (Takamizawa et al., 2004; Yanaihara 
et al., 2006). In 2008, a five-miRNA signature (let-71, miR-221, miR-137, and miR-
182*) was able to predict a poor overall and disease-free survival rates for lung cancer 
patients with high-risk scores in this miRNA signature (Yu et al., 2008). High 
expression of miR-146b has been associated with poor overall survival in squamous cell 
lung cancer patients (Raponi et al., 2009), whereby high expression of miR-16 is 
associated with better survival in lung cancer patients (Wang et al., 2013b). 
Furthermore, overexpression of miR-519c has been correlated with better prognosis, 
while low levels of miR-34a is associated with relapse in lung cancer patients (Cha et 
al., 2010; Wiggins et al., 2010). 
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Reports have also suggested that miRNA expression can be utilized to classify stages 
and subtypes of lung cancers. For instance, miR-205 is a useful marker to differentiate 
SCC from non-SCC NSCLCs with a sensitivity of 96% and specificity of 90% 
(Lebanony et al., 2009). Meanwhile, detection of miR-21, miR-486, miR-375 and miR-
200b in sputum samples, in combination, is one of the best predictors of lung 
adenocarcinoma with 81% sensitivity and 92% specificity (Yu et al., 2010). 
Furthermore, detection of miR-21 expression along with detection of four protein-
coding genes (XPO1, BRCA1, HIF1A, and DLC1) was able to independently classify 
stage 1 adenocarcinomas into two groups with different survival rates (Robles et al., 
2015).     
2.4.4 MiRNA and apoptosis 
Dysregulation of programmed cell death is a significant hallmark of tumour 
development and progression, and various studies have shown that miRNAs influence 
development of cancer through regulation of the apoptotic process (Jovanovic & 
Hengartner, 2006; Wang & Lee, 2009; Li et al., 2012a; Othman & Nagoor, 2014). As 
mentioned previously in section 2.3, the events that culminate in the activation of 
caspases can be categorized into the extrinsic and intrinsic pathways. The extrinsic 
pathway is activated through the binding of appropriate ligands to death receptors, and 
evidence has shown that these molecules are targets of various miRNAs, summarized in 
Figure 2.9. For example, miR-19a, a member of the miR-17-92 cluster, which is often 
overexpressed in lung cancers, targets TNF-𝛼 receptors to inhibit apoptosis (Liu et al., 
2011). On the other hand, miR-34a, miR-34c, and miR-212 are all down-regulated in 
NSCLC and ectopic expression of these miRNAs increases TRAIL-induced cell death 
to inhibit tumourigenesis (Incoronato et al., 2010; Garofalo et al., 2013). Lung cancer 
however, has also developed resistance to TRAIL-induced apoptosis through miRNA 
dependent mechanisms, such as, increased expression of miR-494a, miR-221, and miR-
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222, which impair TRAIL-induced apoptosis. Therefore, blocking of these miRNAs 
through anti-miR transfection resulted in TRAIL-sensitivity in NSCLC (Garofalo et al., 
2008; Romano et al., 2012). 
The intrinsic pathway is characterized by cytochrome c release as a result of the 
permeability of the outer mitochondrial membrane, which is controlled by the presence 
of pro- and anti-apoptotic members of the BCL-2 family of proteins. There are 
numerous miRNAs that have been reported to regulate the expression of various BCL-2 
family members (Figure 2.9). Anti-apoptotic BCL-2 is targeted by miR-503, miR-181b, 
miR-200b/c-429 cluster, miR-497, and miR-7, whose expressions are all down-
regulated in NSCLC cells. Ectopic expression of these miRNAs has been shown to lead 
to a significant reduction of Bcl-2 to induce apoptosis (Zhu et al., 2010; Xiong et al., 
2011; Zhu et al., 2012a; Zhu et al., 2012b; Qiu et al., 2013). BCL-XL, another anti-
apoptotic member, is targeted by let-7c (Cui et al., 2013), whereas miR-125b and miR-
335 suppresses anti-apoptotic BCL-W (Gong et al., 2013; Wang et al., 2013a). Pro-
apoptotic members of the BCL-2 family has also been demonstrated to be targeted by 
miRNAs up-regulated in NSCLC cells, such as, PUMA which is targeted by miR-
221/222 (Zhang et al., 2010a), BIM which is targeted by miR-494, miR-17, miR-30b, 
mR-30c, miR-221, miR-103, and miR-203 (Dai et al., 2011; Garofalo et al., 2011; 
Romano et al., 2012), and BMF and NOXA which are targets of miR-197 (Fiori et al., 
2014). 
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In lung cancer, another component of the intrinsic pathway targeted by miRNAs 
include APAF-1, which is a target of up-regulated miR-21 and miR-155 (Figure 2.9) 
(Kim et al., 2009; Zang et al., 2012; Fiori et al., 2014). Furthermore, BAX 
oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic 
maturation of caspase 9 and caspase 3 have been reported to be modulated by pre-miR-
181a and pre-miR-630 in A549 lung adenocarcinoma cell line (Galluzzi et al., 2010) 
Studies have shown that miRNAs are also able to interfere with apoptosis in lung 
cancer through regulation of the expression and activation of effector caspases. In A549 
lung cancer cells, ectopic expression of miR-1 and miR-15a-3p enhances the activation 
of caspase 3 and caspase 7 (Nasser et al., 2008). On the other hand, inhibition of miR-
133a/b and miR-361-3p was able to activate caspase 3 and caspase 7 in 95D lung cancer 
cells (Du et al., 2013). Furthermore, overexpression of miR-192 was able to inhibit cell 
viability in both in vitro and in vivo lung cancer studies (Feng et al., 2011).  
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Figure 2.9: Scheme depicting up- and down-regulated miRNAs in lung cancer and the 
roles they play in apoptosis (Reproduced from Biomed Research International, Vol. 
2014, Othman & Nagoor, 2014, The Role of MicroRNAs in the Regulation of 
Apoptosis in Lung Cancer and its Application in Cancer Treatment, Article ID 318030, 
with permission from Hindawi). 
2.4.5 MiRNA in cancer treatment 
The targeting of miRNAs as a therapeutic tool is very promising for applications in 
cancer medicine. The short sequences of mature miRNA have proven to be 
advantageous as they are almost always completely conserved across multiple 
vertebrate species. This makes them easy targets therapeutically, while also allowing the 
same miRNA-modulating compound to be used in preclinical efficacy and safety 
studies as well as in clinical trials (van Rooij & Kauppinen, 2014).  Furthermore, as 
miRNAs typically have multiple targets within the same signaling pathway, this may 
potentiate the efficacy of miRNA-based treatments, as they are able to modulate entire 
pathways in a disease state (van Rooij & Kauppinen, 2014; Pichler & Calin, 2015). In 
general, there are two approaches employed in the development of miRNA-based 
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therapies: (i) restoration of tumour suppressor miRNA to reverse the loss of miRNA 
function using synthetic double-stranded miRNA mimics or viral vector-based 
overexpression and (ii) down-regulation of oncogenic miRNAs through the 
administration of chemically-modified anti-sense nucleotides (anti-miR/ antagomiR or 
miRNA inhibitors) (Figure 2.10) (Krutzfeldt et al., 2005; Taylor & Schiemann, 2014).  
 
Figure 2.10: Modulation of miRNA activity by miRNA mimics and anti-miR 
oligonucleotides (Reproduced from EMBO Molecular Medicine, Vol. 6, van Rooij & 
Kauppinen, Development of MicroRNA Therapeutics is Coming of Age, 851-864, 
2014, licensed under CC BY 3.0). 
2.4.5.1 MiRNA mimics 
Utilization of miRNA mimics, also termed miRNA replacement therapy, allows for 
the exploitation of tumour suppressors as it reintroduces lost or down-regulated 
miRNAs in cancer cells, to reactivate pathways that are necessary for normal cellular 
welfare (Bader et al., 2010). MiRNA mimics are double stranded, with the strand 
identical to the miRNA of interest called the guide (anti-sense) strand, while the 
opposite strand is called the passenger (sense) strand. This passenger strand is less 
stable and is linked to a molecule, such as, cholesterol, to boost cellular uptake as well 
as chemical modifications to prevent RISC uptake (Chen et al., 2008; Garzon et al., 
2010; Bader et al., 2011; Thorsen et al., 2012). MiRNA mimics can be delivered 
systemically using technologies already available for therapeutic siRNAs. Furthermore, 
reports have suggested that miRNAs will be well tolerated in normal tissues as they 
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have the same sequence as endogenous miRNAs and will therefore target the same set 
of genes, thus eliminating non-specific off target effects (Bader et al., 2010).  
Based on reports of its strong in vitro tumour-suppressive effects, miR-34, which is 
frequently silenced in lung cancer, has been a focus for clinical trials. MiR-34 mimics, 
using a lipid-based delivery vehicle distributed locally or systemically, was able to 
block tumour growth in mouse models of NSCLC (Wiggins et al., 2010). The anti-
oncogenic effects observed were accompanied by an increase of miR-34 expression in 
tumour tissues along with down-regulation of its direct targets (Wiggins et al., 2010). In 
2013, MiRNA Therapeutics announced that a liposome-formulated miR-34 mimic-
based drug, called MRX34, was going to enter phase 1 study for patients with primary 
liver cancer or metastatic cancer with liver involvement, thus becoming the first miRNA 
mimic to advance into the clinical phase (Bouchie, 2013).  
Another tumour suppressor miRNA of interest was let-7, which is frequently down-
regulated in lung cancer. Studies have shown that intranasal administration of let-7 
mimics induced a significant reduction in tumour growth in lung cancer xenograft 
models (Esquela-Kerscher et al., 2008; Kumar et al., 2008; Trang et al., 2010; Trang et 
al., 2011). This suggests that let-7 replacement therapy may have potential as a 
therapeutic treatment in humans. Other prospective miRNAs for therapeutic lung cancer 
treatment include miR-7, miR-29b, miR-34a, miR-145, miR-150, and miR-200c (Table 
2.3).  
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2.4.5.2 MiRNA inhibitors 
Mature miRNAs can be inhibited by anti-sense nucleotides (antagomiRs), thereby 
inducing their degradation or inhibition of their function. AntagomiRs are single 
stranded oligonucleotides that have miRNA complementary sequences with chemically 
modified backbones to enhance thermal stability, binding affinity, and specificity 
(Meister et al., 2004). Addition of 2’-O-methyl-group or locked nucleic acid (LNA) 
constructs have been shown to improve miRNA stability and affinity towards 
endogenous miRNA, and sequesters them to prevent processing by RISC (Krutzfeldt et 
al., 2005).  
An example of an antagomiR used in lung cancer studies is anti-miR-150 expression 
vector (PR-ASO-150) (Table 2.3). A study demonstrated that PR-ASO-150 was able to 
inhibit A549 lung cancer cell proliferation and induce apoptosis in vitro. Furthermore, 
administration of PR-ASO-150 intratumourally into lung tumour xenografts in nude 
mice led to inhibition of tumour growth (Li et al., 2012c). 
Table 2.3: Pre-clinical miRNA-based therapeutic strategies for lung cancer 
miRNA Administration Modulation 
Strategy 
Delivery 
Technology 
References 
let-7 
Intravenous Replacement Neutral liposomes (Trang et al., 2011) 
Intranasal Replacement Adenoviruses (Esquela-Kerscher et 
al., 2008) 
Intratracheal Replacement Lentiviruses (Kumar et al., 2008) 
miR-200c Intravenous Replacement Liposomes (NOV340) (Cortez et al., 2014) 
miR-29b Intravenous Replacement Cationic liposomes (Wu et al., 2013b) 
miR-145 Intratumoral Replacement PEI (Chiou et al., 2012) 
miR-150 Intratumoral Inhibition Cationic liposomes (Li et al., 2012c) 
miR-7 Intratumoral Replacement Cationic liposomes (Rai et al., 2011) 
miR-34a Intratumoral Replacement Neutral liposomes (Wiggins et al., 2010) 
(Reproduced from International Journal of Molecular Sciences, Vol. 16, Fujita et al., 
Development of Small RNA Delivery Systems for Lung Cancer Therapy, 5254-5270, 
2015, licensed under CC BY 4.0). 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Cell lines 
3.1.1 Cell lines and culture conditions 
Human lung adenocarcinoma cell lines A549 (Cancer Research Initiative Foundation 
(CARIF), Sime Darby Medical Centre, Malaysia) and SK-LU-1 (AseaCyte Sdn. Bhd., 
Malaysia) were cultured in Roswell Park Memorial Institute 1640 medium (RPMI-
1640) (Hyclone, GE Healthcare Life Sciences, USA) and minimum essential medium 
(MEM) α (Gibco, USA), respectively. Both culture mediums were supplemented with 
10% (v/v) heat inactivated fetal bovine serum (FBS) (JR Scientific Inc., USA). Cells 
were grown as a monolayer and maintained in a carbon dioxide (CO2) incubator 
(Memmert, Germany) with high relative humidity (95.0%), stable temperature (37°C), 
controlled CO2 levels (5.0%) and controlled pH (7.2 – 7.4). 
3.1.2 Sub-culturing cell line monolayers: harvesting a cell monolayer 
The cell lines were split every two to three days, or when 80.0 – 90.0% confluency 
was achieved on the culture flask surface. Spent culture medium was removed and 
discarded using a serological pipette. The cell monolayer was rinsed with sterile 
autoclaved 1 × phosphate buffered saline (1 × PBS) to remove any residual serum that 
could inactivate trypsin activity. PBS was removed and discarded using a serological 
pipette. 3.0 ml of dissociating agent, 0.25% trypsin (Sigma-Aldrich, USA) 
ethylenediaminetetraacetic acid (EDTA) (Thermo Fisher Scientific, USA), was added to 
the culture flask. The culture flask was incubated in 37°C in the CO2 incubator for 
approximately 10 min to allow the cells to detach from the bottom of the flask. The 
progress of cell detachment was checked every 5 min using an inverted fluorescence 
microscope (Nikon, Japan). Once cells were detached, equal volume of culture medium 
was added to the culture flask to inactivate trypsin activity and the suspension was 
transferred to a labeled 15.0 ml Falcon tube and centrifuged for 5 min at 1,500 RPM 
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using the Eppendorf Centrifuge 5702 (Eppendorf, Germany). The supernatant in the 
tube was discarded and the cell pellet was resuspended in fresh culture medium. The 
cell suspension was either collected for counting or divided into prepared culture flasks 
for routine maintenance of cell lines. For routine maintenance of cell lines, 2.0 ml of 
cell suspension was transferred to a new T-25 cm2 culture flask with 3.0 ml of fresh 
culture medium and stored at 37°C in the CO2 incubator.  
3.1.3 Cell counting 
A dye exclusion viability assay using a haemocytometer was used to determine the 
number of cells present in a specific population. Cell suspension was gently mixed and 
20.0 µL of the suspension was aliquoted into a 1.5 ml microcentrifuge tube and 20.0 µL 
of 0.08% tryphan blue stain (Sigma-Aldrich, USA) was added to this aliquot and mixed 
well. The tube was left to stand for about 3 min, after which 10.0 µL of the mixture was 
removed and loaded on to a clean haemocytometer (Resistance, Germany) chamber to 
be counted. The counting was conducted under the inverted microscope at 100× 
magnification. Dead cells appeared blue, while viable cells appeared as unstained bright 
spheres. The number of cells in each of the four square grid corners was counted and the 
average number of cells was obtained. Each square grid represents 0.1 mm3 or 10-4 ml 
volume, and the concentration of cells was determined according to the following 
formula, with a dilution factor of two.  
Cell Concentration cell ml = Avg.Number of Cells CountedVolume Counted ml × Dilution Factor 
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3.2 BCL-XL silencing via short interfering RNA (siRNA) transfection 
Silencing of the BCL-XL gene was performed using the Stealth RNAi™ siRNA 
Duplex Oligunucleotides (Invitrogen, USA) (Table 3.1), according to a modified 
version of the manufacturer’s protocol. One day prior to transfection, 1.5 × 105 cells 
were plated in 2.0 ml of appropriate medium in a 6-well plate (SPL Life Sciences, 
Korea). For each transfection sample, a Stealth RNAi™ -Lipofectamine™ 2000 complex 
was prepared as follows: 1.25 µL of 20.0 µM of Stealth RNAi™ oligonucleotide was 
diluted in 250.0 µL of Opti-MEM® I Reduced Serum Medium (Invitrogen, USA) to 
prepare the final concentration of 100.0 nM, and mixed gently (Tube 1). 5.0 µL of 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen, USA) was diluted in 250.0 µL 
of Opti-MEM® I Reduced Serum Medium and mixed gently (Tube 2). Both solutions 
were left to incubate for 15 min at room temperature. After incubation, contents of Tube 
1 and Tube 2 were combined and mixed gently. The combined solution was incubated 
for 15 min at room temperature to allow complexes to form. The complex was then 
added to the 6-well plate containing cells and 1.5 ml culture medium. The plate was 
mixed gently by rocking back and forth, and the cells incubated at 37°C in a humidified 
CO2 incubator for 24 h. The same procedure was carried out with the Stealth RNAi™ 
siRNA Negative Control Low GC (Invitrogen, USA), Stealth RNAi™ siRNA Negative 
Control High GC (Invitrogen, USA), as well as the BLOCK-iT™ Alexa Fluor® Red 
Fluorescent Oligo (Invitrogen, USA). At 24 h post-transfection, total RNA was 
extracted using the miRNeasy® Mini Kit to determine the silencing efficiency of the 
siRNAs. 
Table 3.1: Stealth RNAi™ siRNA Duplex Oligonucleotides used for transfection 
Name  Sequence 
siRNA 1 UCA CUA AAC UGA CUC CAG CUG UAU C 
siRNA 2 AUG GGU UGC CAU UGA UGG CAC UGG G 
siRNA 3 AUC ACC UCC CGG GCA UCC AAA CUG C 
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3.3 Total RNA extraction 
3.3.1 Guanidinium isothiocyanate acidic phenol extraction using TRIzol® 
Reagent (Invitrogen, USA) 
 
Transfected cells were harvested by trypsinization and centrifugation and cell pellet 
was resuspended in 1.0 ml of TRIzol® reagent. The cell lysate was passed through a 
pipette several times. The homogenized sample was transferred to a 1.5 ml 
microcentrifuge tube and incubated for 5 min at room temperature to allow for complete 
dissociation of nucleoprotein complexes. 0.2 ml chloroform (J.T. Baker, USA) was 
added and the tubes capped securely. The tubes were shaken vigorously by hand for 15 
sec and incubated at room temperature for 3 min. The tubes were then centrifuged at 
12,000 × g for 10 min at 4°C in the Sorvall Legend Micro17R (Thermo Fisher 
Scientific, USA) refrigerated centrifuge. Following centrifugation, the mixture 
separated into a lower red phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase. RNA remains exclusively in the aqueous phase. The volume of the 
aqueous phase was about 60.0% of the volume of TRIzol® reagent used for 
homogenization.  
The aqueous phase was transferred to a fresh tube. The RNA was precipitated from 
the aqueous phase by mixing with 0.5 ml isopropanol (Merck, Germany). The samples 
were incubated at room temperature for 10 min and then centrifuged at 12,000 × g for 
10 min at 4°C. The supernatant was removed and the pellet washed once with 1.0 ml of 
75.0% ethanol (J.T. Baker, USA). The sample was mixed by vortexing and then 
centrifuged at 7,500 × g for 5 min at 4°C. 
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  After centrifugation, the supernatant was removed and the RNA pellet was air-
dried for about 5-10 min. The RNA samples were dissolved in nuclease-free water 
(Qiagen, Germany) by passing the solution a few times through a pipette tip, and 
incubated for 10 min in the water bath incubator (Memmert, Germany) at 58°C. 
3.3.2 Silica membrane column-based extraction using miRNeasy® Mini Kit 
(Qiagen, USA) 
 
Transfected cells were harvested by trypsinization and centrifugation and cell pellet 
was resuspended in 700.0 µL QIAzol Lysis Reagent (Qiagen, USA). The sample was 
transferred to a centrifuge tube and homogenized by passing through a pipette several 
times and vortexed vigorously for 15 sec. The homogenate was incubated at room 
temperature for 5 min, 140.0 µL chloroform was added and the tube capped securely. 
The tube was shaken vigorously for 15 sec and left to incubate at room temperature for 
2-3 min. The tube was then centrifuged for 15 min at 12,000 × g at 4°C. The upper 
aqueous phase was transferred to a new collection tube and 1.5 volumes (≈ 525.0 µL) of 
100.0% ethanol was added and mixed thoroughly by pipetting. 700.0 µL of sample was 
pipetted, including any precipitate, into an RNeasy® Mini column (Qiagen, USA) in a 
2.0 ml collection tube. The tube was centrifuged at 8,000 × g for 15 sec, and the flow-
through was discarded. This step was repeated for the remainder of the sample. 700.0 
µL Buffer RWT (Qiagen, USA) was added to the RNeasy® Mini column and 
centrifuged for 15 sec at 8,000 × g and the flow-through discarded. 500.0 µL Buffer 
RPE (Qiagen, USA) was pipetted onto the RNeasy® Mini column and centrifuged at 
8,000 × g and the flow-through discarded. Another 500.0 µL Buffer RPE was added to 
the RNeasy® Mini column and then centrifuged for 2 min at 8,000 × g. The RNeasy® 
Mini column was placed into a new 2.0 ml collection tube and centrifuged at full speed 
for 1 min to further dry the membrane. The RNeasy® Mini column was transferred to a 
new 1.5 ml collection tube and 30.0-50.0 µL RNase-free water was pipetted directly 
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onto the RNeasy® Mini column membrane. The tube was centrifuged for 1 min at 8,000 
× g to elute the RNA. 
3.4 RNA quantitation and quality check 
3.4.1 Quantitation of RNA using NanoDrop 2000 (Thermo Fisher Scientific, 
USA) 
 
The concentration and purification of extracted RNA was analyzed using the 
NanoDrop 2000. When the arm was open 1.0 µL of distilled water was pipetted directly 
on the pedestal and used as a blank. When the measurement was complete, the surfaces 
were wiped with a lint-free KimWipe before going on to the next sample. The RNA 
concentration, OD260, OD280, A260/280, and A260/230 ratio of the samples were measured.  
3.4.2 Determination of RNA integrity using Agilent 2200 TapeStation System 
(Agilent Technologies, Germany) 
 
The quality of extracted RNA was analyzed using the Agilent 2200 TapeStation. 4.0 
µL R6K sample buffer was mixed with 1.0 µL RNA sample. The samples were 
denatured by heating at 72°C for 3 min. The samples were then placed on ice for 2 min 
and briefly centrifuged to allow the contents to collect in the base of the tubes. The 
Agilent 2200 TapeStation software was launched and the samples, ScreenTape R6K and 
loading tips were loaded into the Agilent 2200 TapeStation. The required samples were 
selected on the controller software and the RNA concentration (ng/µL) and RNA 
integrity number (RIN value) of the samples was measured.  
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3.5 Quantification of BCL-XL expression using quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) 
 
3.5.1 Reverse transcription polymerase chain reaction (RT-PCR) 
First strand cDNA was synthesized for use in qRT-PCR using the SuperScript III 
First-Strand Synthesis SuperMix (Invitrogen, USA). The following kit components 
(Table 3.2) were combined on ice. For multiple reactions, a master mix without RNA 
was prepared.  
Table 3.2: Kit components used to prepare cDNA samples 
Component Volume 
2× RT Reaction Mix 10 µL 
RT Enzyme Mix 2 µL 
RNA (up to 1 µg) χ   µL 
DEPC treated water to 20 µL 
 
The tube contents were gently mixed and incubated at room temperature for 10 min. 
The tubes were then incubated at 50°C for 30 min, and the reaction terminated at 85°C 
for 5 min. The tubes were chilled on ice and 1.0 µL of Escherichia coli (E. coli) RNAse 
H was added and the tubes incubated at 37°C for 20 min. The cDNA was then used in 
qPCR. 
3.5.2 Quantitative polymerase chain reaction (qPCR) 
The Platinum® SYBR® Green qPCR SuperMix-UDG with ROX (Invitrogen, USA) 
was used to carry out qPCR. The primers used for qPCR was purchased from First Base 
Laboratories Sdn Bhd, Malaysia (Table 3.3). For each qPCR reaction the following 
components were added to a 0.2 ml microcentrifuge tube. The volumes for a single 50 
µL reaction are listed in Table 3.4. For multiple reactions, a master mix of common 
components was prepared and the appropriate volume added to each tube, and the 
unique reaction components (eg. template) was then added. 
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Table 3.3: Oligonucleotides used for qPCR determination of BCL-XL expression 
Name Sequence Length 
BCL-XL Forward 5’-CGT GGA AAG CGT AGA CAA GGA – 3’ 21 
BCL-XL Reverse 5’ –ATT CAG GTA AGT GGC CAT CCA A– 3’ 22 
β-actin Forward 5’ –AAG CCA CCC CAC TTC TCT CTA A– 3’ 22 
β-actin Reverse 5’ –ACC TCC CCT GTG TGG ACT TG– 3’ 20 
 
Table 3.4: Kit components used to prepare qPCR samples 
Component Volume 
Platinum® SYBR® Green qPCR SuperMix-UDG with ROX 25 µL 
Forward primer, 10 µM 1 µL 
Reverse primer, 10 µM 1 µL 
Template (cDNA generated from 10 pg to 1 µg of total RNA) ≤ 10 µL 
DEPC-treated water to 50 µL 
 
The reaction tubes were capped and gently mixed. The reactions were then placed 
into a preheated real-time instrument, the CFX96™ Real-Time PCR Detection System 
(Bio-Rad Laboratories, USA), and programmed as described in Table 3.5.  
Table 3.5: Real-time PCR instrument conditions 
50°C for 2 minutes hold (UDG incubation) 
90°C for 2 minutes 
40 cycles of: 95°C, 15 seconds 
                      60°C, 30 seconds 
Melting curve analysis 
 
3.6 Protein expression analysis 
3.6.1 Protein isolation using NE-PER® Nuclear and Cytoplasmic Extraction Kit 
(Pierce, USA) 
 
NE-PER® Nuclear and Cytoplasmic Extraction Kit was used to extract the 
cytoplasmic protein from the whole cell lysate. This kit contains three reagents, 
Cytoplasmic Extraction Reagent I (CER I), Cytoplasmic Extraction Reagents II (CER 
II) and Nuclear Extraction Reagent (NER). 1 × Halt™ Protease (Thermo Fisher 
Scientific, USA) and 1 × Phosphatase inhibitor cocktails (Thermo Fisher Scientific, 
USA) were freshly prepared and added to CER I and NER in 1:1,000 dilution to prevent 
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proteolysis and dephosphorylation.  
Cells were harvested by trypsinization and centrifugation, the supernatant in the tube 
was discarded and the pellet resuspended in 100.0 µL ice cold CER I and vortexed 
vigorously for 15 sec to fully resuspend the pellet. The tube was then incubated on ice 
for 10 min. 5.5 µL of ice cold CER II was added to the tube and vortexed for 5 sec. The 
tubes were incubated on ice for 1 min and then vortexed again for 5 sec. The tubes were 
then centrifuged at 16,000 × g for 5 min using the Sorvall Legend Micro 17R 
refrigerated centrifuge and the supernatant containing the cytoplasmic extract was 
transferred to a new pre-chilled tube. The protein solution was used immediately for 
western blotting, otherwise the solubilized proteins was stored at -20°C and the heating, 
centrifugation steps performed at the time of use. 
3.6.2 Protein concentration quantification using Pierce® bicinchoninic acid 
(BCA) protein assay kit (Thermo Fisher Scientific, USA) 
 
The Pierce BCA Protein Assay Kit was used to determine the protein concentration 
of extracted protein samples. Table 3.6 was used to prepare a set of protein standards. 
The contents of one Albumin Standard (BSA) ampule were diluted into several clean 
microcentrifuge tubes. Final BSA concentrations of 2,000, 1,500, 1,000, 750, 500, 250, 
125, and 25 µg/ml were used to create a standard curve. This allows for the 
determination of the unknown sample’s concentration.  
A BCA working reagent was prepared by mixing 50 parts of BCA Reagent A with 1 
part of BCA Reagent B (50:1, Reagent A: Reagent B). 10.0 µL blank, standards and 
samples were diluted with 200.0 µL of working reagent and mixed thoroughly in a 
microcentrifuge tube. The tubes were incubated at 37°C for 30 min. The tubes were 
cooled to room temperature and absorbance was measured at 562 nm using the 
NanoDrop 2000. After obtaining the sample’s concentration, samples were normalized 
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to the same concentration with nuclease free water. All samples were kept at -20°C 
freezer until further use.  
Table 3.6: Preparation of diluted albumin (BSA) standards 
Vial Volume of Diluent (µL) 
Volume and Source of BSA 
(µL) 
Final BSA 
Concentration (µg/ml) 
A 0 300 of Stock 2,500 
B 125 375 of Stock 1,500 
C 325 325 of Stock 1,000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = Blank 
 
3.6.3 Protein sample preparation 
Antibodies typically recognize a small portion of the protein of interest (epitope), and 
this domain may reside within the three dimensional conformation of the protein. To 
enable access of the antibody to this portion it is necessary to denature the protein. Lane 
Marker Reducing Sample Buffer (5×) (Thermo Fisher Scientific, USA) contains 
dithiothreitol (DTT) as a reducing agent to reduce disulphide bridges within tertiary 
protein structures to produce primary protein structures. The sample buffer also contains 
sodium dodecyl sulfate (SDS), which binds to the polypeptides to form complexes with 
fairly constant negative charge to mass ratios. The electrophoretic migration rate 
through the gel is therefore determined only by the size of the complexes.  
First, cytoplasmic protein samples and the Lane Marker Reducing Sample Buffer 
(5×) were equilibrated to room temperature. Cytoplasmic protein concentrations were 
diluted using distilled H2O (dH2O) to a final concentration of 1.0 µg/ml. A final volume 
of 20.0 µL of cytoplasmic protein samples was mixed with 5.0 µL sample buffer. These 
mixtures were vortexed before boiling for 5 min at 95°C using a thermal cycler, and 
then cooled to room temperature.  
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3.6.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a technique for separating proteins according to their molecular 
weight. The separation of protein molecules within a gel is determined by relative size 
of the pores formed within the gel. 12.0% resolving gel was used to separate proteins 
ranging from 14 – 70 kDa. 4.0% stacking gel and 12.0% resolving gel was prepared by 
mixing together the reagents listed in Table 3.7. Freshly prepared 10.0% (w/v) 
ammonium persulfate (APS) was added last to the mixture to initiate gel 
polymerization. Bromophenol blue, an anionic small molecule, was added to the 
stacking gel and functioned as a tracking dye, which monitored the migration front of 
the proteins.  
 18.0 cm × 16.0 cm, with 1.0 mm thickness glass plates (Bio-Rad, USA) were 
aligned and clipped to the casting tray (Bio-Rad, USA). The resolving gel was prepared 
and loaded until 75.0% of the glass was filled. The remaining resolving gel solution was 
kept in a tube rack as an indicator of complete gel polymerization, which takes 
approximately 30 min. Immediately after adding the resolving gel, 0.1% (v/v) SDS was 
added gently on top of the resolving gel to prevent oxidization and dehydration of the 
gel, which can slow down the polymerization process. After polymerization was 
complete, 0.1% SDS solution was rinsed out by tilting the casting tray and blotting out 
the solution with Kim-wipes.  
 The desired volume of 10.0% APS was added into the stacking solution. The 
solution was mixed well and added immediately to the cast above the resolving gel. The 
stacking solution was ensured to completely fill 100.0% of the glass plate until it 
overflows. A 10-well gel comb with a 1.0 mm thickness was inserted at an angle to 
prevent formation of air bubbles. The remaining stacking gel solution was kept in a tube 
rack as an indicator of complete polymerization (approximately 30 min).  
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Table 3.7: Reagents for preparation of stacking resolving gel for SDS-PAGE 
Reagent 
Stacking 
Gel (4.0%) 
(µL) 
Resolving 
Gel (12.0%) 
(µL) 
40% Acrylamide (Promega, USA) 500  4,500  
0.5M Tris-HCl (pH 6.8) 1,260  - 
1.5M Tris-HCl (pH 8.8) - 3,750 
10% SDS 50  150  
Distilled H2O (dH2O) 3,150  6,517.5  
Tetramethyl-ethylenediamine (TEMED) (Acros, USA) 5  7.5  
10%  (w/v) Fresh Ammonium Persulfate (APS) 25  75  
Bromophenol Blue (Fisher Scientific, USA) 10  - 
Total Volume  5,000 15,000  
 
3.6.5 Protein sample loading and running the gel 
The glass plates were transferred to the Mini PROTEAN Tetra System (Bio-Rad, 
USA) and placed in the holder facing each other. The space between the gels was filled 
fully with 1 × Tris/Glycine/SDS (TGS) running buffer. The comb was gently removed 
and the wells were flushed with TGS buffer to allow the wells to form properly and to 
rinse off traces of unpolymerized gel. The tank was filled with sufficient amount of 
buffer according to the number of gels being run. 5.0 µL of biotinylated protein ladder 
(Cell Signaling Technology, USA) was loaded into the first well (Protein ladder sizes 
are listed in Appendix B). 20.0 µL of protein samples pre-mixed with sample buffer was 
then added to subsequent wells. Gels were run at 110 volts with 400 mA until the 
sample front reached the resolving gel (approximately 15 min), followed by 150 volts 
with 400 mA until the end of the gel. Power supply was provided by the Power Pack 
(Bio-Rad, USA).  
3.6.6 Western blot electrotransfer 
The 2.0 µm nitrocellulose membrane (Bio-Rad, USA) and the extra thick blot paper 
(Bio-Rad, USA) were cut to the same size as the gel or slightly larger than the gel. The 
membrane and filter papers were soaked in transfer buffer made up of 1 × TGS with 
20% (v/v) methanol (Merck, Germany), for 10 min. Once the SDS-PAGE has finished 
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running, the glass was removed from the tank carefully. The upper glass was removed 
using a plastic spatula. Using a delicate task wiper, the stacking gel was carefully torn 
away from the resolving gel. The glass plate was then inverted over the transfer buffer 
and lifted so that the surface tension will peel the gel from the glass plate. The gel was 
soaked in transfer buffer for at least 10 min. The “transfer sandwich” was then placed in 
the Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, USA). Each layer of the sandwich 
was rolled out to ensure no air bubbles were formed. Transfer of proteins from gel to 
membrane was run at 50 mA at 25 volts for 90 min using the MP-2AP Power Supply 
(Major Science, Taiwan). 
Transfer sandwich: 
Cathode ( – ) 
Blot paper 
PAGE gel 
Nitrocellulose membrane 
Blot paper 
Anode ( + ) 
After transferring, the membrane was stained with 0.1% (w/v) Ponceau S (Sigma 
Aldrich, USA) for 30 sec to check the efficiency of proteins transferred. After 
observation, the membrane was washed twice with dH2O by shaking slowly on the 
Reciprocal Shaker MS-RC (Major Science, Taiwan) for 2 min each. The membrane was 
then blocked for 1 h at room temperature with agitation in blocking buffer containing 
5.0% (w/v) non-fat skim milk powder (Merck, Germany), 0.05% (v/v) Tween 20 
(Promega, USA) in 1 × tris-buffered saline (TBS), to prevent non-specific binding of 
the primary and secondary antibodies to the membrane. 
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The blocked membrane was washed with TBS with Tween 20 (TBST) buffer three 
times, 5 min each. The membrane was then incubated in primary antibody at 
appropriate dilution in 10.0 ml primary antibody dilution buffer for 1 h at room 
temperature with gentle agitation, followed by 4°C overnight. The following day the 
membrane was incubated at room temperature for 1 h with gentle agitation. The 
membrane was then washed three times with 1 × TBST, 5 min each wash. Antibody 
concentration was determined according to manufacturer’s protocol as mentioned in 
Table 3.8. 
The membrane bound with primary antibody was then probed with anti-rabbit IgG 
HRP-linked antibody (Cell Signaling Technology, USA) and anti-biotin HRP-linked 
antibody (Cell Signaling Technology, USA) at a dilution of 1:1:1000 in appropriate 
secondary antibody dilution buffer, for 1 h at room temperature with gentle agitation 
(Table 3.8). The membranes were then washed three times with 1 × TBST buffer for 5 
min with agitation, followed by a single wash with 1× TBS buffer for 5 min, with 
agitation.  
Table 3.8: Antibodies dilution buffer and dilution ratio 
Antibody Dilution Buffer Dilution 
GAPDH (14C10) Rabbit mAb 5% w/v BSA, 1×TBS, 0.1% Tween 20 1:10,000 
BCL-XL (54H6) Rabbit mAb 5% w/v nonfat dry milk, 1×TBS, 0.1% Tween 20 1:1,000 
AKT (pan) (C67E7) Rabbit mAb 5% w/v BSA, 1×TBS, 0.1% Tween 20 1:1,000 
SMAD2 (86F7) Rabbit mAb 5% w/v nonfat dry milk, 1×TBS, 0.1% Tween 20 1:1,000 
Anti-rabbit IgG, HRP-linked 5% w/v BSA, 1×TBS, 0.1% Tween 20 1:1,000 
Anti-biotin, HRP-linked 5% w/v BSA, 1×TBS, 0.1% Tween 20 1:1,000 
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3.6.7 Exposure of membrane using charged couple device (CCD) camera 
Western Bright Quantum (Advansta, USA) is a high-sensitivity substrate that reacts 
with horseradish peroxidase (HRP) conjugated to the secondary antibodies on the 
membrane by releasing chemiluminescence signal. The kit utilized contained two 
solutions and the working solution was prepared by mixing equal parts of each 
component. The membrane was incubated in the working solution for 2 min and the 
excess substrate on the membrane was blotted away. Bands were then visualized under 
a CCD camera using a chemiluminescent imaging system, the Fusion FX7 system 
(Vilber Lourmat, France) and quantified using the ImageJ v1.48 Analyst software 
(National Institutes of Health, USA) with band intensities normalized to GAPDH. 
3.7 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenltetrazolium bromide (MTT) cell 
viability assay 
 
Cells were harvested by trypsinization and centrifugation, and then re-suspended 
with appropriate culture medium. Using a dye exclusion viability assay, viable cells 
were counted and 1.0 × 104 cells in 100 µL of medium were plated in triplicates onto a 
96-well microtiter plate (Thermo Fisher Scientific, USA). The plate was incubated at 
37°C overnight in a CO2 incubator to allow for cell attachment to the well surface. 
Commencement of siRNA transfection was carried out at 100.0 nM at various 
incubation periods (12 h, 24 h and 48 h). Wells containing Stealth RNAi™ siRNA 
Negative Control Low GC were used as negative controls and solvent controls using 
Opti-MEM® I Reduced Serum Medium and Lipofectamine™ 2000 Transfection Reagent 
were conducted to ensure that decrease in cell viability was not solvent induced. Wells 
containing cells at descending concentrations (10,000 cells, 5,000 cells, 2,500 cells, 
1,250 cells and 0 cells) via a serial dilution was used to construct standard curves for 
quantification purposes. 
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Following incubation, 20.0 µL MTT reagent (5.0 mg/ml) (Calbiochem, USA) was 
added to each well and incubated in the dark at 37°C for 1 h. Periodically cells were 
viewed under an inverted microscope for the presence of purple formazon crystals at the 
bottom of each well. When the purple formazon crystals were clearly visible under the 
microscope, the media containing MTT reagent was aspirated and 200.0 µL of dimethyl 
sulfoxide (DMSO) (Merck, Germany) was added to dissolve the purple formazon 
precipitates. After a few minutes at room temperature, to allow for the complete color 
stabilization of the formazon compound, results were obtained using a microtiter plate 
reader (Tecan Sunrise®, Switzerland) at 570 nM absorbance wavelength and 650 nM 
reference wavelength. The results were then quantified using the Magellan Version 6.3 
(Tecan, Switzerland) software. 
3.8 Annexin V-FITC apoptosis detection assay 
The FITC annexin V apoptosis detection kit (BD Biosciences, USA) was used to 
quantitatively determine the percentage of cells within the population that are actively 
undergoing apoptosis. The kit was made up of three components: 10 × Annexin V 
Binding Buffer, FITC Annexin V and Propidium Iodide (PI) Staining Solution. 
At 72 h post-transfection media from the wells was transferred to a 15 ml Falcon 
tube and placed on ice. This media contains cells that have become detached from the 
wells during the cell death process. The remaining adherent living cells in the wells was 
then gently washed with 1.0 ml 1 × PBS. 1.0 ml 0.25% trypsin EDTA was added and 
the plate incubated for 5 min at 37°C or until the cells appear to be detached when 
evaluated under the microscope. 1.0 ml appropriate media, containing 10.0% FBS, was 
added to deactivate trypsin. Cells were then resuspended in the culture medium that was 
previously transferred into the Falcon tube and centrifuged at 1,500 RPM for 10 min. 
The supernatant was discarded and 500.0 µL of cold PBS was added and the tube 
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centrifuged at 3,263 RPM for 5 min. 
PBS was removed from the tubes and 100.0 µL cold 1 × binding buffer was added 
followed by 5 µL of FITC annexin V and 5 µL propidium iodide. The samples were 
gently vortexed and incubated for 15 min at room temperature in the dark. Another 
400.0 µl of 1 × binding buffer was added to each sample and signals were detected from 
1.0 × 104 cell population using the BD FACSCanto™ II flow cytometer (BD 
Biosciences, USA) and examined on the BD FACSDiva™ (BD Biosciences, USA) 
software.  
3.9 Detection of caspase 3/7 activation 
The Caspase-Glo® 3/7 assay (Promega, USA) is a homogeneous, luminescent assay 
that measures the activities of caspase 3 and 7, which play key effector roles in 
apoptosis. The assay contains two components, the Caspase-Glo® 3/7 buffer and the 
Caspase-Glo® 3/7 substrate (lyophilized). Prior to starting the experiment, the Caspase-
Glo® 3/7 buffer and Caspase-Glo® 3/7 substrate was equilibrated to room temperature 
and the contents of the Caspase-Glo® buffer bottle was transferred to the amber bottle 
containing Caspase-Glo® 3/7 substrate. The contents were mixed by swirling and 
inverting until the substrate is thoroughly dissolved to form Caspase-Glo® 3/7 reagent. 
48 h post-transfection cells were harvested by trypsinization and centrifugation, and 
then re-suspended in a 1:1 ratio of 50.0 µl 1 × PBS and 50 µl of Caspase-Glo® 3/7 
reagent. Samples were incubated at room temperature for 1 h in the dark and 
luminescence was then detected using the GloMax Multi Luminescence Multimode 
Reader (Promega, USA). 
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3.10 Cell cycle analysis 
Cell-cycle analysis was performed by flow cytometry using the BD CycletestTM Plus 
DNA Kit Assay (BD Biosciences, USA) 48 h post-transfection. This kit contains 3 
solutions: Solution A, which contains trypsin in a spermine tetrahydrochloride detergent 
buffer for the enzymatic disaggregation of solid tissue fragments and digestion of cell 
membranes and cytoskeletons; Solution B, which contains trypsin inhibitor and 
ribonuclease A in citrate-stabilizing buffer with spermine tetrahydrochloride to inhibit 
trypsin activity and to digest RNA; and Solution C which contains PI and spermine 
tetrahydrochloride in citrate stabilizing buffer. 
48 h post-transfection cells were harvested by trypsinization and centrifugation, and 
then resuspended in 1.0 ml 1 × PBS before being centrifuged again at 400 × g for 5 min. 
The supernatant was decanted and 250.0 µL Solution A was added and gently mixed by 
tapping. Samples were incubated at room temperature for 10 min, followed by addition 
of 200.0 µL of Solution B and incubated a further 10 min at room temperature. Lastly, 
200.0 µL of cold Solution C was added and samples were incubated on ice for 10 min. 
Signals were detected from 1.0 × 104 cell population using the BD FACSCanto™ II 
flow cytometer (BD Biosciences, USA) and examined on the BD FACSDiva™ (BD 
Biosciences, USA) software. Results were analyzed using the ModFit LT v3.2.1 (Verity 
Software House, USA) and the percentage of cells in G0/G1, S, and G2/M phase were 
counted and compared. 
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3.11 Quantification of miRNA expression using reverse transcription-
quantitative real-time polymerase chain reaction (RT-qPCR) using 
TaqMan® MicroRNA Assays 
 
The primers used for RTq-PCR was obtained from Applied Biosystems, USA (Table 
3.9). 
Table 3.9: TaqMan® MicroRNA Assays used for qRT-PCR 
Assay ID Accession Number Assay Name 
000480 MIMAT0000256 hsa-miR-181a  
001998 MIMAT0003886 hsa-miR-769-5p  
000554 MIMAT0000703 hsa-miR-361-5p  
002874 MIMAT0005892 hsa-miR-1304-5p  
001571 MIMAT0003276 hsa-miR-608  
001093 - U6  
 
3.11.1 Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the TaqMan® MicroRNA Reverse Transcription Kit 
(Applied Biosystems, USA) according to a modified version of the manufacturer’s 
protocol. The components of the kit were first allowed to thaw on ice. The RT master 
mix was then prepared by combining the components listed in Table 3.10.  
Table 3.10: Kit components used to prepare RT master mix 
Component Master mix volume per 10 µL 
reaction* 
100 nM dNTPs (with dTTP) 0.10 µL 
MultiScribe™ Reverse Transcriptase, 50 U/µL 0.67 µL 
10× Reverse Transcription Buffer  1.00 µL 
RNase Inhibitor 20 U/ µL 0.13 µL 
Nuclease-free water 2.78 µL 
Total Volume 4.68 µL 
* Each 10 µL RT reaction consists of 4.68 µL master mix, 2.00 µL of 5× RT primer, and 3.30 µL 
RNA samples.   
The components were mixed gently and centrifuged to bring solution to the bottom 
of the tube. The RT master mix was then placed on ice until the RNA reaction was 
prepared. 
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The 5 × RT primer and RNA template was thawed on ice. The RT primer tubes were 
then vortexed to mix and then briefly centrifuged. For each 10.0 µL RT reaction, the RT 
master mix was combined with 10.0 ng of total RNA in the ratio of 4.68 µL RT master 
mix : 3.30 µL total RNA. The mixture was mixed gently, and centrifuged briefly to 
bring the solution to the bottom of the tube. 2.0 µL RT primer from each assay set was 
added to the corresponding RT reaction tube. The reaction tube was sealed and mixed 
gently, followed by a brief centrifugation. The reactions were incubated on ice for 5 
minutes and then loaded into the thermal cycler, and run according to the following 
conditions (Table 3.11): 
Table 3.11: Thermal cycler conditions for cDNA synthesis 
Time Temperature 
30 minutes 16°C 
30 minutes 42°C 
5 minutes 85°C 
∞ 4°C 
 
3.11.2 Quantitative real-time PCR (qPCR) 
The following components (Table 3.12) were placed on ice and gently mixed. The 
volumes required, based upon the number of reactions and a reaction volume of 10 µL 
was calculated. 
Table 3.12: Components used to prepare qPCR master mix 
Component Master mix volume per 10 µL reaction 
TaqMan® Fast Advanced PCR Master Mix 5.00 µL 
Nuclease-free water 3.84 µL 
TaqMan® MicroRNA Assay (20) 0.50 µL 
Product from RT reaction 0.67 µL 
Total Volume 10.01 µL 
 
The reaction components were combined in a microcentrifuge tube and gently mixed 
by inversion and then centrifugation. 10.0 µL was transferred into low-profile 
microcentrifuge tubes and the tubes were sealed and briefly centrifuged. The reactions 
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were then loaded into the real-time PCR instrument, and run according to the following 
conditions (Table 3.13).  
Table 3.13: Real-time PCR instrument conditions for qPCR 
Step 
 
Optional 
AmpErase 
UNG Activity 
Enzyme 
Activation PCR 
HOLD HOLD CYCLE (40 Cycles) Denature Anneal/Extend 
Temperature  50°C 95°C 95°C 60°C 
Time  2 min 10 min 15 sec 60 sec 
 
3.12 Transfection of mimics/ hairpin inhibitors 
miRIDIAN miRNA mimics and hairpin inhibitors were purchased from GE 
Healthcare Dharmacon, USA (Table 3.14). MiRNA mimics were designed as double-
stranded oligonucleotides to mimic the function of endogenous mature miRNA, 
whereas miRNA hairpin inhibitors are RNA oligonucleotides with novel secondary 
structures that are designed to inhibit the function of endogenous miRNA. Negative 
control sequences were based on Caenorhabditis elegans (C. elegans) miRNA (cel-
miR-67) and have minimal sequence identity in humans, mouse and rats. The 
miRIDIAN microRNA mimic and inhibitor transfection control with Dy547 are also 
based on C. elegans miRNA cel-miR-67, and were used as a transfection control for 
monitoring delivery into the cells. 
Table 3.14: Mature miRNA accession number and sequences 
ID Accession Number Sequence 
Hsa-miR-769-5p MIMAT0003886 UGAGACCUCUGGGUUCUGAGCU 
Hsa-miR-361-5p MIMAT0000703 UUAUCAGAAUCUCCAGGGGUAC 
Hsa-miR-1304-5p MIMAT0005892 UUUGAGGCUACAGUGAGAUGUG 
Hsa miR-608 MIMAT0003276 AGGGGUGGUGUUGGGACAGCUCCGU 
Cel-miR-67 MIMAT0000039 UCACAACCUCCUAGAAAGAGUAGA 
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One day prior to transfection, 1.0 × 106 cells were plated in 5.0 ml of appropriate 
medium, without antibodies, in a T-25 cm2 culture flask. A 20.0 µM miRNA stock 
solution in 1 × siRNA buffer (GE Healthcare Dharmacon, USA) was prepared. In 
separate tubes, 20.0 µL of 20.0 µM miRNA was diluted in 480.0 µL serum-free medium 
(Tube 1) to prepare the final concentration of 80.0 nM, and 6.0 µL DharmaFECT 1 
Transfection Reagent (GE Healthcare Dharmacon, USA) was diluted in 494.0 µL  
serum free medium (Tube 2). The contents of each tube was gently mixed by pipetting 
carefully up and down, and incubated for 5 min at room temperature. After incubation, 
the contents of Tube 1 was added to Tube 2 and mixed gently by pipetting up and down. 
The combined solution was incubated for 20 min at room temperature to form the 
transfection mix. 4.0 ml complete medium was added to the transfection mix for the 
desired transfection volume. The culture medium from the T-25 cm2 culture flask was 
removed and 5.0 ml of the appropriate transfection mix was added to the flask. The 
flask was then incubated at 37°C in 5% CO2 for 24 h. If cell toxicity was observed after 
24 h, the transfection medium was replaced with complete medium and incubation 
continued. Transfection efficiencies were assessed 24 h post-transfection by visualizing 
uptake of miRIDIAN MicroRNA Mimic/ Hairpin Inhibitor Transfection Control with 
Dy547 using fluorescence microscopy. For mRNA analysis, 24 h post-transfection, total 
RNA was isolated using miRNeasy® Mini Kit (Section 3.3.2) and analyzed using the 
ScreenTape R6K on the Agilent 2200 TapeStation (Section 3.4.2). RT-qPCR analysis of 
miRNA expression was carried out using TaqMan® MicroRNA Assays (Section 3.11). 
Expressions of miRNAs were normalized to the expression of the U6 small nuclear 
RNA. The 2-ΔΔCt method was used to determine relative quantitation of miRNA, and 
fold difference relative to scrambled negative controls was determined as Log2 (2-ΔΔCt). 
The detection of caspase 3/7 activity was performed 48 h post-transfection using the 
Caspase-Glo® 3/7 assay (Section 3.9) while apoptosis was detected 72 h post-
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transfection using the FITC annexin V apoptosis detection kit (Section 3.8), as 
described previously. Cell cycle analysis was also carried out 48 h post-transfection 
using the BD CycletestTM Plus DNA Kit Assay (Section 3.10). 
3.13 Combined transfection with siBCL-XL and miR-608 inhibitors or miR-361-
5p mimics 
 
To observe the connection between BCL-XL, miR-608, miR-361-5p and cell death, 
cells were plated for 24 h prior to transfection with 100.0 nM siRNA 1, as described in 
Section 3.2. 24 h post-transfection, spent media was removed and cells were transfected 
with 80.0 nM of either miR-608 hairpin inhibitor, miR-361-5p mimic, or their 
appropriate negative controls, as described in Section 3.12. The detection of caspase 3/7 
activity was performed 48 h post-transfection using the Caspase-Glo® 3/7 assay 
(Section 3.9), while apoptosis was detected 72 h post-transfection using the FITC 
annexin V apoptosis detection kit (Section 3.8) as described previously. 
3.14 Zebrafish care and use 
Experiments involving zebrafish were approved by the University of Malaya, Faculty 
of Medicine, Institutional Care of Use Committee (FOM, IACUC) (Ethics reference 
number: 2015-181006/IBS/R/NO) and complied with all relevant animal welfare laws, 
guidelines and policies. Wild-type Danio rerio zebrafish adults were cared for and 
maintained in the Zebrafish Laboratory (Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC) accredited), Department of Biomedical 
Science, Faculty of Medicine, University of Malaya, using standard husbandry 
conditions: 14 hours:10 hours light:dark cycle, regulated conductivity (500.0 µS), pH 
(7.0) and temperature (28°C), in a ZebTEC zebrafish housing system (Tecniplast, Italy). 
Adult zebrafish were fed daily, twice with Hikari dry food pellets and once with live 
Artemia salina (brine shrimp). 
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3.14.1 Zebrafish breeding 
The evening prior to collection of eggs, random pairwise mating of zebrafish was 
performed. At a ratio of 2:1 female:male adult zebrafish were placed in a plastic tank 
with a breeding insert (Tecniplast, Italy) that has been marbled. Marbles are used to 
cover the bottom of the tank to prevent breeding fish from eating freshly laid eggs that 
sink between the marbles to safety. Adult zebrafish will initiate breeding behavior that 
results in the laying and fertilization of eggs, at the onset of the light cycle. 
An hour after the onset of the light cycle, eggs were harvested and transferred to a 
clean 60 mm × 15 mm petri dish (Corning, NY, USA) containing system water. The 
eggs were rinsed with clean system water 3 to 6 times to remove any debris. 
Alternatively, the eggs are swirled around the petri dish and a Pasteur pipette was used 
to remove any remaining debris, as it swirls for a longer time around the dish. Once the 
eggs are cleaned, they were transferred into a clean petri dish filled with system water 
and incubated at 28.5°C. At 3.5 h post-fertilization (hpf), embryos were observed under 
a Leica EZ4 dissecting microscope (Leica Microsystems, Germany) for any dead or 
unhealthy embryos to be removed. Embryos were left to incubate and develop in system 
water containing methylene blue (Sigma Aldrich, USA), and transferred into system 
water with 75 µM 1-phenyl 2-thiourea (PTU) (Sigma Aldrich, USA) 1 day post-
fertilization (dpf) to inhibit pigment formation. Embryos were again incubated at 28.5°C 
until they were used for experiments at 2 dpf. 
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3.15 In vivo apoptosis model 
3.15.1 Cell staining 
One day after A549 cells are transfected with miR-608 mimics / inhibitors, miR-361-
5p mimics / inhibitors, and mimic and inhibitor negative controls in a 6-well plate, cells 
were labeled with 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate 
(Dil) dye, a lipophilic fluorescent tracking dye (red fluorescence; excitation: 549 nm; 
emission: 565nm) that is stable in live zebrafish for at least 2 weeks. Dil stock solution 
(20 mg/ml) was diluted at 1:1,000 in Dulbecco's phosphate-buffered saline (DPBS) with 
calcium and magnesium.  
Spent media was removed from the wells and cells were washed with 2.0 ml of 1 × 
DPBS. 2.0 ml Dil labeling solution was added to the wells and left to incubate for 30 
min at 37°C in the dark. Following incubation, the medium containing detached labeled 
cells was collected and transferred to a 15 ml Falcon tube and centrifuged for 1,000 × g 
for 3 min. Supernatant was discarded and cell pellet resuspended in 2.0 ml 1 × DPBS 
and centrifuged for 1,000 × g for 3 min. This process was repeated one more time. The 
cell pellet was then resuspended in 2.0 ml fresh complete medium and added back to the 
wells. The plate was then incubated overnight at 37°C in the CO2 incubator. 
3.15.2 Embryo preparation 
Chorions of 2 dpf embryos were removed with sharp microsurgical forceps 
(Watchmaker #5) (Samco, UK). The embryos were held with one forcep and with the 
help of another pair of forceps a tear was gently made in the chorion and turned upside 
down so that the embryos fall out with the help of another pair of forceps. The embryos 
can be brought to the center of the dish for viewing by gently swirling the medium in a 
circular motion. The embryos were rinsed thoroughly in system water three times and 
transferred to fresh PTU water. 
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3.15.3 Embryo microinjection 
Labeled transfected cells were harvested and resuspended in culture medium 
containing 1.0% FBS, at a density of 1.0 × 105 cells/ml. Cells were kept on ice and in 
the dark until time of injection.  Dechorionated embryos were anaesthetized by 
transferring them into 10.0% benzocaine (Sigma Aldrich, USA) in system water for 2 
min before aligning them onto a 1.0% (w/v) modified agarose gel plate. Excess water 
was removed with a Pasteur pipette. 
A microloader (Eppendorf, Germany) was used to load 10.0 µL cell suspension into 
a 20 µm TransferTip (Eppendorf, Germany), which was connected to A FemtoJet 
Microinjector (Eppendorf, Germany). Using the InjectMan NI 2 Micromanipulator 
(Eppendorf, Germany) and the automated Leica M205 A stereo microscope (Leica 
Microsystems, Germany), the cell suspension was injected into the middle of the 
embryonic yolk sac region with constant injection pressure (Pi) (100 hpa), compensation 
pressure (Pc) (45 hpa) and injection time (ti) (0.1 sec). The injection volume and cell 
suspension was calibrated to be approximately 100-200 cells/injection in each embryo. 
After transplantation, embryos were rinsed with system water and then transferred into 
fresh PTU water and placed at 37°C overnight. 
3.15.4 Whole mount caspase 3 immunofluorescence 
At 24 h post-injection (hpi), live zebrafish embryos were rinsed twice with 1 × PBS 
with 0.1% Tween 20 (PBST, pH 7.0) for 5 min each. PBST was removed leaving liquid 
just above the embryos, and embryos were euthanized with an overdose of 10.0% 
benzocaine. Embryos were then fixed in 4.0% (w/v) paraformaldehyde (PFA) (Sigma 
Aldrich, USA) overnight at 4°C. 
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The following day, PFA was removed and embryos were washed twice in 1 × PBST, 
5 min each. 1.0 ml of ice-cold 100.0% methanol was added drop-wise to permeabilize 
the embryos, and left to incubate at -20°C for 2 h. Methanol was then removed and 1.0 
ml 1 × PBST with 0.3% Triton X (Scharlab, Spain) and 1.0% dimethyl sulfoxide 
(DMSO) (Merck, USA) (PDT) was added. PDT was removed and 1.0 ml fresh PDT 
was added and embryos were incubated for 30 min at room temperature, with gentle 
agitation. This step was repeated once. After the washes, PDT was removed and 500.0 
µL of blocking buffer made of 1 × PBST with 10.0% FBS and 2.0% BSA was added 
and embryos were incubated for 1 h at room temperature, with gentle agitation. 
Embryos were then stained with purified rabbit anti-active caspase 3 antibody (BD 
Biosciences, USA) (1:500 dilution) for 2 h at 25°C with gentle agitation, followed by 
two washes in PDT, 30 min each. Again embryos were incubated with blocking buffer 
for 1 h at room temperature, then stained with anti-rabbit IgG Fab2 Alexa Fluor 647 
Conjugate (Cell Signaling Technologies, USA) (1:500 dilution) overnight at 4°C. 
The following day, blocking buffer/antibody solution was removed and embryos 
were washed twice with PDT, 30 min each wash. Embryos were then visualized and 
imaged using the Leica confocal laser-scanning microscope SP5 II (Leica 
Microsystems, Germany), at low magnification (5×) (excitation: 650 nm; emission: 665 
nm), and Leica Application Suite (LAS) software v5.0 (Leica Microsystems, Germany). 
Fluorescence of activated caspase 3 was quantified using ImageJ v1.48 Analyst 
software. A fluorescence intensity threshold of 130-160 was set to eliminate background 
fluorescence and the “analyze measurement” tool was used to generate arbitrary 
fluorescence intensity measurements in the threshold area. 
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3.16 Bioinformatics analyses of miRNA gene targets 
An in silico approach was used to identify the putative miRNA targets by using 
TargetScan Human v6.2 (Lewis et al., 2005) (Whitehead Institute for Biomedical 
Research, USA), the database of conserved 3’UTR miRNA targets, found at 
http://www.targetscan.org/. Gene-annotation enrichment analyses of the predicted 
miRNA targets, with total context scores below 0, were then performed using the web 
tool Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 
(Huang et al., 2009) (SAIC-Frederick, Inc., USA) at http://david.abcc.nciferf.gov 
/summary.jsp using default parameters. Data from TargetScan and DAVID were 
combined to generate a hypothetical pathway of the relationship between the miRNAs 
and their gene targets. 
3.17 Construction of wild type 3’-UTR dual luciferase reporter plasmid 
3.17.1 Preparation of Insert DNA (3’-UTR) 
3.17.1.1 Primer design 
The miRNA 3’UTR target sites of the gene of interest and the Homo sapiens 3’UTR 
was blasted against National Center for Biotechnology Information (NCBI) RefSeq 
RNA database using the Nucleotide Basic Local Alignment Search Tool (Blastn Suite) 
(National Center for Biotechnology Information, USA) to obtain the full length mRNA 
sequence. Forward and reverse primers were then designed using NCBI Primer-Blast by 
default parameters (Table 3.15). 
Table 3.15: Primers used for PCR amplification of genes 
Primer Name Sequence Length 
AKT2 
3’UTR 
Forward 5’ – ATA CTC GAG GGG ATT AAA ACC TGA ATC TCC AAC CG - 3’ 33 
Reverse 5’ – TAC GCT AGC TGT ACT TCG ATG ATG AAT TTA CCG CC - 3’ 31 
SMAD2 
3’UTR 
Forward 5’ – ATA TTC TCG AGA CTC GAG CAG AAC AGA CTG GG- 3’ 32 
Reverse 5’ – TAA TTG CTA GCT GCC CTA AAG TGC CTG GGA TT- 3’ 32 
Luc_F 	 GAT CGC CGT GTA ATT CTA GTT GTT T 25 
SV40_R 	 CTT CCT TTC GGG CTT TGT TAG C 22 
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3.17.1.2 Complementary DNA (cDNA) synthesis 
First strand cDNA was synthesized for use in PCR using the RevertAid H Minus 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA). After thawing, the 
components of the kit were mixed, briefly centrifuged and stored on ice. The following 
reagents were then added into a sterile, nuclease-free tube on ice (Table 3.16). The 
mixture was incubated at 65.0°C for 5 minutes, centrifuged briefly and placed on ice. 
Table 3.16: Kit components used to prepare First Strand cDNA synthesis mix 
Component Volume 
Template RNA (Total RNA – 5 µg/ 20µL) 5 µg 
Primer (Gene specific primer – 2.0 µm) 4 µL 
Nuclease-free H2O to 12 ul 
Total Volume 12 ul 
 
The following components were then added according to the volumes listed below in 
Table 3.17. The contents of the tube were gently mixed and centrifuged. The reactions 
were then loaded into the thermal cycler and run according to the following conditions 
(Table 3.18).  
Table 3.17: Kit components used to prepare First Strand cDNA synthesis mix 
Component Volume 
5× Reaction Buffer 4 µL 
RiboLock RNase Inhibitor (20 U/µL) 1 µL 
10 mM dNTP Mix 2 µL 
RevertAid H Minus M-MuLV Reverse Transcriptase (200 U/µL) 1 µL 
Total Volume 20 µL 
 
Table 3.18: Thermal cycler conditions for cDNA synthesis 
Time Temperature 
60 minutes 42°C 
5 minutes 70°C 
∞ 4°C 
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3.17.1.3 Amplification by PCR 
The product of the first strand cDNA synthesis was used directly in PCR. The 
Phusion Flash High Fidelity PCR Master Mix (Thermo Fisher Scientific, USA) was 
used to carry out PCR. For each PCR reaction the following components were added to 
a 0.2 ml microcentrifuge tube. The volumes for a single 20.0 µL reaction are listed in 
Table 3.19. For multiple reactions, a master mix of common components was prepared 
and the appropriate volume added to each tube, and the unique reaction components (eg. 
template) was then added. The reaction tube was centrifuged briefly and loaded into the 
thermal cycler using the conditions in Table 3.20.  
Table 3.19: Kit components used to prepare PCR samples 
Component Volume 
2× Phusion Flash PCR Master Mix 10 µL 
Forward Primer (1.0 µM) 0.2 µL 
Reverse Primer (1.0 µM) 0.2 µL 
Template (cDNA) 2 µL 
H2O (Add up to 20 µL) 12.4 µL 
Total Volume 20 µL 
 
Table 3.20: PCR cycling conditions 
Cycle Step Temperature Time Cycles 
Initial denaturation 98°C 10 sec. 1 
Denaturation 98°C 1 sec. 
30 Annealing 62.5°C 5 sec. 
Extension 72°C 23 sec. 
Final Extension 72°C 1 min. 1 
 4°C Hold ∞ 
 
3.17.1.4 Agarose gel electrophoresis 
To prepare 1.0% agarose gel, 1.0 g of agarose powder (Sigma Aldrich, USA) was 
poured into a microwavable flask along with 100.0 ml of 1 × Tris base/ acetic acid/ 
EDTA (TAE) buffer (Thermo Fisher Scientific, USA). The flask was microwaved for 3 
min (until the agarose is completely dissolved and has a nice rolling boil). The agarose 
solution was cooled down for 5 min and 1.5 µl of RedSafe Nucleic Acid Staining 
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Solution (20,000×) (iNtRON Biotechnology, South Korea) was added. Gel was poured 
into the casting tray with the well comb in place, and left to sit at room temperature for 
20-30 min or until it has completely solidified.  
10.0 µL of DNA sample was mixed with 1.0 µL of Blue/Orange 6× loading dye 
(Promega, USA). Once solidified, the gel was placed into the BG-Submidi Submarine 
Unit (BayGene, China) and the tank filled with 1 × TAE until the gel was covered. 5.0 
µL of O’GeneRuler 1 kb DNA ladder (Thermo Fisher Scientific, USA) was loaded into 
the first lane of the gel and the samples were loaded into the additional wells of the gel 
(DNA ladder sizes are listed in Appendix B).  
After DNA samples were loaded, the lid was assembled onto the electrophoresis 
chamber so that the DNA can be migrated towards the positive lead. The electric source 
was provided by Power Supply-PowerPac (Bio-Rad, USA). Gel electrophoresis was run 
at 80 volts and 400 mA of free running current for approximately 60 min or until the 
dye line is approximately 75.0-80.0% of the way down the gel. The gel was then 
visualized under UV transillumination and analyzed by the Imager Kit Digital, 
AlphaImager™ 2000 (Alpha Innotech, USA) at 302 nm wavelength. 
3.17.1.5 DNA purification from gel using QIAquick Gel Extraction Kit (Qiagen, 
USA) 
 
PCR products were purified from the gel using the QIAquick Gel Extraction Kit. 
This kit contains three components: Buffer QG, Buffer PE and Buffer EB. The DNA 
fragment was excised from the agarose gel using a clean, sharp scalpel. The gel slice 
was weighed in a colourless tube and 3 volumes of Buffer QG was added to 1 volume 
of gel (100.0 mg gel ~ 100.0 µL). The maximum amount of gel per spin column is 400.0 
mg. For > 2% agarose gels, 6 volumes of Buffer QG was added. The tubes were 
incubated at 50°C for 10 min (or until the gel has completely dissolved). The tubes were 
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vortexed every 2-3 min to help dissolve the gel. Once the gel slice was dissolved 
completely, the colour of the mixture was checked to ensure it was yellow. If the colour 
of the mixture is orange or violet, 10.0 µL of 3 M sodium acetate, pH 5.0, was added to 
the mix and the mixture would turn yellow. 1 volume of isopropanol was added to the 
sample and mixed. A QIAquick spin column was placed in a provided 2.0 ml collection 
tube and 800.0 µL of the sample was applied to the QIAquick column and centrifuged 
for 1 min to bind the DNA. The flow-through was discarded and the QIAquick column 
was placed back into the same tube. This step was repeated for the remainder of the 
sample. 500.0 µL of Buffer QG was added to the column and the tube centrifuged for 1 
min. The flow-through was discarded and the QIAquick column placed back into the 
same tube. To wash the sample, 750.0 µL Buffer PE was added to the QIAquick 
column, left to stand for 3 min at room temperature and then centrifuged for 1 min. The 
flow-through was discarded and the QIAquick column placed back into the same tube. 
The QIAquick column with its 2.0 ml collection tube was then centrifuged at full speed 
for 2 min to remove residual wash buffer. The QIAquick column was then placed into a 
clean 1.5 ml microcentrifuge tube and the DNA eluted by adding 50 µL of Buffer EB 
(10 mM Tris Cl, pH 8.5) to the center of the QIAquick membrane and centrifuged for 1 
min. After the addition of elution buffer to the QIAquick membrane, increasing the 
incubation time up to 4 min can increase the yield of purified DNA. If the purified DNA 
was to be analyzed on a gel, 1 volume of Loading Dye was added to 5 volumes of 
purified DNA. The solution was pipetted up and down before loading onto the gel. 
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3.17.2 Preparation of vector DNA (pmirGLO Dual-Luciferase miRNA 
Expression Vector (Promega, USA)) 
 
3.17.2.1 pmirGLO Dual-Luciferase miRNA Expression Vector propagation in E. 
coli competent cells JM109 (Promega, USA) 
 
Ten 1.0 ml centrifuge tubes were chilled on ice. Frozen competent cells were 
removed from -80°C and placed on ice for 5 min, or until just thawed. Once thawed, the 
JM109 competent cells were pipetted quickly to prevent warming above 4°C. The 
thawed cells were gently mixed by flicking, and 100.0 µL was transferred to each 
chilled tube. While moving the pipette tip through the competent cells, 50 ng of DNA 
was dispersed into each tube. Tubes were immediately returned to ice for 10 min, after 
which the cells were heat shocked at 42°C exactly in a water bath. Following this, tubes 
were immediately placed back on ice for 10 min. 900 µL of ice-cold lysogeny broth 
(LB) (Sigma Aldrich, USA)/ampicillin (Thermo Fisher Scientific) medium was added 
to each transformation reaction and incubated for 1 h at 37°C in an incubator shaker 
(BioSan, Latvia) (225 RPM). For each transformation reaction the cells were diluted 
1:10, 1:100 and 100.0 µL undiluted cells on LB/ampicillin agar plates. The plates were 
then incubated for 12-24 h at 37°C. 
3.17.2.2 Purification of pmirGLO Dual-Luciferase miRNA Target Vector from E. 
coli culture using PureYield Plasmid Miniprep System (Promega, USA) 
 
The PureYield Plasmid Miniprep System contains 5 components: the Cell Lysis 
Buffer (CLC), Neutralization Solution (NSC), Endotoxin Removal Wash (ERB), 
Column Wash Solution (CWC) and Elution Buffer (EBB). 
 A single, well-isolated colony from a fresh LB/ampicillin agar plate was chosen, 
and used to inoculate 10.0 ml of LB broth containing 10% ampicillin. The inoculated 
broth was incubated overnight (12-18 h) at 37°C. 3.0 ml of bacterial culture growth in 
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LB broth was transferred to a 15 ml Falcon tube and spun down. The supernatant was 
discarded and 600.0 µL Tris/EDTA (TE) buffer was added to the cell pellet and 
resuspended by vortexing. Contents were transferred to a 1.5 ml centrifuge tube and 
100.0 µL CLC was added. The tube was mixed by inverting the tube 6 times. The 
solution changes from opaque to clear blue, indicating complete lysis. Experiment was 
proceeded to the next step within 2 min as excessive lysis will result in denatured 
plasmid DNA. 350.0 µL ice-cold NSC was added, and mixed thoroughly by inverting 
the tube. The sample will turn yellow when neutralization is complete and a yellow 
precipitate will form. The tube was inverted an additional 3 times to ensure complete 
neutralization. The tube was then centrifuged at maximum speed for 3 min. Supernatant 
(≈ 900.0 µL) was transferred to a PureYield minicolumn placed in a PureYield 
collection tube. The column was centrifuged at maximum speed for 15 sec.  The flow-
through was discarded and the minicolumn placed back into the same PureYield 
collection tube.  200.0 µL ERB was added to the minicolumn and centrifuged at 
maximum speed for 15 sec. 400.0 µL CWC was then added to the minicolumn and 
centrifuged at maximum speed for 30 sec. The minicolumn was transferred to a clean 
1.5 ml microcentrifuge tube and 30.0 µL EBB was added directly to the minicolumn 
matrix and left to stand at room temperature for 1 min. The column was then 
centrifuged at maximum speed for 15 sec. The eluted plasmid DNA was stored at -
20°C. 
3.17.3 Cloning 
The insert DNA (3’UTR) was cloned into 3’ end of the pmirGLO Dual-Luciferase 
miRNA Target Vector using restriction enzyme pairs SacI / SalI by a third party vendor, 
First BASE Laboratories Sdn Bhd, Malaysia. All constructs were verified by 
sequencing, also performed by the outside vendor. Sequencing results were analyzed 
using the chromatogram viewer Geospiza’s Finch TV (PerkinElmer, USA) and the full 
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sequence of the insert DNA and pmirGLO/gene constructs was analyzed and compared 
to sequences in the Human Standard Nucleotide BLAST (National Center for 
Biotechnology Information, USA) (Appendix C and Appendix D). 
3.18 Construction of mutated 3’-UTR pmirGLO Dual Luciferase Reporter 
Plasmid 
 
To create mutations in the miRNA binding sequence, the cloned pmiRGLO/gene 
constructs were submitted to a third party vendor, First BASE Laboratories Sdn. Bhd, 
Malaysia, to undergo their site-directed mutagenesis service. All mutated constructs 
were verified by sequencing, also performed by the outside vendor.  
3.19 Dual Luciferase Reporter Assay System (Promega, USA) 
Luciferase activity, indicative of translation from the plasmid, was assayed using the 
Dual Luciferase Reporter Assay System. One day prior to transfection, 1.5 × 105 cells 
were plated in 2.0 ml of appropriate medium in a 6-well plate. Cells were co-transfected 
with 80.0 nM of miRNA mimics / inhibitors or their corresponding negative controls (as 
described in Section 3.12) and 40.0 ng of wildtype or mutated 3’UTR plasmids. 
For plasmid transfection, in separate tubes, 0.8 µL of 50.0 ng/µL plasmid stock 
solution was diluted in 199.2 µL serum-free culture medium (Tube 1) to prepare a final 
concentration of 40.0 ng, and 2.0 µL of DharmaFECT 1 transfection reagent was diluted 
in 198.0 µL serum-free culture medium (Tube 2). The contents of each tube was gently 
mixed and incubated for 5 min at room temperature. After the 5 min incubation, the 
contents of Tube 1 was added to Tube 2 and mixed gently by pipetting up and down. 
The combined solution was incubated for 20 min at room temperature to form the 
transfection mix.  1.6 ml of complete medium was added to the mixed solution for the 
desired transfection volume. The culture medium from the 6-well plate was removed 
and 2 ml of the appropriate transfection mix was added to the flask.  
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At 24 h post-transfection spent media was removed, cells washed with PBS, and 
fresh media added back into the wells. The plates were then placed back into the CO2 
incubator for another 24 h. Luciferase activity was detected 48 h post-transfection using 
the Dual Luciferase Reporter Assay System according to manufacturer’s protocol.  
Prior to starting the luciferase assay experiments, the content of Dual-Glo Luciferase 
Buffer was transferred to the bottle of Dual-Glo Luciferase substrate, to create the Dual-
Glo Luciferase Reagent. The contents are mixed by inversion until the substrate was 
fully dissolved. Cells were harvested by trypsinization and centrifugation, and then 
resuspended in 50.0 µL 1× PBS and transferred to a 1.5 ml centrifuge tube. 50.0 µL 
Dual-Glo Luciferase Reagent was added and mixed by pipetting.  The sample was left 
to incubate for 10 min and then firefly luminescence was measured using the Glomax 
Multi - Luminescence Multimode Reader (Promega, USA). 50.0 µL Dual-Glo Stop & 
Glo Reagent was then added and mixed by pipetting. The sample was incubated for 10 
min and then Renilla luminescence was measured. The ratio of luminescence from the 
firefly luciferase reporter to luminescence from the Renilla luciferase reporter was 
calculated. This ratio was normalized to the ratio of the control samples that are treated 
consistently. This normalization provides optimal and consistent results from the Dual-
Glo Luciferase Assay System. Renilla luciferase was used as an internal control due to 
its constitutive expression.  
3.20 Gene rescue experiments 
3.20.1 Gene silencing using siRNAs 
Silencing of the AKT2 gene was performed using a set of three unique 27 mer siRNA 
duplexes purchased from OriGene Technologies Inc., USA (Table 3.21). A universal 
scrambled negative control siRNA (siRNA NC) was used as a control. SiRNA 
duplexes, provided as 2.0 nM per vial, were reconstituted by resuspension in 100.0 µl of 
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1 × siRNA buffer (GE Healthcare Dharmacon, USA), yielding a final concentration of 
20.0 µM. The duplex solutions were heated to 95°C for 2 min to ensure fully duplexed 
contents and allowed to cool to room temperature, prior to being stored at -20°C. 
One day prior to transfection 1.0 × 106 cells were plated in 5 ml of appropriate 
medium, without antibodies, in a T-25 cm2 culture flask. Cells were then transfected 
with 80 nM of miR-608 inhibitors or inhibitor NC as described in Section 3.12. 6 h 
post-transfection, spent media was removed and cells were washed with 1 × PBS before 
being transfected with 10.0 nM siRNA or siRNA NC. 
In separate tubes 2.5 µL of 20.0 µM siRNA stock solution was diluted in 495.0 µL 
serum-free culture medium (Tube 1) to prepare a final concentration of 10.0 nM, and 
6.0 µL of DharmaFECT 1 transfection reagent was diluted in 494.0 µL serum-free 
culture medium (Tube 2). The contents of each tube was gently mixed and incubated for 
5 min at room temperature. After the 5 min incubation, the contents of Tube 1 was 
added to Tube 2 and mixed gently by pipetting up and down. The combined solution 
was incubated for 20 min at room temperature to form the transfection mix. 4.0 ml of 
complete medium was added to the mixed solution for the desired transfection volume. 
The culture medium from the T-25 cm2 culture flask was removed and 5.0 ml of the 
appropriate transfection mix was added to the flask.  
Transfected cells were incubated in 37°C in the CO2 incubator prior to determination 
of gene rescue effects by functional assays. AKT2 protein levels were determined via 
western blot 72 h post-transfection (Section 3.6). The detection of caspase 3/7 activity 
was performed 48 h post-transfection using the Caspase-Glo® 3/7 assay (Section 3.9), 
while apoptosis was detected 72 h post-transfection using the FITC annexin V apoptosis 
detection kit (Section 3.8) as described previously. 
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Table 3.21: siRNA duplexes used for AKT2 silencing 
siRNA Duplex Sequence 
siRNA A GCAUCAUAAAUUGGUAGUUUCCUGC 
siRNA B AGCGUGGUGAAUACAUCAAGACCTG 
siRNA C ACAGCAAAGCAGGAGUAUAAGAAAG 
  
3.20.2 Gene overexpression using pCMV6 plasmids 
The mammalian pCMV6/SMAD2 plasmid was purchased from OriGene 
Technologies Inc., USA, and was designed to contain the cDNA open reading frame of 
SMAD2 without its 3’UTR. The empty pCMV6 plasmid (OriGene Technologies Inc., 
USA) was used as a control plasmid. DNA plasmids, provided as dried plasmids, were 
reconstituted with 100.0 µl nuclease free H2O, yielding a final concentration of 10.0 µg.  
One day prior to transfection 1.0 × 106 cells were plated in 5.0 ml of appropriate 
medium, without antibodies, in a T-25 cm2 culture flask. Cells were then transfected 
with 80.0 nM of miR-608 inhibitors or inhibitor NC as described in Section 3.12. 6 h 
post-transfection, spent media was removed and cells were washed with 1 × PBS before 
being transfected with 50.0 ng pCMV/SMAD2 or pCMV6 vectors.  
In separate tubes 0.5 µL of 10.0 µg plasmid stock solution was diluted in 499.5 µL 
serum free culture medium (Tube 1) to prepare a final concentration of 50.0 ng, and 6.0 
µL of DharmaFECT 1 transfection reagent was diluted in 494.0 µL serum free culture 
medium (Tube 2). The contents of each tube was gently mixed and incubated for 5 min 
at room temperature. After the 5 min incubation, the contents of Tube 1 was added to 
Tube 2 and mixed gently by pipetting up and down. The combined solution was 
incubated for 20 min at room temperature to form the transfection mix. 4.0 ml of 
complete medium was added to the mixed solution for the desired transfection volume. 
The culture medium from the T-25 cm2 culture flask was removed and 5.0 ml of the 
appropriate transfection mix was added to the flask.  
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Transfected cells were incubated in 37°C in the CO2 incubator prior to determination 
of gene rescue effects by functional assays. SMAD2 protein levels were determined via 
western blot 72 h post-transfection (Section 3.6). The detection of caspase 3/7 activity 
was performed 48 h post-transfection using the Caspase-Glo® 3/7 assay (Section 3.9), 
while apoptosis was detected 72 h post-transfection using the FITC annexin V apoptosis 
detection kit (Section 3.8) as described previously.  
3.21 Statistical analysis 
All experiments were performed in triplicate independent experiments. All data were 
presented as mean ± standard deviation. Student’s t-test was used to determine the 
statistical significance of the difference between two groups of data, where a p-value of 
≤ 0.05 was considered statistically significant. Analysis of statistical significance 
between three or more groups of data was performed using the one-way analysis of 
variance (ANOVA), followed by post-hoc Tukey test, where a p-value of ≤ 0.05 was 
considered statistically significant. 
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CHAPTER 4: RESULTS 
4.1 Silencing of BCL-XL using siRNA-based transfection resulted in a 
reduction of SK-LU-1 cell viability and increased apoptosis 
 
4.1.1 siRNA transfection efficiency in SK-LU-1 cells 
To assess whether BCL-XL plays a similar role in the apoptotic properties of lung 
adenocarcinoma SK-LU-1 cells, as observed in the A549 cell line previously reported in 
my Masters study (Othman, 2012), the expression of BCL-XL in SK-LU-1 cells was 
first transiently silenced via transfection with Stealth RNAi™ siRNA Duplex 
Oligonucleotides. Visual monitoring of the uptake of 100.0 nM of BLOCK iT™ Alexa 
Fluor® Red Fluorescent Oligo using fluorescence microscopy showed a satisfactory 
transfection efficiency of ≥ 80.0% for samples treated with the BLOCK-iT™ Alexa 
Fluor® Red Fluorescent Oligo (Figure 4.1). The percentage of transfection efficiency 
shown is representative of mean values from independent triplicate experiments with 
mean  ± SD. 
 
Figure 4.1: Visual monitoring of BLOCK-iT Alexa Fluor Red Fluorescent Oligo 
transfection efficiency. Fluorescent and merged images of SK-LU-1 cells transfected 
with 100 nM BLOCK-iT Alexa Fluor Red Fluorescent Oligo. Percentage of mean 
transfection efficiency ± SD is indicated and all images shown are a representative of 
triplicate independent experiments. 
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4.1.2 Determination of siRNA silencing efficiency via qRT-PCR 
To evaluate the silencing efficiency of the siRNAs, qRT-PCR was performed to 
allow for the evaluation of the BCL-XL expression in siRNA-transfected and non-
transfected cells. Amongst the three siRNAs utilized, silencing efficiency of siRNA 1 
indicated the highest negative fold induction of 4.03 ± 0.01 in SK-LU-1 cells (Figure 
4.2 and Table 4.1) with a knockdown of 75.16 ± 0.92% in BCL-XL expression when 
compared with non-transfected cells (Table 4.1).  
 
Figure 4.2: qRT-PCR analysis of BCL-XL normalized to endogenous β-actin 
expression in siRNA-transfected and non-transfected SK-LU-1 cells. Data presented as 
mean ± SD, n=3, with significant differences denoted with * p-value ≤ 0.05. NTC 
denotes non-transfected cells. Hi GC NC denotes high GC content scramble RNA 
negative control-transfected cells. Lo GC NC denotes low GC content scramble RNA 
negative control-transfected cells. 
Table 4.1: Fold change and percentage knockdown of BCL-XL gene expression in 
siRNA-transfected SK-LU-1 cells in comparison to non-transfected cells. Data 
presented as mean ± SD, n=3, with significant differences between siRNA-transfected 
cells and non-transfected cells denoted with p-value ≤ 0.05. Hi GC NC denotes high GC 
content scramble RNA negative control-transfected cells. Lo GC NC denotes low GC 
content scramble RNA negative control-transfected cells. 
Sample Fold Change†  
± S.D. 
p-Value % Knockdown 
± SD 
p-Value 
siRNA 1 -4.03 ± 0.01 0.000 75.16 ± 0.92 0.000 
siRNA 2 -2.07 ± 0.05 0.004 51.28 ± 5.43 0.004 
siRNA 3 -1.85 ± 0.06 0.005 45.58 ± 5.83 0.005 
Hi GC NC -1.31 ± 0.11 0.047 22.58 ± 11.41 0.047 
Lo GC NC 1.22 ± 0.07 0.013 -21.54 ± 6.74 0.013 
† Negative values denote down-regulation, while positive values denote up-regulation 
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4.1.3 Reduced BCL-XL protein levels in response to siRNA silencing 
Correspondingly, BCL-XL protein levels were decreased by 98.33 ± 0.50% in 
siRNA 1-transfected SK-LU-1 cells, as determined by densitometry analysis of western 
blot bands (Figure 4.3). As siRNA 1 (henceforth referred to as siBCL-XL) had the 
greatest silencing efficiency amongst the three siRNAs, it was selected for further 
downstream work. 
 
Figure 4.3: Quantification of BCL-XL protein levels in siRNA-transfected SK-LU-1 
cells in comparison to non-transfected cells. (A) Western blot analysis of BCL-XL 
protein following siRNA transfection. (B) Densitometry analysis of BCL-XL bands 
using the ImageJ Analyst software. Results were standardized against GAPDH levels 
and presented as relative protein levels. Data presented as mean ± SD, n=3, with 
statistically significant differences denoted with * p-value ≤ 0.05. NTC denotes non-
transfected cells. Hi GC NC denotes high GC content scramble RNA negative control-
transfected cells. Lo GC NC denotes low GC content scramble RNA negative control-
transfected cells. 
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4.1.4 Reduced viability and increased cell death in SK-LU-1 cells in response to 
BCL-XL silencing  
 
To determine the biological effects of BCL-XL silencing on SK-LU-1 cells, MTT cell 
viability assay was performed and revealed that knockdown of BCL-XL resulted in a 
reduction of cell viability, 48 h post-transfection, in comparison to non-transfected SK-
LU-1 cells (Figure 4.4). A comparison between non-transfected cells and mock-
transfected cells (cells treated with transfection reagent only) did not disclose any 
changes in viability, hence ruling out toxicity effects of the transfection reagent (Table 
4.2). A double fluorescence staining of annexin V-FITC conjugate and propidium 
iodide was then performed on siBCL-XL-transfected cells and non-transfected cells, and 
analyzed using a flow cytometer to determine if cell death was occurring through the 
process of apoptosis. After silencing of BCL-XL in SK-LU-1 cells, the population of 
cells indicated a shift from viable cells to early and late stage apoptosis with an increase 
of apoptosis to 18.54 ± 1.62% (Figure 4.5).  Taken together, these results demonstrated 
that BCL-XL plays a similar role in the regulation of apoptosis in both lung 
adenocarcinoma cells, A549 and SK-LU-1. 
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Figure 4.4: Cell viability analysis of BCL-XL silencing on SK-LU-1 cells over 48 h as 
observed using MTT assay. Data presented as mean ± SD, n=3. NTC denotes non-
transfected cells. MTC denotes mock-transfected cells. siBCL-XL denotes siRNA-
transfected cells. Lo GC NC denotes low GC content scramble RNA negative control-
transfected cells. 
Table 4.2: Total cell viability levels (%) as obtained from MTT assays over 48 h. Data 
presented as mean ± SD, n=3, with statistically significant differences in comparison to 
NTC denoted with p-value ≤ 0.05. NTC denotes non-transfected cells. MTC denotes 
mock-transfected cells. siBCL-XL denotes siRNA-transfected cells. Lo GC NC denotes 
low GC content scramble RNA negative control-transfected cells. 
Treatment Time (h) Viability (%) ±  SD p-Value 
NTC 
12 104.57 ± 5.61 - 
24 103.61 ± 2.12 - 
48 103.29 ± 3.69 - 
MTC 
12 97.95 ± 3.03 0.306 
24 97.95 ± 7.56 0.289 
48 95.58 ± 11.97 0.250 
siBCL-XL 
12 89.29 ± 8.06 0.009 
24 72.80 ± 1.15 0.003 
48 58.22 ± 0.98 0.002 
Lo GC NC 
12 89.31 ± 0.92 0.123 
24 84.65 ± 1.78 0.099 
48 97.81 ± 2.02 0.011 
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Figure 4.5: Detection of apoptosis 48 h post-siBCL-XL transfection using flow 
cytometry following annexin V-FITC/ propidium iodide (PI) staining. Viable cells are 
in the lower left quadrant, early apoptotic cells are in the lower right quadrant, late 
apoptotic cells are in the upper right quadrant and non-viable necrotic cells are in the 
upper left quadrant. Dot plots are representative of 1.0 × 104 cells from a single replicate 
with percentage of apoptosis indicated. Data presented as mean ± SD, n=3, with 
statistically significant differences in comparison to NTC denoted with p-value ≤ 0.05. 
NTC denotes non-transfected cells. Lo GC NC denotes low GC content scramble RNA 
negative control-transfected cells. siBCL-XL denotes siRNA-transfected cells. 
4.2 Validation of candidate miRNA expression levels via RT-qPCR, identified 
to be dysregulated in A549 cells following BCL-XL silencing   
 
In my previous Masters project, a global miRNA expression profile was established 
using miRNA microarray, which compared total RNA extracted from siBCL-XL-
transfected and non-transfected A549 cells, and it was determined that miRNA 
expression changes occur in response to BCL-XL silencing. Ten miRNAs were 
significantly differentially expressed, of which seven miRNAs were down-regulated 
while three were up-regulated (Othman, 2012). To corroborate whether this 
dysregulation also occurs in SK-LU-1 cells, five representative differentially expressed 
miRNAs (miR-181a, miR-769-5p, miR-361-5p, miR-1304, and miR-608) were selected 
to undergo RT-qPCR validation based on highest fold change as well as putative targets 
as identified by the TargetScan web tool. RT-qPCR results confirmed that the same 
pattern of dysregulation was exhibited in both A549 and SK-LU-1 cells following BCL-
XL silencing, with miR-181a, miR-769-5p, miR-361-5p, and miR-1304 being down-
regulated, while miR-608 was up-regulated (Figure 4.6 and Table 4.3). 
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Figure 4.6: RT-qPCR validation of candidate miRNAs. RT-qPCR of the five candidate 
miRNAs (miR-181a, miR-769-5p, miR-361-5p, miR-1304, and miR-608) validated 
against A549 results, and presented as normalized fold change. Data presented as mean 
± SD, n=3, with statistically significant differences between siBCL-XL -transfected cells 
and non-transfected cells denoted with * p-value ≤ 0.05. 
Table 4.3: Fold change of candidate miRNA expression in siBCL-XL-transfected cells 
in comparison to non-transfected cells (p ≤ 0.05). 
MicroRNA A549 SK-LU-1 Fold Change† p-Value Fold Change† p-Value 
miR-181a -2.17 ± 0.21 0.051 -1.97 ± 0.21 0.004 
miR-769-5p -2.43 ± 0.18 0.035 -2.84 ± 0.06 0.000 
miR-361-5p -1.16 ± 0.01 0.041 -1.50 ± 0.13 0.007 
miR-1304 -1.49 ± 0.16 0.057 -1.33 ± 0.16 0.068 
miR-608 3.45 ± 0.62 0.003 2.55 ± 0.04 0.000 
† Negative values denote down-regulation, while positive values denote up-regulation 
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4.3 Up-regulation of miR-608 expression and down-regulation of miR-361-5p 
expression increases cell death in A549 and SK-LU-1 cells 
 
4.3.1 Determination of miRNA mimic and inhibitor transfection efficiency in 
A549 and SK-LU-1 cells 
 
Of the five representative dysregulated miRNAs validated, miR-181a was found to 
be well studied and established to play a role in cancer progression; therefore further 
downstream work was focused on the four remaining miRNAs: miR-769-5p, miR-361-
5p, miR-1304 and miR-608. Overexpression and knockdown studies were performed 
via transfection of miRNA mimics and inhibitors to determine the biological effects of 
these miRNAs. Monitoring of miRIDIAN miRNA Mimic and Inhibitor Transfection 
Control with Dy547 uptake using fluorescence microscopy showed a transfection 
efficiency of ≥ 80% across all samples (Figure 4.7). Quantification of miRNA 
overexpression by RT-qPCR, post-transfection, indicated a positive fold change in 
A549 and SK-LU-1 transfected cells, when compared with cells transfected with 
scrambled negative controls (Figure 4.8 and Table 4.4), confirming successful 
transfection of miRNAs. 
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Figure 4.7: Visual monitoring of miRIDIAN microRNA Mimic/Hairpin Inhibitor 
Transfection Control with Dy547 transfection efficiency. Fluorescent and merged 
images of (A) A549 and (B) SK-LU-1 cells transfected with 80.0 nM miRIDIAN 
microRNA Mimic/Hairpin Inhibitor Transfection Control with Dy547. Percentage of 
mean transfection efficiency ± SD is indicated, and all images shown are a 
representative of triplicate independent experiments. 
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Figure 4.8: Normalized fold change of miR-769-5p, miR-361-5p, miR-1304, and miR-
608 mimic/inhibitor-transfected cells. (A) A549 and (B) SK-LU-1 mimic/inhibitor-
transfected cells, in comparison to cells transfected with scrambled negative controls. 
Samples were normalized to the endogenous control RNU6. Data presented as mean ± 
SD, n=3, with statistically significant differences between transfected cells and 
scrambled negative control-transfected cells denoted with * p-value ≤ 0.05. NC denotes 
cells transfected with scrambled RNA negative control. 
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Table 4.4: Fold change of miRNA in miRNA-transfected cells in comparison to fold 
change in scrambled negative control transfected cells. Data presented as mean ± SD, 
n=3, with statistically significant differences between transfected cells and scrambled 
negative control-transfected cells denoted with p-value ≤ 0.05. NC denotes cells 
transfected with scrambled RNA negative control. 
Treatment 
A549 SK-LU-1 
Fold 
Change† ± 
SD 
p-Value 
Fold 
Change† ± 
SD 
p-Value 
miR-769-5p Mimic 14.01 ± 1.46 0.0000 15.05 ± 0.36 0.0000 
miR-361-5p Mimic 11.26 ± 0.23 0.0000 10.51 ± 0.33 0.0000 
miR-1304 Mimic 23.39 ± 0.35 0.0000 23.31 ± 0.40 0.0005 
miR-608 Mimic 17.19 ± 0.76 0.0003 12.99 ± 0.46 0.0002 
Mimic NC 0.00 ± 0.00 n/a 0.00 ± 0.00 n/a 
miR-769-5p Inhibitor -2.50 ± 0.51 0.0000 -1.93 ± 0.11 0.0000 
miR-361-5p Inhibitor -1.76 ± 0.77 0.0013 -3.04 ± 0.73 0.0000 
miR-1304 Inhibitor 3.61 ± 0.69 0.0060 0.39 ± 0.21 0.0420 
miR-608 Inhibitor 0.33 ± 0.17 0.0393 -1.81 ± 0.46 0.0872 
Inhibitor NC 0.00 ± 0.00 n/a 0.00 ± 0.00 n/a 
† Negative values denote down-regulation, while positive values denote up-regulation 
4.3.2 Increased apoptosis observed in A549 and SK-LU-1 cells transfected with 
miR-608 mimics and miR-361-5p inhibitors 
 
Cell death in miRNA mimic and inhibitor transfected cells was detected 72 h post-
transfection using flow cytometry after annexin V-FITC/ PI staining in A549 and SK-
LU-1 cells. An increase in miR-608 expression and a knockdown of miR-361-5p 
expression resulted in a significant increase in the apoptotic population of A549 (43.96 
± 0.30 % and 23.10 ± 2.94 %, respectively) and SK-LU-1 cells (15.17 ± 1.27 % and 
49.93 ± 6.01 %, respectively) in comparison to total percentage of apoptosis observed in 
cells transfected with negative controls (Figure 4.9). Correspondingly, an increase in 
miR-608 and a decrease in miR-361-5p expression resulted in an increase in the relative 
caspase 3/7 activity in A549 (1.53 ± 0.17 and 1.20 ± 0.17 relative activity, respectively) 
and SK-LU-1 (1.71 ± 0.31 and 1.67 ± 0.07 relative activity, respectively) cells, 
indicating cell death was occurring through the mitochondrial apoptotic pathway 
(Figure 4.10). No significant changes in percentage of apoptosis and caspase 3/7 activity 
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were detected in cells transfected with miR-769-5p and miR-1304, therefore further 
downstream work was focused only on miR-608 and miR-361-5p. 
 
Figure 4.9: Detection of apoptosis 72 h post-transfection with miRNA mimics and 
inhibitors. (A) MiR-769-5p (B) miR-361-5p, (C) miR-1304, and (D) miR-608-induced 
apoptosis detection using flow cytometry after annexin V-FITC/ PI staining in A549 
and SK-LU-1 cells. Data presented as mean ± SD, n=3, with statistically significant 
differences between miRNA-transfected cells and scrambled negative control-
transfected cells denoted with * p-value ≤ 0.05. NC denotes cells transfected with 
scrambled RNA negative control. 
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Figure 4.9, continued. 
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Figure 4.10: Detection of caspase 3/7 activity 48 h post-transfection with miRNA 
mimics and inhibitors. (A) A549 and (B) SK-LU-1-miRNA transfected cells detection 
of caspase 3/7 activity. Data presented as mean ± SD, n=3, with statistically significant 
differences between transfected cells and scrambled negative control-transfected cells 
denoted with * p-value ≤ 0.05. NC denotes cells transfected with scrambled RNA 
negative control. 
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4.4 Transfection with miR-608 inhibitors and miR-361-5p mimics blocks 
siBCL-XL-induced apoptosis 
 
To determine the relationship between BCL-XL, miR-608/miR-361-5p and apoptosis, 
a combination study was carried out whereby cells were first transfected with siBCL-
XL, followed by transfection with either miR-608 inhibitors or miR-361-5p mimics. It 
was found that the apoptotic populations of BCL-XL-silenced A549 and SK-LU-1 cells 
were significantly decreased following miR-608 inhibitors (11.95 ± 1.18% from 22.09 ± 
1.47 and 12.36 ± 3.57% from 21.49 ± 3.350% in A549 and SK-LU-1 cells 
respectively) and miR-361-5p mimic transfection (5.13 ± 0.12% from 11.53 ± 0.83% 
and 12.03 ± 0.72% from 28.70 ± 0.56% in A549 and SK-LU-1 cells respectively) 
indicating that antagomiRs of miR-608 and mimics of miR-361-5p were able to block 
siBCL-XL-induced apoptosis (Figure 4.11). Correspondingly, a decrease in caspase 3/7 
activation was observed in BCL-XL-silenced A549 and SK-LU-1 cells co-transfected 
with miR-608 inhibitors (0.81 ± 0.10 from 2.64 ± 0.27 and 0.85 ± 0.10 from 3.83 ± 0.45 
relative activity, respectively) and miR-361-5p mimics (0.72 ± 0.09 from 2.60 ± 0.72 
and 0.85 ± 0.02 from 3.45 ± 0.44 relative activity, respectively) (Figure 4.12), thus 
suggesting that miR-608 and miR-361-5p plays an important role in the regulation of 
apoptotic properties.  
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Figure 4.11: Detection of apoptosis 72 h post co-transfection with siBCL-XL and 
miRNAs. (A) MiR-608 inhibitors and (B) miR-361-5p mimics blocks siBCL-XL-
induced cell death in A549 cells and SK-LU-1 cells. Data presented as mean ± SD, n=3, 
* p-value ≤ 0.05. siBCL-XL denotes siRNA-transfected cells. NC denotes cells 
transfected with scrambled RNA negative control.  
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Figure 4.12: Caspase 3/7 activity detection 48 h post co-transfection with siBCL-XL 
and miRNAs. (A) MiR-608 inhibitors and (B) miR-361-5p mimics blocks siBCL-XL-
induced caspase 3/7 activation in A549 cells and SK-LU-1 cells. Data presented as 
mean ± SD, n=3, * p-value ≤ 0.05. NC denotes cells transfected with scrambled RNA 
negative control. siBCL-XL denotes siRNA-transfected cells.  
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4.5 Up-regulation of miR-608 and down-regulation of miR-361-5p expression 
induces cell cycle arrest in A549 and SK-LU-1 cells 
 
To examine the effects of miRNA on cell cycle progression, transfected cells were 
stained with propidium iodide and analyzed using flow cytometry. Results indicate that 
the number of cells in S phase was substantially increased in cells transfected with miR-
608 mimics, in comparison to mimic NC-transfected cells, with a decrease in G0/G1 
phase cell population, suggesting that miR-608 induced S phase cell cycle arrest (Figure 
4.13A – Figure 4.13B). On the other hand, an increase in S phase cell population was 
seen in miR-361-5p inhibitor-transfected cells (Figure. 4.13C – Figure 4.13D), in 
comparison to inhibitor NC-transfected cells, thus suggesting that miR-361-5p plays a 
role in promoting cell cycle progression. Thus far, results have suggested that miR-608 
plays a tumour suppressive role in lung cancer progression while miR-361-5p appears to 
play an oncogenic role.  
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Figure 4.13: Cell cycle analysis 48 h post-transfection with miRNa mimics and 
inhibitors. Effect of (A – B) miR-608 and (C – D) miR-361-5p mimics and inhibitors on 
cell cycle distribution in A549 and SK-LU-1 cells. Data presented as mean ± SD, n=3,  
* p-value ≤ 0.05. NC denotes cells transfected with scrambled RNA negative control. I: 
G0/G1 Phase, II: S Phase, III: G2/M Phase. 
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Figure 4.13, continued. 
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Figure 4.13, continued. 
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Figure 4.13, continued. 
4.6 Up-regulation of miR-608 expression and down-regulation of miR-369-5p 
expression increases apoptosis in vivo 
 
To analyze the in vivo apoptotic effects of miR-608 and miR-361-5p, zebrafish were 
used as an animal model. A549 cells transfected with either miR-608 or miR-361-5p 
mimics, inhibitors or its corresponding negative controls, were microinjected into 
zebrafish embryos. Following staining with anti-rabbit fluorophore-conjugated 
antibodies, embryos were visualized using a Leica confocal microscope (Figure 4.14A 
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and Figure 4.15A). Analysis of fluorescent images using the ImageJ Analyst software 
indicated that detection of active caspase 3 was significantly increased by a 6.53 ± 2.08 
fold change in zebrafish embryos injected with miR-608 mimics (Figure 4.14B) and 
6.41 ± 1.04 fold change in miR-361-5p inhibitor-transfected cells (Figure 4.15B), in 
comparison to negative control-injected embryos. These results implied that miR-608 
mimics and miR-361-5p inhibitors are also able to induce apoptosis in vivo via caspase 
3 activation. 
 
Figure 4.14: Up-regulation of miR-608 induces caspase 3 activation in vivo. (A) 
Examination of zebrafish embryos by confocal microscopy following miR-608 
injection. Arrows indicate positive active caspase 3 staining. (B) Fluorescence was 
quantified and analyzed using ImageJ Analyst software to generate normalized arbitrary 
fluorescence units. Data presented as mean ± SD, n=15. Statistically significant 
differences between mimic-injected groups and mimic NC-injected groups denoted with 
* p-value ≤ 0.05. Statistically significant differences between non-injected group and 
injected untreated groups denoted with # p-value ≤ 0.05. NC denotes cells transfected 
with scrambled RNA negative control. 
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Figure 4.15: Inhibition of miR-361-5p induces caspase 3 activation in vivo. (A) 
Examination of zebrafish embryos by confocal microscopy following miR-361-5p 
injection. Arrows indicate positive active caspase 3 staining. (B) Fluorescence was 
quantified and analyzed using ImageJ Analyst software to generate normalized arbitrary 
fluorescence units. Data presented as mean ± SD, n=15. Statistically significant 
differences between inhibitor-injected groups and inhibitor NC-injected groups denoted 
with * p-value ≤ 0.05. Statistically significant differences between non-injected group 
and injected untreated groups denoted with # p-value ≤ 0.05. NC denotes cells 
transfected with scrambled RNA negative control. 
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4.7 MiR-608 and miR-361-5p-mediated apoptosis in A549 and SK-LU-1 cells is 
through the regulation of various signaling pathways 
 
4.7.1 MiR-608 and miR-361-5p are predicted to bind to AKT2 and SMAD2 
3’UTR, respectively 
 
To understand the underlying molecular mechanism behind miR-608 and miR-361-
5p mediated apoptosis, an in silico approach was used to identify the putative target 
genes using the TargetScan Human v5.2 algorithm, followed by gene-annotation 
enrichment analyses using the web tool DAVID v6.7. Enrichment of genes involved in 
cancer pathways indicated possible involvement of the TGFβ, PI3K/AKT, MAPK, 
WNT, and the intrinsic and extrinsic apoptotic pathways (Figure 4.16 and Figure 4.17). 
The 3’UTR of V-Akt Murine Thymoma Viral Oncogene Homolog 2 (AKT2) and 
Mothers Against Decapentaplegic Homolog 2 (SMAD2) contains miR-608 and miR-
361-5p binding sites, respectively, and are involved with apoptosis and proliferation and 
was thus chosen for further validation (Figure 4.18). 
 
111 
 
Figure 4.16: Hypothetical signaling network depicting the interactions of up-regulated 
miR-608 and it’s putative targets in various biological pathways including apoptosis, 
proliferation and angiogenesis. Key signaling pathways were predicted to include the 
TGFβ, PI3K/AKT, MAPK, WNT, and the intrinsic and extrinsic pathway. Genes in red 
indicate those predicted to be targets of miR-608. Numbers in red indicate total context 
score for that specific target with miR-608. 
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Figure 4.17: Hypothetical signaling network showing the interaction of down-regulated 
miR-361-5p and it’s putative targets in various biological pathways including apoptosis, 
proliferation and angiogenesis. Key signaling pathways of apoptosis regulation were 
predicted to include the TGFβ, PI3K/AKT, MAPK, and the intrinsic and extrinsic 
pathway. Genes in blue indicate those predicted to be targets of miR-361-5p. Numbers 
in dark blue indicate total context score for that specific target with miR-361-5p. 
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Figure 4.18: MiR-608 and miR-361-5p are predicted to target AKT2 and SMAD2 
3’UTR, respectively. (A) Sequence alignment of miR-608 and AKT2 3’UTR. AKT2 
3’UTR contains two predicted miR-608 binding sites at nucleotide 96 – 102 and 150 – 
158. (B) Sequence alignment of miR-361-5p and SMAD2 3’UTR. SMAD2 3’UTR 
contains two predicted miR-361-5p binding sites at nucleotide 7447 – 7454 and 7695 – 
7701. The seed-recognizing sites in the 3’UTR and the seed regions of the miRNA are 
highlighted in grey, while the mutated 3’UTR sequences are indicated in bold 
underlined font. 
 
4.7.2 MiR-608 and miR-361-5p directly binds to AKT2 and SMAD2 3’UTR, 
respectively, subsequently decreasing its protein expression 
 
To verify the interaction between miRNAs and their putative gene targets, AKT2 and 
SMAD2 3’UTR and their corresponding mutant counterparts, were cloned into the 3’ 
end of the pmirGLO Dual-Luciferase miRNA Target Expression Vector and the 
constructs verified by sequencing. Relative firefly luciferase activity, indicative of 
translation from the plasmid, was then assayed using the Dual Luciferase Reporter 
Assay System and measured in the presence of miR-608 or miR-361-5p mimics, or 
mimic negative control, and normalized using Renilla luciferase activity. Luciferase 
reporter assay confirmed that miR-608 and miR-361-5p mimics had a significant 
inhibitory effect on wild-type 3’UTR of AKT2 and SMAD2, (0.73 ± 0.05 and 0.35 ± 
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0.05 relative luciferase activity, respectively) but not on mutant 3’UTR (Figure 4.19). It 
was further demonstrated that mimic negative controls had no effect on either wild-type 
or mutant luciferase activity. In line with these results no significant difference in the 
wild-type or mutant luciferase activities was observed in cells transfected with miR-608 
and miR-361 inhibitors and inhibitor negative controls. This observation indicates that 
miR-608 and miR-361-5p can directly bind to the binding sites in AKT2 and SMAD2 
respectively; and this was further verified by a decrease in AKT2 and SMAD2 protein 
levels as analyzed by western blot (Figure 4.20 and Figure 4.21).  
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Figure 4.19: Dual luciferase reporter assay on miR-608 and miR-361-5p interaction 
with AKT2 and SMAD2 3’UTR, respectively. Normalized relative luciferase activity in 
(A) wildtype and mutant pmirGLO/AKT2 constructs in response to transfection with 
miR-608 mimic, inhibitor or their respective negative controls in A549 cells; (B) 
wildtype and mutant pmirGLO/SMAD2 constructs in response to transfection with miR-
361-5p mimic, inhibitor or their respective negative controls in A549 cells. Samples 
were normalized to Renilla luciferase activity. Data presented as mean ± SD, n=3, * p-
value ≤ 0.05. NC denotes cells transfected with scrambled RNA negative control. 
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Figure 4.20: Validation of interaction between miR-608 and AKT2 via western blot 
analysis. (A) Western blot bands of AKT2 protein following miR-608 transfection. (B) 
Densitometry analysis of AKT2 protein bands using the ImageJ Analyst software. 
Results were standardized against GAPDH levels and presented as relative protein 
levels. Data presented as mean ± SD, n=3, * p-value ≤ 0.05. NC denotes cells 
transfected with scrambled RNA negative control. 
Figure 4.21: Validation of interaction between miR-361-5p and SMAD2 via western 
blot analysis. (A) Western blot bands of SMAD2 protein following miR-361-5p 
transfection. (B) Densitometry analysis of SMAD2 protein bands using the ImageJ 
Analyst software. Results were standardized against GAPDH levels and presented as 
relative protein levels. Data presented as mean ± SD, n=3, * p-value ≤ 0.05. NC denotes 
cells transfected with scrambled RNA negative control. 
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4.8 MiR-608 and miR-361-5p regulate apoptosis in A549 and SK-LU-1 cells 
through the manipulation of AKT2 and SMAD2 expression, respectively 
 
4.8.1 siRNA-mediated silencing of AKT2 restores miR-608-induced effects in 
A549 and SK-LU-1 cells 
 
Together, results have demonstrated that miR-608 plays an important role in the 
regulation of apoptosis, and miR-608 has been identified as direct a regulator of AKT2. 
It can be hypothesized that low expression of miR-608 in NSCLC may inhibit its 
suppressive effects towards AKT2, thus causing AKT2 expression to be up-regulated, 
which in turn blocks apoptosis. To investigate this hypothesis, co-transfection of miR-
608 inhibitors and siRNA inhibiting AKT2 was performed in A549 and SK-LU-1 cells. 
SiRNAs were provided as a set of three siRNA duplexes, therefore to evaluate the 
silencing efficiency of the siRNAs, densitometry analysis of western blot bands was 
performed to evaluate the AKT2 protein expression in siRNA-transfected cells in 
comparison to siRNA NC transfected cells. Amongst the three siRNAs utilized, siRNA 
C was able to significantly decrease AKT2 protein levels to 72.86 ± 17.85% and 72.52 
± 17.83% in A549 and SK-LU-1 cells, respectively (Figure 4.22). As siRNA C (referred 
to as siAKT2 henceforth) had the greatest silencing efficiency amongst the three 
siRNAs, it was selected for further downstream work. 
 Cells transfected with miR-608 inhibitors alone led to an increased AKT2 
protein expression, while co-transfection of miR-608 inhibitors with siAKT2 was able to 
reverse this observation (Figure 4.23). Furthermore, siAKT2 was able to partially rescue 
the inhibition of apoptosis and caspase 3/7 activation induced by miR-608 inhibitors 
(Figure 4.24 and Figure 4.25), leading to a significant increase in apoptosis. 
Collectively, these results demonstrate the miR-608 plays a tumour suppressive role in 
NSCLC and this is at least partially through its inhibition of AKT2. 
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Figure 4.22: Quantitation of AKT2 bands following siRNA-based silencing of AKT2. 
(A) Western blot bands of AKT2 protein following transfection with siRNA duplexes 
used for AKT2 silencing. (B) Densitometry analysis of AKT2 protein bands using the 
ImageJ Analyst software. Results were standardized against the levels of GAPDH and 
presented as relative protein levels. Data presented as mean ± SD, n=3, with statistically 
significant differences denoted with * p-value ≤ 0.05. siRNA denotes siRNA-
transfected cells. siRNA NC denotes universal scrambled negative control siRNA-
transfected cells. 
Figure 4.23: Silencing of AKT2 decreased AKT2 protein levels. (A) Western blot 
analysis of AKT2 protein expression following co-transfection of miR-608 inhibitors 
and siAKT2. (B) Densitometry analysis of AKT2 protein bands using the ImageJ 
Analyst software. Results were standardized against the levels of GAPDH and presented 
as relative expression. Data presented as mean ± SD, n=3, * p-value ≤ 0.05. NC denotes 
cells transfected with scrambled RNA negative control. siAKT2 denotes siRNA-
transfected cells. siRNA NC denotes universal scrambled negative control siRNA-
transfected cells. 
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Figure 4.24: Detection of apoptosis 48 h post co-transfection with miR-608 inhibitors 
and siAKT2. Data presented as mean ± SD, n=3, * p-value ≤ 0.05. Inhibitor NC and 
siRNA NC were used as negative controls. NC denotes cells transfected with scrambled 
RNA negative control. siAKT2 denotes siRNA-transfected cells. siRNA NC denotes 
universal scrambled negative control siRNA-transfected cells. 
 
Figure 4.25: Detection of caspase 3/7 activity 48 h post co-transfection with miR-608 
inhibitors and siAKT2. Data presented as mean ± SD, n=3, * p-value ≤ 0.05. NC denotes 
cells transfected with scrambled RNA negative control. Inhibitor NC and siRNA NC 
were used as negative controls. siAKT2 denotes siRNA-transfected cells. siRNA NC 
denotes universal scrambled negative control siRNA-transfected cells. 
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4.8.2 Ectopic overexpression of SMAD2, without 3’UTR, restores miR-361-5p 
induced effects in A549 and SK-LU-1 cells 
 
Results have indicated that miR-361-5p suppresses apoptosis in A549 and SK-LU-1 
cells, and inhibits SMAD2 expression. It was thus predicted that miR-361-5p-mediated 
apoptosis inhibition could in part be credited to the SMAD2 gene. To further validate 
that the effect of miR-361-5p on apoptosis is mediated by SMAD2, gene rescue 
experiments were performed whereby SMAD2 overexpression vector 
(pCMV6/SMAD2), lacking its 3’UTR, was co-transfected into A549 and SK-LU-1 cells 
along with miR-361-5p mimic. SMAD2 protein expression levels were measured 48 h 
post transfection, and it was found that pCMV6/SMAD2 rescued the decreased protein 
expression that was observed in cells transfected with miR-361-5p mimics only (Figure 
4.26). Furthermore, pCMV6/SMAD2 was able to partially reverse the apoptosis 
inhibition caused by miR-361-5p (Figure 4.27 and Figure 4.28). Taken together, these 
observations suggest that the oncogenic role of miR-361-5p in lung adenocarcinoma 
cells is at least partially by inhibiting its target gene SMAD2. 
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Figure 4.26: Overexpression vector pCMV/SMAD2 increased SMAD2 protein levels. 
(A) Western blot analysis of SMAD2 protein expression following co-transfection of 
miR-361-5p mimics and pCMV6/SMAD2. (B) Densitometry analysis of SMAD2 
protein bands using the ImageJ Analyst software. Results were standardized against the 
levels of GAPDH and presented as relative protein levels. Data presented as mean ± SD, 
n=3, * p-value ≤ 0.05. NC denotes cells transfected with scrambled RNA negative 
control. pCMV6/SMAD2 denotes SMAD2 overexpression vector. pCMV6 denotes 
empty vectors. 
 
Figure 4.27: Detection of apoptosis 48 h post co-transfection with miR-361-5p mimics 
and pCMV6/SMAD2 vectors. Data presented as mean ± SD, n=3, * p-value ≤ 0.05. 
Mimic NC and pCMV6 were used as negative controls. NC denotes cells transfected 
with scrambled RNA negative control. pCMV6/SMAD2 denotes SMAD2 
overexpression vector. pCMV6 denotes empty vectors. 
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Figure 4.28: Detection of caspase 3/7 activity 48 h post co-transfection with miR-361-
5p mimics and pCMV6/SMAD2 vectors. Data presented as mean ± SD, n=3, * p-value ≤ 
0.05. Mimic NC and pCMV6 were used as negative controls. NC denotes cells 
transfected with scrambled RNA negative control. pCMV6/SMAD2 denotes SMAD2 
overexpression vector. pCMV6 denotes empty vectors. 
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CHAPTER 5: DISCUSSION 
5.1 BCL-XL silencing induces a decrease in cell viability and an increase in 
apoptosis in A549 and SK-LU-1 cells 
 
BCL-XL expression is generally found to be significantly increased in human 
cancers. Analysis of BCL-XL expression using immunohistochemistry, reverse 
transcription PCR or western blotting has revealed that BCL-XL is positively expressed 
in invasive ductal adenocarcinomas (Miyamoto et al., 1999), squamous cell carcinoma 
of the head and neck (Pena et al., 1999) and ovarian tumours (Marone et al., 1998) in 
comparison to neighboring normal tissues. Therefore, BCL-XL can be used as an 
important marker for various cancers. Reports have also indicated that up-regulation of 
BCL-XL contributes to protection of cancer cell lines from apoptosis stimulated by a 
wide array of chemotherapeutic agents including teniposide, etoposide, methotrexate, 
fluorouracil, hydroxyurea and cisplatin (Simonian et al., 1997). In metastatic malignant 
melanoma, high levels of BCL-XL lead to avoidance of the normal cell death pathway, 
and may contribute to melanoma progression and chemotherapy resistance (Tang et al., 
1998). Similarly an increased expression of BCL-XL in ovarian cancer cell lines 
contributes to chemoresistance against cisplatin through the blockage of caspase 3 
activity and Poly (ADP-ribose) polymerase (PARP) cleavage (Yang et al., 2004). High 
expression of BCL-XL in diffuse large B cell non-Hodgkin’s lymphoma was also 
demonstrated to be associated with chemoresistance in short survival group of patients 
(Bairey et al., 1999). Other studies have reported that BCL-XL plays a critical role in the 
development of tumours and malignant transformation. BCL-XL expression is 
significantly higher in tongue carcinoma tissues than in normal tongue tissues, with a 
higher expression found in oral tongue squamous cell carcinoma (OTSCC) tissues in 
comparison to oral tongue adenocarcinoma (OTA) tissues (Zhang et al., 2014a). Zhang 
et al. (2014) also discovered that expression of BCL-XL was considerably higher in 
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tissues with lymph node metastasis than in those without lymph node metastasis. Up-
regulation of BCL-XL in squamous cell carcinoma of the tongue was thus concluded to 
be associated with the early progression of this disease but also inhibits the 
differentiation of the cancer (Zhang et al., 2014a). Similarly, two studies have shown 
that in human colon cancer, BCL-XL was found to be overexpressed, and was strongly 
correlated with the pathological grade, lymph node metastasis and Duke’s stage of 
colorectal carcinoma (Krajewska et al., 1996; Biroccio et al., 2001; Zhang et al., 2008), 
suggesting that overexpression of BCL-XL was associated with the progression and 
invasion of this cancer. Together these results indicate the usefulness of BCL-XL 
expression as a prognostic marker in cancers. 
Correspondingly, expression of BCL-XL was found to be frequently up-regulated 
significantly in NSCLC (Groeger et al., 2004; Karczmarek-Borowska et al., 2006; 
Sanchez-Ceja et al., 2006). Interestingly, high expression of BCL-XL in NSCLC cells, 
specifically in the lung adenocarcinoma subgroup, is usually accompanied with a low 
expression or non-detectable levels of BCL-2, suggesting that BCL-XL is the major 
apoptosis-repressor protein in these cells (Reeve et al., 1996; Koty et al., 2002; 
Berrieman et al., 2005). Various studies have shown that anti-sense treatment of BCL-
XL induces a strong apoptotic response and increased chemosensitivity in lung 
adenocarcinoma cells that lack significant levels of BCL-2, while the same response was 
not observed in SCLC cells most probably due to protection by increased levels of BCL-
2 that are also expressed in these cells (Leech et al., 2000; Lei et al., 2007; Park et al., 
2013). Together, these results suggest that BCL-XL may be a useful diagnostic marker 
and can be a potential specific therapeutic target. 
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In this present study, BCL-XL expression in SK-LU-1 lung adenocarcinoma cells was 
silenced via siRNA transfection to corroborate the findings in A549 lung 
adenocarcinoma cells previously reported in my Masters study (Othman, 2012). A set of 
three siRNAs were utilized, and since the siRNAs do not fluoresce, visual monitoring of 
transfection efficiency was first determined using the BLOCK-iT™ Alexa Fluor® Red 
Fluorescent Oligo, which is a highly stable, fluorescein-labeled, non-targeted dsRNA 
compound. As seen in Figure 4.1, results indicated that a satisfactory transfection 
efficiency of greater than 80.0% was obtained 24 h post-transfection, thus allowing for 
silencing efficiency of the three siRNAs to be determined using qRT-PCR. 
qRT-PCR results revealed that BCL-XL expression levels were significantly 
decreased for all siRNA-transfected SK-LU-1 cells, in comparison to non-transfected 
cells (Figure 4.2). Amongst the three siRNAs utilized, siRNA 1 had a greatest negative 
fold change of -4.03 ± 0.01 with a percentage BCL-XL gene knockdown of 75.16 ± 
0.92% (Table 4.1). Western blot analysis was then performed to confirm successful 
silencing of BCL-XL, and correspondingly, siRNA 1 was demonstrated to induce the 
greatest decrease in BCL-XL protein levels with a 98.33 ± 0.50% decrease in siRNA 1-
transfected SK-LU-1 cells, as determined by densitometry analysis of western blot 
bands (Figure 4.3). As siRNA 1 (henceforth referred to as siBCL-XL) had the greatest 
silencing efficiency amongst the three siRNAs, it was selected for further downstream 
work.  
MTT viability assay and annexin V-FITC detection was then performed to determine 
the biological effects of BCL-XL silencing in SK-LU-1 cells. Results indicated that a 
knockdown of BCL-XL expression led to a significant decrease in cell viability, 48-h 
post-transfection, in siBCL-XL -transfected cells (58.22 ± 0.98%) in comparison to non-
transfected cells (103.29 ± 3.69) (Figure 4.4 and Table 4.2). A shift in population of 
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cells from viable cells to early and late stage apoptosis was also observed in siBCL-XL-
transfected cells (Figure 4.5). At this point, the biological effects of BCL-XL silencing 
in SK-LU-1 cells correlate with those observed in A549 cells (Othman, 2012). More 
importantly, these findings are consistent with other BCL-XL antisense treatment 
studies, as described previously, thus validating that BCL-XL may be the critical 
apoptosis repressor protein in lung adenocarcinoma cell lines. 
5.2 BCL-XL silencing dysregulates the miRNA expression profile in A549 and 
SK-LU-1 cells 
 
While silencing of BCL-XL leads to an increase of apoptosis mediated cell death as 
observed through the annexin V-FITC/PI assay, the specific mechanism by which cell 
death occurs cannot be solely ascribed towards BCL-XL inhibition alone. There exists 
the possibility of rippling effects from miRNA expression alterations towards gene 
targets associated with other cell death-inducing factors, in response to BCL-XL 
silencing.  
The expression of miRNAs can be controlled by various mechanisms which when 
disrupted can lead to deregulated expression of miRNAs in human diseases including 
cancer. For example, the expression of miRNAs can be modulated by defects or 
changes that occur in the activity of important miRNA biogenesis enzymes such as 
Dicer and Drosha, due to mutations or epigenetic modifications of these enzymes 
(Thomson et al., 2006; Nakamura et al., 2007; Merritt et al., 2008; Kawahara, 2014). 
The effects of endogenous (hormones, cytokines) and exogenous (xenobiotics) 
compounds can also play a role in the regulation of miRNA expression (Chen, 2010; 
Huumonen et al., 2014; Marrone et al., 2016). Epigenetic changes, such as, DNA 
hypermethylation has also been reported to cause changes in miRNA expression as 
many miRNAs are associated with CpG islands (Weber et al., 2007; Lehmann et al., 
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2008; Toyota et al., 2008). Finally, an important contributor to miRNA expression is 
alterations in transcription factor activity (Chang et al., 2007; Burk et al., 2008; Mott et 
al., 2010).  
BCL-XL has been reported to play a role in the indirect regulation of an important 
transcription factor, nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB). In a study by Gabellini and colleagues (2008), up-regulation of BCL-XL was 
found to decrease the cytoplasmic expression of IκBα protein with a corresponding 
phosphorylation at Ser32 and Ser36 amino acid residues of this protein, leading to its 
subsequent degradation (Gabellini et al., 2008). Following this, an increase in nuclear 
p65 protein expression was found in the glioblastoma cell lines overexpressed with 
BCL-XL (Gabellini et al., 2008). In turn, NFκB has been reported to be able to regulate 
the expression of various miRNAs including miR-9 (Bazzoni et al., 2009), miR-143 
(Zhang et al., 2009), miR-146 (Pacifico et al., 2010; Suzuki et al., 2010), miR-21 (Niu 
et al., 2012), miR-34a (Li et al., 2012b) and miR-224 (Scisciani et al., 2012). With this 
in mind, it can be assumed that silencing of BCL-XL will cause a dysregulation of 
miRNA expression profiles, whether it is a direct or indirect regulation. 
To date, there have been no studies conducted to identify miRNAs regulated or 
affected by the expression of BCL-XL. MiRNAs play an integral role in the regulation 
of apoptosis in tumourigenesis, and numerous studies have reported dysregulated 
miRNA expression profiles in cancers. Therefore, profiling of differences in miRNA 
expression in BCL-XL-silenced human lung adenocarcinoma cells and non-silenced 
cells is useful in identification of specific miRNAs that influence the apoptosis process. 
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Previously in my Masters project, a global miRNA expression profile was produced 
detailing the dysregulation of miRNAs between BCL-XL-silenced and non-silenced 
A549 cells. To determine whether the same pattern can be observed in a secondary lung 
adenocarcinoma cell line, SK-LU-1, the expression of five candidate miRNAs (miR-
181a, miR-769-5p, miR-361-5p, miR-1304, and miR-608) were evaluated using RT-
qPCR. Results confirmed that the same pattern of dysregulation for these five miRNAs 
was present in both A549 and SK-LU-1 (Figure 4.6 and Table 4.3), suggesting that 
these miRNAs may be cancer specific and may be suitable markers for NSCLC. 
At the time experimentation was being conducted for this study, there were a number 
of publications implicating the candidate miRNAs selected for this study in a wide 
variety of cancers. For example, miR-769-5p expression is reported to be up-regulated 
in mutated Merkel cell polyomavirus (MCV) positive Merkel cell carcinoma (MCC) 
(Xie et al., 2014) and in hypoxic lung cancer cells (Geng et al., 2016), where it 
exhibited its functions in hypoxia-induced lung cancer cells through the regulation of 
AT-rich interaction domain 1A (ARID1A) and SMAD2 (Geng et al., 2016). On the other 
hand, miR-1304 is up-regulated in response to paclitaxel treatment in hypopharynx 
cancer (HPC) cells, Fadu, and can potentially be a biomarker or therapeutic target for 
paclitaxel-based therapy in HPC patients (Xu et al., 2013). Furthermore, miR-1304 was 
one amongst four miRNAs that was able to discriminate cases as high or low risk 
prognosis in lower-grade glioma with isocitrate dehydrogenase (IDH) 1/2 mutations 
(Cheng et al., 2017). 
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Expression of miR-361-5p was reported to vary depending on the type of cancer, and 
it has been shown that this miRNA can function as either a tumour suppressor or an 
oncomiR. In colorectal and gastric cancer, miR-361-5p plays a tumour suppressive role 
and inhibits cell proliferation, invasion and metastasis through the direct binding of 
staphylococcal nuclease domain containing-1 (SND1) (Ma et al., 2015). MiR-361-5p 
also behaves as a tumour suppressor in hepatocellular carcinoma (Sun et al., 2016) and 
prostate cancer (Liu et al., 2014), inhibiting cell proliferation and inducing apoptosis 
through direct inhibition of C-X-C chemokine receptor type 6 (CXCR6) and signal 
transducer and activator of transcription 6 (STAT6), respectively. In NSCLC, miR-361-
5p expression is significantly down-regulated in cancerous tissues and is associated with 
low survival in NSCLC patients (Zhuang et al., 2016). Conversely, in cervical cancer, 
miR-361-5p functions as an oncomiR; enhancing cell growth and promoting increased 
migration and invasion capacity of cervical cells through mediation of the epithelial-to-
mesenchymal (EMT) transition (Wu et al., 2013a). 
MiR-608 expression is a prognostic marker in carcinogenesis with its expression 
being down-regulated in various cancers including chordoma cancer (Zhang et al., 
2014b), colon cancer (Yang et al., 2016), glioblastoma (Wang et al., 2016), and 
osteosarcoma (Wu et al., 2016).  Single nucleotide polymorphisms (SNPs) 
rs4919510 of miR-608 is shown to serve as predictors of clinical outcomes in colorectal 
cancer (Ryan et al., 2012), esophageal squamous cell carcinoma (ESCC), (Yang et al., 
2014), breast cancer (Huang et al., 2012; Hashemi et al., 2016b) and bladder cancer 
(Hashemi, 2016a). MiR-608 is also a marker to predict locoregional recurrence in 
radiotherapy-treated nasopharyngeal carcinoma (Zheng et al., 2013). rs4919510 SNP in 
miR-608 has also been reported to influence HER2-positive breast cancer risk and 
tumour proliferation (Huang et al., 2012). In chordoma cancer, miR-608 induces 
apoptosis and hinders cell proliferation via regulation of epidermal growth factor 
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receptor (EGFR) and BCL-XL (Zhang et al., 2014b). MiR-608 has also been shown to 
directly target macrophage migration inhibitory factor (MIF), inhibiting proliferation, 
migration and invasion, and inducing apoptosis in both osteosarcoma cell lines (Wu et 
al., 2016) and glioma stem cells (Wang et al., 2016). Furthermore, miR-608 has been 
demonstrated to repress tumourigenesis of colon cancer cells both in vitro and in vivo 
through the regulation of N-a-acetyltransferase 10 protein (NAA10) (Yang et al., 2016). 
Out of the five candidate miRNAs dysregulated by BCL-XL silencing, miR-181a was 
the most extensively studied. The altered expression of miR-181a has been discovered 
in various cancers, with its expression significantly up-regulated in thyroid cancer (He 
et al., 2005), esophageal squamous cell carcinoma (Xiang et al., 2014), hepatocellular 
carcinoma (Zhang et al., 2011), breast cancer (Ouyang et al., 2014), colon cancer (Wei 
et al., 2014), and cutaneous T-cell lymphoma (Sandoval et al., 2015). Up-regulation of 
miR-181a in gastric cancer promotes cell proliferation (Chen et al., 2013), while 
increased levels in ovarian cancer induces increased cellular survival, migration, 
invasion and drug resistance (Parikh et al., 2014). MiR-181a is elevated in colorectal 
cancer with metastasis, with increased expressions promoting cell motility and invasion 
as well as tumour growth and liver metastasis, through the inhibition of WNT inhibitory 
factor 1 (WIF-1) (Ji et al., 2014). However, in glioblastoma multiforme, the most 
malignant type of brain tumour, expression of miR-181a is down-regulated and ectopic 
overexpression was able to inhibit invasive proliferation of glioblastoma cells (She et 
al., 2014). MiR-181a has also been reported to be down-regulated in oral squamous cell 
carcinoma (OSCC), with ectopic overexpression suppressing proliferation and 
anchorage independent growth ability of OSCC (Shin et al., 2011). MiR-181a was 
discovered to play a tumour suppressive role in OSCC partially through the regulation 
of the KRAS gene (Shin et al., 2011). As miR-181a was already well studied, the 
functional roles of miR-181a were not further evaluated in this study. 
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5.3 MiR-608 and miR-361-5p plays a significant role in the apoptotic 
properties of A549 and SK-LU-1 cells 
 
The function of miRNAs dysregulated in response to BCL-XL silencing was then 
elucidated via gain-of-function and loss-of-function studies. Overexpression of miRNA 
using transfectable synthetic miRNA mimics was performed to supplement endogenous 
miRNA activity to determine the functional roles, whereas knockdown or down-
regulation of miRNAs using miRNA hairpin inhibitors was intended to suppress 
endogenous miRNAs. A combination of up-regulation and down-regulation of miRNAs 
can aid in the identification of genes and cellular processes regulated by specific 
miRNAs. 
Transfection efficiency was first evaluated through the visual monitoring of the 
Transfection Controls with Dy547 using fluorescence microscopy (Figure 4.7), to 
ensure an ≥ 80.0% transfection efficiency was achieved when transfecting a final 
concentration of 80.0 nM into the cells. Following this, the degree of amplification and 
suppression of miRNA levels achieved by transfection of 80.0 nM mimics and/or 
inhibitors were quantified using RT-qPCR. MiRNA mimics were able to induce at least 
a 10-fold increase in expression; while miRNA inhibitors were able to silence 
endogenous miRNA levels to a smaller extent (Figure 4.8 and Table 4.4). This subtle 
decrease in miRNA expression may be explained by the mechanism by which miRNA 
inhibitors function in the cells, as they are required to compete with cellular target 
mRNAs to sequester mature miRNA. A smaller decrease in fold change of miRNA 
expression may thus indicate unsuccessful competition of the miRNA inhibitors with 
mRNAs. 
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The functional roles miRNAs play in apoptosis was then assessed using the FITC 
annexin V apoptosis detection kit. An early feature of apoptosis is the loss of plasma 
membrane asymmetry, in which case the membrane phospholipid phosphatidylserine 
(PS) becomes translocated from the inner to the outer leaflet of the plasma membrane 
(Fadok et al., 1992). Exposure of the PS to the external cellular environment allows for 
binding to a fluorochrome-tagged protein annexin V, which has a high affinity for PS, 
thus enabling detection by flow cytometry of cells undergoing apoptosis (Koopman et 
al., 1994; van Engeland et al., 1998). In the later stages of cell death, when loss of 
membrane integrity has occurred, staining with annexin V in conjunction with a vital 
dye, such as, PI allows for discrimination of early and late apoptotic cells, as viable cells 
exclude PI due to their intact membranes whereas damaged or dead cells are permeable 
to PI (Nicoletti et al., 1991). Therefore, viable live cells will have minimal annexin V 
and PI fluorescence, cells in early stage of apoptosis will have bright annexin V 
fluorescence but still exclude PI, and advance to late stage of apoptosis and secondary 
necrotic cells will stain strongly with both annexin V and PI.  
Of the four miRNAs evaluated, only miR-608 and miR-361-5p were able to elicit 
significant changes in apoptosis. Overexpression of miR-608 expression via mimics and 
a down-regulation of miR-361-5p through miRNA inhibitors were able to significantly 
increase the apoptotic population in both A549 and SK-LU-1 as demonstrated via flow 
cytometry analysis of annexin V (Figure 4.9). No significant changes in apoptosis were 
observed with the transfection of either miR-769-5p or miR-1304, indicating that they 
may not play critical roles in the apoptotic properties of lung adenocarcinoma. 
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To confirm the presence of an apoptosis process, activation of caspase 3 and 7 were 
analyzed using the Caspase-Glo® 3/7 assay. As previously described in Chapter 2, 
caspases are a large protein family that maintains homeostasis through the regulation of 
cell death and inflammation (Thornberry & Lazebnik, 1998). The activation of effector 
caspase 3 and caspase 7 cleaves downstream targets that result in the irreversible 
commitment of cells to apoptotic death, thus making them reliable markers for 
apoptosis. The Caspase-Glo® 3/7 assay is a homogenous, luminescent assay that 
measures the activities of caspase 3 and 7, whereby the amount of luminescence 
measured is proportional to the amount of caspase activity present. Corresponding to 
flow cytometry analysis of annexin V, caspase 3/7 activity in A549 and SK-LU-1 was 
significantly increased following transfection with miR-608 mimics and miR-361-5p 
inhibitors (Figure 4.10). Similarly, no significant changes in caspase 3/7 activity were 
detected in cells transfected with miR-769-5p and miR-1304.  
Thus far, two independent results were observed in the form that BCL-XL regulates 
the expression profile of miRNAs, and miRNAs in turn regulate the apoptotic properties 
of lung adenocarcinoma cells. To confirm the association between BCL-XL, miRNA 
and cell death, a combination study was performed whereby cells were first transfected 
with siBCL-XL, followed by transfection with either miR-608 inhibitors or miR-361-5p 
mimics. Results revealed that the increased apoptotic population seen in BCL-XL 
silenced cells was significantly decreased following miR-608 inhibitor and miR-361-5p 
mimic transfection as determined through flow cytometric analysis of annexin V 
(Figure 4.11) and luminescence analysis of caspase 3/7 activation (Figure 4.12). This 
suggests that miR-608 and miR-361-5p play a significant role in blocking BCL-XL 
induced cell death. 
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Taken together, results have shown the ability of miR-608 and miR-361-5p to play a 
role in the regulation of apoptosis in lung adenocarcinoma cells and at this point provide 
the first indication that miR-608 may play a tumour suppressive role while miR-361-5p 
may play an oncogenic role in lung adenocarcinoma.  
As mentioned previously in Section 5.2, previous studies in NSCLC have described 
miR-361-5p as a tumour suppressor, however opposing results were obtained in this 
present study. Results from this study have demonstrated that inhibition of miR-361-5p 
increases apoptosis and caspase 3/7 activation, suggesting that miR-361-5p may also 
play an oncogenic role in the regulation of apoptosis in NSCLC. The opposing roles of 
miR-361-5p in different cancers is still not well understood, however it can be 
hypothesized that the specific functions of miR-36-5p may be tissue- or cell-specific 
and strongly depends upon their downstream targets. The previous findings of miR-361-
5p have been obtained from studies using tissue samples (Zhuang et al., 2016) or the 
H23 lung adenocarcinoma cell line (Ma et al., 2015). Meanwhile results of this study 
examine the expression of miR-361-5p in response to BCL-XL silencing and in two 
different cell lines, A549 and SK-LU-1. Therefore, further experiments should be 
conducted to further understand the roles miR-361-5p play in various cancers and cell 
lines. 
5.4 MiR-608 and miR-361-5p induces cell cycle arrest at the S phase in A549 
and SK-LU-1 cells 
 
The balance between cell proliferation and cell death must be regulated in order to 
maintain tissue homeostasis. The connection between the two processes can be achieved 
through coupling of cell cycle and cell death through the use, or control, of a shared set 
of key factors (King & Cidlowski, 1995). Accumulating evidence has shown that in 
certain situations, deregulation of cell cycle components can prevent or induce apoptotic 
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responses (Fotedar et al., 1996), involving key proteins, such as, v-Myc avian 
myelocytomatosis viral oncogene homolog (c-MYC) (Amati et al., 1993), tumour 
protein p53 (Levine, 1997), and retinoblastoma protein, pRB (Haas-Kogan et al., 1995) 
in the regulation of both apoptosis and cell cycle (Alenzi, 2004).  
The BCL-2 family of proteins has also been associated in the control of apoptosis 
and cell proliferation. The most prominent effect on cell cycle exhibited by BCL-2 and 
BCL-XL is the delay of cell progression into the S phase from quiescence, through the 
inhibition of MYC activation by elevating expression of the cell cycle inhibitor, p27 
(Huang et al., 1997; Greider et al., 2002). Furthermore, it was found that a mutation of 
the conserved residue tyrosine 22 (Y22) in the BH4 domain of BCL-XL removed their 
capability to delay entry into S phase, without affecting their ability to inhibit apoptosis, 
suggesting that the regulation of anti-apoptosis and cell proliferation by BCL-XL is 
genetically separate (Huang et al., 1997). With this knowledge, it was therefore of 
interest to determine whether miRNAs dysregulated by the silencing of BCL-XL, can 
also be involved in the progression of cell cycle in lung adenocarcinoma cells.  
Analysis of PI stained miR-608 and miR-361-5p-transfected cells via flow cytometry 
revealed the ability of these miRNAs to regulate cell cycle. Ectopic expression of miR-
608 and silencing of miR-361-5p was shown to induce a cell cycle arrest in both A549 
and SK-LU-1 cells, with an increase in cell population in the S phase and a decrease in 
the G0/G1 phase (Figure 4.13). Bioinformatics analysis of putative miRNA gene targets 
identified retinoblastoma-associated protein, E2F, as a target of miR-608 and pRB as a 
target of miR-361-5p. As miRNAs are negative regulators, overexpression of miR-608 
may lead to a decrease in E2F, which is a positive regulator of genes required for 
transition from G0 to S phase (Dyson, 1998; Nevins, 1998). On the other hand, 
inhibition of miR-361-5p may lead to an increase in its target gene pRB, which is a 
136 
negative regulator of cell growth, blocking transcription of S phase genes (Weintraub et 
al., 1995). However, these conclusions are only speculative and further experimental 
work would have to be performed to confirm direct regulation of E2F and pRB by miR-
608 and miR-361-5p, respectively. 
5.5 MiR-608 and miR-361-5p induces caspase 3 activation in vivo 
In vitro assays are only approximate reconstitutions of biological processes occurring 
under controlled conditions, it is therefore advantageous to validate the results of in 
vitro experimentations in an in vivo model. Zebrafish (Danio rerio) have been widely 
used in cancer research. An evaluation of the zebrafish genome with the human genome 
sequence demonstrates many human cancer genes are structurally and functionally 
conserved in zebrafish (Amatruda et al., 2002; Stoletov & Klemke, 2008). Certain 
advantages, such as, rapid generation time, transparent embryos, large clutch size, ex 
utero development of the embryo, and lower maintenance costs make the use of 
zebrafish, over traditional vertebrate models, very appealing (Lieschke & Currie, 2007; 
Feitsma & Cuppen, 2008; Shive, 2013).  
Another benefit of using zebrafish embryos is that xenotransplantation in the early 
life-stages of zebrafish do not require immunosuppression as their adaptive immune 
system only matures at 3-4 weeks after fertilization (Willett et al., 1999; Lam et al., 
2004). The first report of successful xenotransplantation of human cancer cells into 
zebrafish was in 2005, whereby Lee and colleagues transplanted zebrafish embryos with 
human metastatic melanoma cells and discovered that the cells were able to survive, 
divide and migrate (Lee et al., 2005). Since then there have been many reports of 
successful xenotransplantation, by microinjection, of human cancer cells into zebrafish 
embryo (Haldi et al., 2006; Nicoli et al., 2007; Marques et al., 2009; Pruvot et al., 2011; 
Yang et al., 2013). Zebrafish embryos have thus been used to study the behavior of 
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xenografted cells in regards to various biological pathways including metastasis 
(Marques et al., 2009), invasion (Yang et al., 2013), angiogenesis (Lee et al., 2009), as 
well as for the screening of various anti-cancer agents (Pruvot et al., 2011; Jung et al., 
2012).  
The yolk is the ideal location for injection, as it provides a nutrient rich environment 
for injected cells allowing for cell growth and migration (Haldi et al., 2006). The yolk 
sac is also able to retain a large number of injected cells, approximately 50-100 cells, 
without expulsion into the embryo media (Haldi et al., 2006). Furthermore, successful 
engraftment in zebrafish can be achieved from fewer cells in comparison to 
xenotransplantation in immunosuppressive mouse strains; therefore host numbers can 
be scaled up easily, which improves the validity of statistical analyses (Veinotte et al., 
2014). 
Another advantage of using zebrafish embryo is its optical transparency which 
allows for the real-time observation of tumour mass formation of fluorescently labeled 
cancer cells (Haldi et al., 2006; Eguiara et al., 2011; Zhao et al., 2011), as well as 
allowing the possibility to perform immunostaining and in situ hybridization on whole 
embryos without the need for xenograft biopsies (Veinotte et al., 2014). The pigment 
formation in zebrafish develop rapidly, so to increase signal detection by whole mount 
in situ hybridization and confocal microscopy, embryos are treated with 1-phenyl 2-
thiourea (PTU) during embryogenesis which help to inhibit melanogenesis (Whittaker, 
1966; Eppig, 1970). In this study zebrafish embryos were maintained in system water 
containing PTU 24 h prior to microinjection with transfected A549 cells. Optical 
transparency achieved by PTU treatment then allowed for visualization of fluorophore-
conjugated active caspase 3 antibodies using a confocal microscope. Analysis of 
fluorescent images using the ImageJ Analyst software demonstrated that zebrafish 
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embryos injected with miR-608 mimic and miR-361-5p inhibitor-transfected cells led to 
a significant increase in active caspase 3 detection in comparison to negative control 
injected zebrafish (Figure 4.14 and 4.15). These results were in accordance with the 
miRNA’s in vitro ability to induce apoptosis via caspase 3 activation.  
5.6 MiR-608 and miR-361-5p are predicted to target signaling pathways 
associated with NSCLC apoptosis and proliferation 
 
Mature miRNAs recognize their target mRNA through base-pairing interactions at a 
seed region of 2-8 nucleotides on the miRNA and complementary nucleotides in the 
3’UTR of mRNAs. Gene expressions of the mRNAs are then inhibited by translational 
repression or cleavage (Bartel, 2004; Zamore & Haley, 2005). Each individual miRNA 
has hundreds of evolutionarily conserved targets (Bentwich et al., 2005) and it is 
estimated that miRNAs may regulate approximately 60% of all human genes (Lewis et 
al., 2005). For this reason, it is a challenge to identify the gene targets of miRNA; and 
sophisticated computational algorithms thus play a central role to aid in prediction of 
miRNA targets (Bentwich, 2005; Rajewsky, 2006; Doran & Strauss, 2007; Maziere & 
Enright, 2007). In this study, the TargetScan algorithm was utilized which predicts 
miRNA targets conserved across various genomes through the combination of 
thermodynamics-based modeling of RNA:RNA duplex interactions and comparative 
sequence analysis (Grimson et al., 2007). The list of putative miRNA targets obtained 
from TargetScan were then subjected to gene annotation enrichment using the DAVID 
software which is a bioinformatics resource that consists of an integrated biological 
knowledge-base and analytical tools that allow for extraction of biological meaning 
from large gene lists (Huang da et al., 2009). Results of the bioinformatics analysis in 
this study implicated various signaling pathways to be targeted by miR-608 and miR-
361-5p, which included the TGFβ, PI3K/AKT, MAPK, WNT, and the intrinsic and 
extrinsic pathways (Figure 4.16 and Figure 4.17). As discussed in Chapter 2, all six of 
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these pathways play a significant role in the regulation of apoptosis and cell 
proliferation.  
5.6.1 Targeting of the TGFβ signaling pathway 
MiR-608 and miR-361-5p were found to target various genes in the TGFβ signaling 
pathway, which is essential for the regulation of numerous cellular processes including 
differentiation, motility, lineage determination, cell proliferation, adhesion, and cell 
death (Massagué, 2008; Jeon & Jen, 2010). In silico analysis identified TGFβ, TGFβR1 
and SMAD2/4 as targets of down-regulated miR-361-5p indicating an increase of gene 
expression allowing them to perform their tumour suppressive activities. An increase in 
SMAD2 and SMAD4 levels will result in a decrease of X-linked inhibitor of apoptosis 
protein (XIAP) expression (Van Themsche et al., 2010), which in turn releases caspase 3 
allowing it to induce apoptosis. Furthermore, activation of SMAD2/4 will induce the 
transcription of p15, a cylin-dependent kinase inhibitor, leading to growth arrest (Feng 
et al., 2000). On the other hand, cyclin D and E2F are positive regulators of cell cycle 
progression and they are predicted to be targeted by up-regulated miR-608, leading to 
cyclin dependent kinase (CDK) inhibition and accumulation of hypo-phosphorylated 
pRB, which in turn induces cell cycle arrest (Reynisdottir et al., 1995; Hanahan & 
Weinberg, 2000). 
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5.6.2 Targeting of the PI3K/AKT signaling pathway 
The PI3K/AKT pathway is an important regulator of cell survival and proliferation in 
lung cancer (Vivanco & Sawyers, 2002), and various members of this pathway were 
targeted by miR-608 and miR-361-5p. AKT plays a critical role in the activation of 
numerous biological processes imperative for tumourigenesis including inhibition of 
apoptosis, angiogenesis, cell proliferation, and tumour cell invasiveness (Testa & 
Bellacosa, 2001), and this study identified AKT as a putative target of up-regulated miR-
608. PI3K, which phosphorylates AKT, was also a target of miR-608, further reducing 
expression of AKT. As AKT is imperative for the regulation of many downstream 
transcription factors that control cell death genes (Brunet et al., 1999), inhibition of this 
survival factor would cause a subsequent increase in apoptosis. Forkhead transcription 
factor (FKHR) is a downstream protein inhibited by AKT, and pathway analysis 
predicted FKHR to be a target of miR-361-5p. Therefore, release of inhibition of FKHR 
by a decreased AKT and miR-361-5p expression would allow translocation of FKHR 
into the nucleus to induce target genes including pro-apoptotic BIM and FAS ligand to 
further trigger apoptosis (Brunet et al., 1999). 
5.6.3 Targeting of the MAPK signaling pathway 
The MAPK signaling pathway, specifically the ERK pathway, was also predicted to 
be targeted by miR-608 and miR-361-5p. RET proto-oncogene and coiled-coil domain 
containing 6 (CCDC6) are both targets of down-regulated miR-361-5p. An increase in 
the expression of RET and CCDC6 can lead to the formation of a CCDC6-Ret fusion 
protein (Matsubara et al., 2012), which will allow RET to be constitutively active 
resulting in increased activation of RAS (Plaza-Menacho et al., 2007). Activation of 
RAS leads to stimulation of various pathways, including the RAF-MEK-ERK pathway, 
which subsequently results in tumour cell metastasis, apoptosis, growth, proliferation, 
invasion and angiogenesis (Slebos et al., 1990; Aviel-Ronen et al., 2006). However 
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pathway analysis also predicted EGFR and hepatocyte growth factor receptor (MET) to 
be targets of miR-608. Both EGFR and MET had a higher TargetScan context score of       
-0.64 and -0.13, respectively, then that of RET (-0.23) and CCDC6 (-0.01), indicating 
that EGFR and MET may be a more positive predicted target. Therefore, decrease in 
EGFR and MET will indirectly lead to a decreased activation of RAS. Furthermore, 
RAF a proto-oncogene serine/threonine-protein kinase, found downstream of RAS, is 
also a target of miR-608. Inhibition of RAF will prevent phosphorylation of MEK and 
ERK. Therefore, even though MEK and ERK were targets of miR-361-5p, they would 
not be able to perform their tumourigenic functions, as upstream proteins would not be 
able to phosphorylate and activate them. Together up-regulation of miR-608 and down-
regulation of miR-361-5p could hypothetically work together to inhibit angiogenesis in 
lung adenocarcinoma cells. 
5.6.4 Targeting of the WNT signaling pathway 
Members of the WNT signaling pathway were also predicted to be targets of up-
regulated miR-608. Cell proliferation of A549 and SK-LU-1 can hypothetically be 
inhibited through the suppression of disheveled (DSH) and adenomatous polyposis coli 
(APC). Decreased expression of DSH and APC will result in the prevention of glycogen 
synthase-kinase-3-beta (GSK-3β)/APC/Axin complex activation and subsequent 
phosphorylation of β-catenin. Furthermore, inhibition of DSH will block survivin 
activation, via inhibition of T-cell factor/lymphoid enhancer factor (TCF/LEF), 
resulting in caspase activation and reinstating the cell’s ability to perform apoptosis 
(Uematsu et al., 2003; Mazieres et al., 2005; Van Scoyk et al., 2008). Downstream 
targets of the WNT pathway include CDK4/6 and cyclin D, which as described 
previously, will induce cell cycle arrest.   
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5.6.5 Targeting of the intrinsic and extrinsic signaling pathway 
The BCR-ABL fusion protein is a potent anti-apoptotic molecule that is formed 
when the ABL gene from chromosome 9 joins onto the BCR gene on chromosome 22 
(Prieto et al., 1970). This fusion protein is involved in the activation of various 
downstream effectors and signal transducers that regulate cell proliferation and 
apoptosis, including PI3K, AKT, ERK and STAT5 (Lugo et al., 1990; Shuai et al., 
1996; Skorski et al., 1997). BCR-ABL has also been found to elicit anti-apoptotic 
behavior through the induction of BCL-XL expression (Gesbert & Griffin, 2000; Horita 
et al., 2000). In regards to the intrinsic pathway, both BCR and BCL-XL are putative 
targets of miR-608, which hypothetically can result in increased apoptosis through 
cytochrome C release and activation of caspase 3. 
In the extrinsic pathway, the cell-surface FAS receptor is predicted to be targeted by 
both up-regulated miR-608 and down-regulated miR-361-5p. However, the context 
score for miR-361-5p is lower than that of miR-608, at -0.19, and is thus a more 
favourable positive target prediction. Activation of FAS receptors will lead to the 
recruitment of intracellular adaptor proteins, such as, Fas-associated death domains 
(FADD) to form scaffolding complexes (Strasser et al., 2009). These complexes will in 
turn recruit caspase 8, a member of the caspase family of cell death proteases, to be 
cleaved into an active enzyme. Pathway analysis indicate that activation of caspase 8 is 
not inhibited by the actions of either miR-608 or miR-361-5p, which will thus allow for 
pro-caspase 3 to be directly activated by pro-caspase 8 (Garrido et al., 2006), enabling 
an alternative pathway for apoptosis to be initiated in lung adenocarcinoma cells. 
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5.7 MiR-608 and miR-361-5p directly target AKT2 and SMAD2, respectively 
In silico analysis predicted many genes as targets of miR-608 and miR-361-5p. A 
reporter system was utilized to experimentally validate the direct binding of miRNA to 
specific mRNA targets. The rationale for using such an assay was that the binding of 
miRNA to the mRNA target site would inhibit the production of a reporter protein, 
leading to a decreased activity that can be measured and compared to a control (Kuhn et 
al., 2008). MiR-608 has sequence complementary to two regions in the 3’UTR of v-Akt 
Murine Thymoma Viral Oncogene Homolog 2 (AKT2) at bases 96 to 102 and 150 to 
158, while miR-361-5p has sequence complementary to two regions in the 3’UTR of 
Mothers Against Decapentaplegic Homolog 2 (SMAD2) at bases 7447 to 7454 and 7695 
to 7701 (Figure. 4.18). In this study, a fragment of the 3’UTR of the target gene of 
interest was cloned downstream of the luciferase open reading frame sequence 
contained in the pmirGLO reporter plasmid. Co-transfection of miR-608 and miR-361-
5p mimics with their respective wild-type 3’UTR plasmid constructs produced a 
decreased luciferase signal in comparison to the control (Figure 4.19). This signifies that 
the miRNA was able to directly bind to the regions of sequence complementary in the 
gene of interest, leading to its mRNA being destabilized and repression of luciferase 
reporter gene translation. On the other hand, co-transfection of miRNA inhibitors with 
the wild-type 3’UTR plasmid constructs resulted in a slight increase in luciferase 
activity. In this situation, it can be hypothesized that introduction of miRNA inhibitors 
prevents endogenous miRNAs from binding to wild-type 3’UTR plasmids, thus leading 
to increased translation and detection of luciferase, in comparison to cells transfected 
with the inhibitor negative control. 
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To validate whether the gene of interest is a true target of the miRNA, changes in the 
miRNA expression should correspond to a predictable change in the protein levels 
encoded by the target mRNA (Kuhn et al., 2008). Overexpression and silencing of 
miRNA expression using miRNA mimics and inhibitors was thus performed and 
western blot analysis was carried out using specific antibodies against AKT2 and 
SMAD2. Corresponding to the results obtained in the luciferase assay, a significant 
decrease was seen in the protein levels following transfection with miRNA mimics, 
whereby a significant increase in protein levels was seen in cells transfected with 
miRNA inhibitors (Figure 4.20 and Figure 4.21). Together, results have identified and 
confirmed AKT2 and SMAD2 to be novel targets of miR-608 and miR-361-5p, 
respectively.   
5.8 Regulatory mechanism of miR-608 and miR-361-5p-induced NSCLC 
apoptosis 
 
Thus far, results of this study have revealed that both miR-608 and miR-361-5p is 
critical for the regulation of apoptosis in lung adenocarcinoma cells.  In addition, miR-
608 was shown to directly target AKT2 whereas miR-361-5p binds directly to SMAD2 
3’UTR. However the association of AKT2 and SMAD2 with NSCLC apoptotic 
properties had to be further elucidated, and this was evaluated through gene rescue 
studies utilizing siRNAs and overexpression plasmids.  
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AKT2 is a serine/threonine protein kinase that contributes significantly in regulation 
of numerous biological pathways including angiogenesis, proliferation, metabolism, cell 
survival, and growth (Testa & Bellacosa, 2001; Martelli et al., 2012). Hyperactivation 
of AKT2 has been reported widely to play a role in human malignancy, with 
overexpression being reported in many cancers including ovarian (Cheng et al., 1992; 
Yuan et al., 2000), thyroid (Ringel et al., 2001), pancreatic (Altomare et al., 2002), 
colorectal (Itoh et al., 2002), breast (Arboleda et al., 2003; Santi & Lee, 2011), glioma 
(Mure et al., 2010; Cui et al., 2012) and lung cancer (Balsara et al., 2004; Lee et al., 
2011; Attoub et al., 2015).  
Frequent activation of AKT is an early and important event in the progression of 
lung cancer (Balsara et al., 2004) and its constitutive activation has been demonstrated 
in cell lines originating from premalignant and malignant human bronchial epithelial 
cells, but is not present in normal bronchial cells (West, 2003). AKT also plays a 
significant role in invasiveness; therefore frequent activation of AKT may potentially be 
important in the transformation of a precursor lung lesion to a malignant carcinoma 
(Balsara et al., 2004). In lung cancer, AKT has also been shown to contribute resistance 
towards chemotherapy, radiation and tyrosine kinase inhibitors through the regulation of 
survival signals that protect cells from undergoing apoptosis (Brognard; Nakashio et al., 
2000). Activated AKT overexpression in lung cancer has also been positively correlated 
with reduced patient survival (David et al., 2004). Furthermore, down-regulation of 
AKT2 in NSCLC cells resulted in cleavage of anti-apoptotic BCL-2 family protein, 
MCL-1, disruption of mitochondrial membrane potential, cytochrome c release and 
caspase cascade activation (Lee et al., 2011).  
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In this study, AKT2 was identified as a novel direct target of miR-608, and the pro-
apoptotic effects exhibited by inhibitors of miR-608 was reversed by the silencing of 
AKT2 via siRNAs in both A549 and SK-LU-1 cells (Figure 4.23 – Figure 4.25). This 
finding suggests that targeting of AKT2 could be the mechanism by which miR-608 
functions as a tumour suppressor in NSCLC. These results are in accordance to previous 
findings of the role AKT2 plays in regulation of apoptosis in NSCLC (Brognard; David 
et al., 2004). 
On the other hand, expression of miR-361-5p is down-regulated in response to 
silencing of BCL-XL and luciferase assay analysis has confirmed that miR-361-5p 
negatively regulates SMAD2 levels. Gene rescue studies using SMAD2 overexpression 
vectors demonstrated that ectopic up-regulation of SMAD2 was able to rescue the 
apoptotic inhibition effect exerted by miR-361-5p (Figure 4.26 – Figure 4.28). Taken 
together, these observations suggest that the oncogenic role of miR-361-5p in lung 
adenocarcinoma cells is at least partially by inhibiting its target gene SMAD2. 
SMADS, a family of structurally related proteins, function as signal transducers of 
TGFβ family member proteins and are important in the regulation of cell growth 
inhibition, cellular senescence, differentiation and apoptosis (Derynck et al., 1998; Itoh 
et al., 2000; Massagué, 2000; Massague & Wotton, 2000; Miyazono et al., 2000). 
SMAD2, a receptor-regulated SMAD, functions as a tumour suppressor and its 
expression has been reported to be decreased in various human cancers (Hoot et al., 
2008; Munker S, 2012; Samanta & Datta, 2012; Wu et al., 2012). Furthermore, 
emerging evidence has reported the critical role SMAD2 plays in apoptosis. Yang and 
colleagues provided one of the first reports of SMAD2 functioning as a tumour 
suppressor in 2009, whereby SMAD2 was identified to be a critical mediator of TGFβ-
induced apoptosis of prostate epithelial cells (Yang, 2009). They later reported that 
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apoptosis in prostate epithelial cells was induced through the suppression of survivin, an 
inhibitor of apoptosis, by SMAD2 together with pRB/E2F3 and cell cycle-regulated 
repressor element (CDE) and cell cycle gene homology region (CHR) (Yang et al., 
2008). SMAD2 is also associated with mitochondrial-based pro-apoptotic events 
through the activation of DAP-kinase promoter (Jang et al., 2002), and various studies 
have also shown that SMAD2 can down-regulate XIAP to induce caspase 3 activation 
and TRAIL-induced apoptosis (Wang et al., 2006; Xu et al., 2006; Van Themsche et al., 
2010; Xu et al., 2016). 
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CHAPTER 6: CONCLUSION 
In summary, this thesis has provided evidence that miR-608 and miR-361-5p play 
opposing roles in the regulation of apoptosis in NSCLC. MiR-608 was concluded to 
play a tumour suppressive role while miR-361-5p functions as an oncogenic miRNA. 
Ectopic overexpression and inhibition of miR-608 and miR-361-5p, respectively, was 
able to stimulate cell cycle arrest and promote apoptosis both in vitro and in vivo. 
Furthermore, miR-608 and miR-361-5p were found to directly target AKT2 and 
SMAD2, respectively. Together these findings suggest that down-regulation of SMAD2 
by miR-361-5p is likely to be an authentic mechanism of miR-361-5p-mediated 
oncogenesis, whereby targeting of AKT2 could be the mechanism by which miR-608-
mediated apoptosis is induced.  
This study has demonstrated that miR-608 and miR-361-5p could serve as 
therapeutic targets for the treatment for lung adenocarcinoma. Studies have shown that 
there is great potential for the use of miRNAs as targets for cancer treatment, however 
there are many challenges that must be addressed. Both miR-608 and miR-361-5p are 
postulated to target many different genes as identified by TargetScan alone, and only a 
few have been experimentally validated to be genuine targets of these miRNAs. 
Therefore, more analyses must be performed to assess the biological effects of both 
miR-608 and miR-361-5p treatment in other normal and neoplastic cell lines in vitro 
and in vivo.   
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 Other challenges faced in the development of miRNA-based therapeutics 
include concerns regarding delivery, potential off-target effects, as well as long-term 
safety concerns in humans (Garzon et al., 2010). Further improvements must be made in 
terms of the chemical design of miRNA mimics and antagomiRs as well as 
development of delivery methods to overcome the cellular uptake of synthetic 
oligonucleotides to attain inhibition of the target. Pharmacokinetic and 
pharmacodynamics studies must also be performed to warrant that the required miRNA 
concentrations are attained in tissues and that the targets are down-regulated (Garzon et 
al., 2010). Nevertheless, the notion of miRNA targeting to re-programme miRNA 
networks in cancer has a strong potential and chance for success. 
Furthermore, studies have shown that the effects of individual miRNAs induces only 
a subtle reduction of protein expression, whereby miRNAs acting in concert have a 
greater ability to strengthen the functions of individual gene targets and together they 
can also target numerous genes that are expressed together, or associated with common 
pathways (Ivanovska & Cleary, 2008). For example, in a study conducted by Krek and 
colleagues, miR-375, miR-124 and let-7b were found to share a common gene target, 
MTPN (Krek et al., 2005). The expression of MTPN was found to be significantly 
decreased in response to co-transfection of miR-124 and let-7b, similar to the effects 
induced by transfection of miR-375 alone. However, a combined transfection of miR-
124 and let-7b together with miR-375 led to a substantially greater target inhibition than 
effects observed by any other combinations (Krek et al., 2005). In another study, 
Ivanovska and Cleary identified three miRNAs (miR-34a, miR-16 and miR-106b) that 
regulate networks of genes that are involved in common cellular processes, but through 
distinct molecular mechanisms (Ivanovska  & Cleary, 2008). The possibility of 
interactions among the miRNAs was investigated, and it was discovered that co-
transfection of miR-34a and miR-16 induced a block in the G1 cell cycle phase that was 
150 
greater than that exhibited by each miRNA alone. However, combination of miR-106b 
with either miR-34a or miR-16, or both together, only induced an intermediate change 
in phenotype, which reflected the contributions of each miRNA (Ivanovska  & Cleary, 
2008). These studies suggest that it would be of great interest to look into the effects of 
co-transfecting miR-608 and miR-361-5p together, on the regulation of apoptotic 
pathways in NSCLC. Further work on miR-608 and miR-361 may thus provide a 
platform for anti-sense gene therapy and has the potential to bring them to clinical trails 
to improve lung adenocarcinoma patient outcomes. 
Lastly, while the zebrafish model has many advantages and can serve as invaluable 
screening tools in early stages of study; they can never replace rodents in the later stages 
of cancer research. Therefore it would be beneficial to complement these preliminary in 
vivo zebrafish results with further experimentation in mouse models. 
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APPENDIX 
APPENDIX A: Solutions and formulations 
i) Roswell Park Memorial Institute 1640 (RPMI 1640) 
To prepare 250.0 ml RPMI 1640 culture media supplemented with heat inactivated 
10.0% (v/v) FBS, 25.0 ml FBS was added into a sterile autoclaved bottle and mixed 
with 225.0 ml RPMI 1640, and stored at 4°C. 
ii) Minimum Essential Medium Eagle, Alpha (MEM α) 
To prepare 250.0 ml MEM α culture media supplemented with heat inactivated 
10.0% (v/v) FBS, 25.0 mL FBS was added into a sterile autoclaved bottle and mixed 
with 225.0 ml of MEM α, and stored at 4°C. 
iii) 10 ×  Phosphate-Buffered Saline (PBS) (10x PBS) 
1.0 L liter 10 × PBS solution was prepared by dissolving 80.0 g sodium chloride  
(NaCl) (Merck, USA), 2.0 g potassium chloride (KCl) (Merck, USA), 14.4 g di-sodium 
hydrogen phosphate (Na2HPO4) (Merck, USA), and 2.4 g potassium di-hydrogen 
phosphate (KH2PO4) (Merck, USA) in 600 ml of distilled water (dH2O). The solution 
was adjusted to pH 7.4 with hydrogen chloride (HCl) (Merck, USA) and the total 
volume brought up to 1.0 L liter with sterile dH2O. The solution was autoclaved at 
121°C, 15 psi for 45 minutes and stored at room temperature. 1.0 L of 1 × PBS was 
prepared by diluting 100.0 ml 10 × PBS with 900.0 ml sterile dH2O. 
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iv) 0.1% (v/v) Trypsin - 0.53mM EDTA 
98.0 mg EDTA was dissolved in 500.0 ml 1 × PBS to prepare 1 × PBS-0.53 mM 
EDTA. The solution was autoclaved at 121°C, 15 psi for 45 minutes and stored at room 
temperature. 100.0 ml of 0.1% (v/v) of trypsin solution was prepared by mixing 10.0 ml 
2.5% (v/v) trypsin with 96.0 ml sterile 1 × PBS-0.53mM EDTA, and stored at room 
temperature.  
v)  0.5 M Tris-HCl, pH 6.8 
200.0 ml of 0.5 M Tris-HCl was prepared by dissolving 12.1 g Tris base powder 
(Promega, USA) in 100.0 ml sterile dH2O. The solution was adjusted to pH 6.8 with 
hydrogen chloride (HCl) (Merck, USA) and the total volume brought up to 200.0 ml 
with sterile dH2O. 
vi)  1.5 M Tris-HCl, pH 8.8 
200.0 ml of 1.5 M Tris-HCl was prepared by dissolving 36.6 g Tris base powder in 
100.0 ml sterile dH2O. The solution was adjusted to pH 8.8 with HCl and the total 
volume brought up to 200.0 ml with sterile dH2O.   
vii) 10.0% (w/v) sodium dodecyl sulfate (SDS) 
10.0 g SDS powder (Promega, USA) was added to a sterile autoclaved bottle and 
topped up to 100.0 ml with sterile dH2O, and stored at room temperature. To prepare 
500.0 ml of 0.01% SDS, 500.0 µL 10.0% SDS was diluted in 500.0 ml sterile dH2O. 
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viii) 10% (w/v) ammonium persulfate (APS) 
10.0% APS was prepared fresh each time in a microcentrifuge tube. 10.0 mg APS 
(Pierce, USA) was dissolved in 100.0 µL sterile dH2O. The solution was mixed well 
using a vortex.  
ix) 10 ×  Tris/Glycine/SDS (TGS) buffer 
1.0 L of 1 × TGS buffer was prepared by dissolving 30.29 g Tris base powder, 
144.19 g glycine (Merck, USA), 10.0 g SDS powder in 1.0 L sterile dH2O, and stored at 
room temperature. To prepare 1.0 L of 1 × TGS buffer, 100.0 ml 10 × TGS buffer was 
diluted in 900.0 ml sterile dH2O. 
x) Transfer buffer (1 ×  TGS + 10% MeOH (v/v)) 
500.0 ml of transfer buffer was prepared by mixing 100.0 ml methanol (MeOH) with 
40.0 ml 10 × TGS buffer (Merck, Germany) and topped up to 500.0 ml with sterile 
dH2O. 
xi)  1 ×  Tris-buffered saline (TBS) buffer 
1.0 L of 10 × TBS buffer was prepared by dissolving 12.11 g Tris Base powder and 
87.66 g sodium chloride (NaCl) (Merck, USA) in 800.0 ml sterile dH2O. The solution 
was adjusted to pH 7.6 with HCl and the total volume brought up to 1.0 L with sterile 
dH2O. 1.0 L of 1 × TBS was prepared by diluting 100.0 ml 10 × TBS with 900.0 ml 
sterile dH2O. 
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xii) 1 ×  Tris-buffered saline - 0.05% (v/v) Tween20 (TBST) buffer 
1.0 L of 10 × TBST buffer was prepared were mixing 12.11 g Tris Base powder, 
87.66 g NaCl, 5.0 ml Tween20, and 800.0 ml of sterile dH2O. The solution was adjusted 
to pH 7.6 with HCl and the total volume brought up to 1.0 L with sterile dH2O. 1.0 L of 
1 × TBST was prepared by diluting 100.0 ml 10 × TBST with 900.0 ml dH2O. 
xiii) Blocking buffer containing 5.0% (w/v) non-fat skim milk powder, 0.05% 
(v/v) Tween 20 
50.0 ml blocking buffer was prepared by mixing 2.5 g non-fat skim milk powder 
with 0.5 ml of Tween 20 and topped up to 50.0 ml with 1 × TBS. 
xiv) MTT reagent 
MTT reagent was prepared by adding 50.0 mg of MTT (Calbiochem, USA) to 10.0 
ml 1 × PBS. The reagent was shaken vigorously and vortexed to ensure that MTT 
granules were completely dissolved. MTT working solutions were stored in the dark at 
room temperature, and the MTT stock was stored in the dark at 4°C. The final 
concentration of MTT working solution in the MTT cell viability assay was 5 mg/ml.  
xv) 1.0 mg/ml methylene blue 
1.0 L of 1.0 mg/ml methylene blue stock solution was prepared by dissolving 1.0 g 
methylene blue powder in 1.0 L sterile dH2O. To prepare 1.5 L working solution, 600.0 
µL methylene blue stock solution was mixed with 1.5 L system water. 
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xvi) 0.3% PTU (20 mM) solution 
1.0 L of 0.3% PTU stock solution was prepared by dissolving 3.0 g PTU powder in 
1.0 L sterile dH2O. To prepare 500.0 ml of 75 µM PTU working solution, 1.88 ml 0.3% 
PTU stock solution was diluted in 500.0 mL system water. 
xvii) 20.0 mg/ml Dil dye 
1.0 ml Dil dye was prepared by diluting 20.0 mg Dil powder in 1.0 ml DMSO. Tubes 
were sealed by parafilm and wrapped with aluminium foil to protect from light. Tubes 
were stored at -20°C. 
xviii) 1 × Dulbecco's phosphate-buffered saline (DPBS) with calcium and 
magnesium 
To prepare Solution 1, 80.0 g NaCl, 2.0 g potassium chloride (KCl), 11.5 g disodium 
hydrogen phosphate (Na2HPO4) and 2.0 g potassium dihydrogen phosphate (KH2PO4) 
were dissolved in 700.0 ml sterile dH2O. The solution was adjusted to pH 7.4 with HCl 
and the total volume brought up to 800.0 ml with sterile dH2O. To prepare Solution 2, 
1.0 g magnesium chloride (MgCl2) was dissolved in 100.0 ml sterile dH2O. To prepare 
Solution 3, 1.0 g calcium chloride (CaCl2) was dissolved in 100.0 ml sterile dH2O. 
Solutions 1, 2 and 3 were then autoclaved at 121°C, 15 psi for 45 min. Solutions 1 and 2 
were then mixed together inside a laminar flow hood into a new sterile autoclaved 
bottle, this solution is now called Solution 4. Solutions 3 and 4 were stored at room 
temperature. 
 To prepare 1 × DPBS, 10.0 ml Solution 4 was diluted in 80.0 ml dH2O and 1.0 
ml Solution 3 was diluted in 9.0 ml dH2O. The diluted 10.0 ml of Solution 3 was slowly 
added to the diluted Solution 4 with agitation.  
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xix) 10.0% benzocaine 
100.0 ml of 10% benzocaine was prepared by dissolving 10.0 g of benzocaine 
powder in 100.0 ml system water. 
xx) 1.0% (w/v) modified agarose gel plate 
0.6 g agarose powder was poured into a microwavable flask along with 60.0 ml 
sterile dH2O. The flask was microwaved for 3 min and 30.0 ml was poured into a petri 
dish and allowed to solidify. The agarose in the flask was warmed up again and the 
remaining 30.0 ml was poured on top of the solidified agar. Agar plate was parafilmed 
and stored upside down at 4°C. After use, plates were rinsed with sterile dH2O and 
reused. 
xxi) PBS with 0.1% Tween20 (1 × PBST) 
1.0 L of 1 × PBST was prepared by adding 1.0 ml Tween20 to 800.0 ml 1 × PBS. 
The solution was adjusted to pH 7.0 with HCl and the total volume brought up to 1.0 L 
with 1 × PBS.  
xxii) 4.0% (w/v) paraformaldehyde (PFA) 
40.0 g PFA powder was added to 600.0 ml dH2O heated to 60°C, and solution was 
stirred at 60°C using a magnetic stirrer. One drop of sodium hydroxide (NaOH) was 
added and solution became clear rapidly. Solution was removed from heat and 300.0 ml 
3 × PBS was added. The solution was adjusted to pH 7.2 with HCl and the total volume 
brought up to 1.0 L with sterile dH2O. The bottle was wrapped in aluminium foil and 
stored at 4°C. 
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xxiii) PBST with 0.3% Triton X and 1.0% DMSO (1 × PDT) 
100.0 ml of PDT was prepared by mixing 0.3 ml Triton X with 1.0 ml DMSO, and 
the total volume brought up to 100.0 ml with 1 × PBST. 
xxiv) Blocking buffer containing 10.0% FBS and 2.0% BSA 
7.0 ml of blocking buffer was prepared by mixing 0.14 g bovine serum albumin 
(BSA) with 700.0 µL FBS and the solution topped up to 7.0 ml with 1 × PBST. 
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APPENDIX B: Molecular markers 
i) Biotinylated protein ladder  
The biotinylated protein ladder consisted of 10 proteins ranging in apparent 
molecular weights from 9 to 200 kDa. 
 
ii) DNA molecular weight marker  
O’GeneRuler™ 1kb DNA Ladder with 250-10,000 basepairs as reference sizes 
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APPENDIX C: Sequencing analysis of AKT2 insert and pmirGLO/AKT2 
constructs 
 
i) Sequencing analysis of AKT2 insert  
The full sequence of AKT2 insert sequence provided by First BASE Laboratories 
Sdn. Bhd, Malaysia, was analyzed using the chromatogram viewer Geospiza’s Finch 
TV and compared to sequences in the Human Standard Nucleotide BLAST, and the 
sequence was found to have a match (Identity: 99%). 
Appendix Table 1: Comparative analysis of AKT2 insert sequence provided by First 
BASE Laboratories against sequences found in Human Standard Nucleotide BLAST. 
Sequence highlighted in grey indicate miRNA binding sites 
First BASE Laboratories sequence: 
ANNGTAGGAGTCTTCCAAATGCGAGTCTGGGCACAAAGGTGAGGCTGGAGGCTGGAGGCAGGGGCTGCAGGGGCCG
CTGGGGTGCGTCTGGGAGGGGCCTGAAGAAGAACTGGAAAGGGGGTGAGGAGGTGGGGGTGGGGACACAAACCAAAAA
GGCTAAGTAAAAAGTTAGGGGTAAAAAACCACCCAGCGGTGATGGCAGCGAGCGTGCGTCCTCTGCGTGGGCAGACTG
CTCACTCGCGGATGCTGGCCGAGTAGGAGAACTGGGGGAAGTGGGTCCGCTGGTCCAGCTCCAGTAAGCCCAGGCTGT
CATAGCGGTCAGGGGGTGTGATTGTGATGGACTGGGCGGTAAATTCATCATCGAAGTACAGCTTAGCGTAAA 
NCBI cDNA sequence: 
GGATTAAAACCTGAATCTCCAACCGCCCAACAGCCCAGGCCTGGGCGGGAGGTGGAGTCTTCCAAATGCGAGTCTG
GGCACAAAGGTGAGGCTGGAGGCTGGAGGCAGGGGCTGCAGGGGCCGCTGGGGTGCGTCTGGGAGGGGCCTGAAGAAG
AACTGGAAAGGGGGTGAGGAGGTGGGGGTGGGGACACAAACCAAAAAGGCTAAGTAAAAAGTTAGGGGGAAAAAACCA
CCCAGCGGTGATGGCAGCGAGCGTGCGTCCTCTGCGTGGGCAGACTGCTCACTCGCGGATGCTGGCCGAGTAGGAGAA
CTGGGGGAAGTGGGTCCGCTGGTCCAGCTCCAGTAAGCCCAGGCTGTCATAGCGGTCAGGGGGTGTGATTGTGATGGA
CTGGGCGGTAAATTCATCATCGAAGTAC 
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Appendix Figure 1: (A) Sequence of AKT2 insert amplified using PCR analyzed using 
the chromatogram viewer Geospiza’s FinchTV. (B) Analysis of sequenced AKT2 insert 
using NCBI BLAST. Sequence analysis showed that the AKT2 sequence obtained from 
PCR matched the Homo sapiens v-akt murine thymona viral oncogene homolog 2 
sequence. 
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ii) Sequencing analysis of wild-type pmirGLO/AKT2 constructs 
The full sequence of pmirGLO/AKT2 constructs provided by First BASE 
Laboratories Sdn. Bhd, Malaysia, was analyzed using the chromatogram viewer 
Geospiza’s Finch TV and compared to sequences in the Human Standard Nucleotide 
BLAST. 
Appendix Table 2: Comparative analysis of pmirGLO/AKT2 construct sequence 
provided by First BASE Laboratories against sequences found in Human Standard 
Nucleotide BLAST. Sequence highlighted in grey indicates full sequence of AKT2 
insert in pmirGLO vector. Sequence highlighted in grey indicate miRNA binding sites 
First BASE Laboratories sequence: 
NNNNNGCTGCTGCTGTACTTCGATGATGATTTACCGCCCAGTCCATCACAATCACACCCCCTGACCGCTATGACAG
CCTGGGCTTACTGGAGCTGGACCAGCGGACCCACTTCCCCCAGTTCTCCTACTCGGCCAGCATCCGCGAGTGAGCAGT
CTGCCCACGCAGAGGACGCACGCTCGCTGCCATCACCGCTGGGTGGTTTTTTCCCCCTAACTTTTTACTTAGCCTTTT
TGGTTTGTGTCCCCACCCCCACCTCCTCACCCCCTTTCCAGTTCTTCTTCAGGCCCCTCCCAGACGCACCCCAGCGGC
CCCTGCAGCCCCTGCCTCCAGCCTCCAGCCTCACCTTTGTGCCCAGACTCGCATTTGGAAGACTCCACCTCCCGCCCA
GGCCTGGGCTGTTGGGCGGTTGGAGATTCAGGTTTTAATCCCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTG
GGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAA
TGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC
AATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATGT
GGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGT
ATTTCACACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCT
TCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAA
GTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGC
AAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCTTAATTCCNCCAAGTT
CCGCCCATTCTCGGCCCCATGGCTGACTAATTTTTTTTATTTTTGCAAAAGGCCGAAGCCCCCCTCGCCTNTTGAACT
ATTCCAAAAATNTGGAGGAAGCCTTTTTTGGAGGCTTAGGCTTTGGCAAAAACTTNGATTTTCTGACNAACAGTTCNG
ACACAAAGGTGGGGCACCATGGNTTCCAGGGGTGACACCCCCAGAAAAGAAACGCANGTATCTGGGCNTCANTGGGGG
GCGCNCCGTTCAAATANAGAACGTNGGNGCTCTNCTCNNANCNTAGNGTNCGAANAAACNCNCNNAANNACNNNGTAG
ATCTGCTGNNGNNACCAACGCNCNCTCNNCC 
NCBI mRNA sequence: 
GTACTTCGATGATGAATTTACCGCCCAGTCCATCACAATCACACCCCCTGACCGCTATGACAGCCTGGGCTTACTG
GAGCTGGACCAGCGGACCCACTTCCCCCAGTTCTCCTACTCGGCCAGCATCCGCGAGTGAGCAGTCTGCCCACGCAGA
GGACGCACGCTCGCTGCCATCACCGCTGGGTGGTTTTTTCCCCCTAACTTTTTACTTAGCCTTTTTGGTTTGTGTCCC
CACCCCCACCTCCTCACCCCCTTTCCAGTTCTTCTTCAGGCCCCTCCCAGACGCACCCCAGCGGCCCCTGCAGCCCCT
GCCTCCAGCCTCCAGCCTCACCTTTGTGCCCAGACTCGCATTTGGAAGACTCCACCTCCCGCCCAGGCCTGGGCTGTT
GGGCGGTTGGAGATTCAGGTTTTAATCC 
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Appendix Figure 2: (A) Sequence of pmirGLO/AKT2 construct analyzed using the 
chromatogram viewer Geospiza’s FinchTV. (B) Analysis of sequenced pmirGLO/AKT2 
using NCBI BLAST. Sequence analysis showed that the sequence of AKT2 insert in 
pmirGLO vector matched the Homo sapiens v-akt murine thymona viral oncogene 
homolog 2 sequence. 
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iii) Sequencing analysis of mutated pmirGLO/AKT2 constructs 
The mutated pmirGLO/AKT2 constructs provided by First BASE Laboratories Sdn. 
Bhd, Malaysia, was analyzed using the chromatogram viewer Geospiza’s Finch TV and 
compared to sequences in the Human Standard Nucleotide BLAST. Results indicated 
that the miRNA binding sites in AKT2 were successfully mutated. 
Appendix Table 3: Comparative analysis of mutated pmirGLO/AKT2 sequence 
provided by First BASE Laboratories against sequences found in Human Standard 
Nucleotide BLAST. Sequence highlighted in yellow indicates full sequence of mutated 
SMAD2 insert in pmirGLO vector. Sequences highlighted in red indicate mutated 
miRNA binding sites. (First site: Mutation of CCACCCC to TGATTGG, Second site: 
Mutation of CACCCC to GAATAA). Sequences highlighted in grey indicate wild-type 
miRNA binding sites. 
First BASE Laboratories sequence: 
NNNNNNNNTGCTGCTGTACTTCGATGATGATTTACCGCCCAGTCCATCACAATCACACCCCCTGACCGCTATGACA
GCCTGGGCTTACTGGAGCTGGACCAGCGGACCCACTTCCCCCAGTTCTCCTACTCGGCCAGCATCCGCGAGTGAGCAG
TCTGCCCACGCAGAGGACGCACGCTCGCTGCCATCACCGCTGGGTGGTTTTTTCCCCCTAACTTTTTACTTAGCCTTT
TTGGTTTGTGTCCTGATTGGCACCTCCTCACCCCCTTTCCAGTTCTTCTTCAGGCCCCTCCCAGACGGAATAAAGCGG
CCCCTGCAGCCCCTGCCTCCAGCCTCCAGCCTCACCTTTGTGCCCAGACTCGCATTTGGAAGACTCCACCTCCCGCCC
AGGCCTGGGCTGTTGGGCGGTTGGAGATTCAGGTTTTAATCCCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCT
GATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT
GGGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAA
ATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAA
CAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATG
TGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGG
TATTTCACACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACC
TTCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGA
AGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTTGGAAAGTCCCCAGGCTCCCCAGCAGGCAAAAGTAT
GCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAAATCCGCCAAG
TTCCGCCCATTCTCCGCCCCAGGGCTGACTAATTTTTTTTTATTTATGCAAGAGGCCGAAGGCCCGCCTTCGGCTCTT
GAACCTTTTCCCAAAAATAATNGAGGAGGCCTTTTTTTGGGAGGCCTAAGGCTTTTTGCAAAA 
NCBI cDNA Sequence: 
GTACTTCGATGATGAATTTACCGCCCAGTCCATCACAATCACACCCCCTGACCGCTATGACAGCCTGGGCTTACTG
GAGCTGGACCAGCGGACCCACTTCCCCCAGTTCTCCTACTCGGCCAGCATCCGCGAGTGAGCAGTCTGCCCACGCAGA
GGACGCACGCTCGCTGCCATCACCGCTGGGTGGTTTTTTCCCCCTAACTTTTTACTTAGCCTTTTTGGTTTGTGTCCC
CACCCCCACCTCCTCACCCCCTTTCCAGTTCTTCTTCAGGCCCCTCCCAGACGCACCCCAGCGGCCCCTGCAGCCCCT
GCCTCCAGCCTCCAGCCTCACCTTTGTGCCCAGACTCGCATTTGGAAGACTCCACCTCCCGCCCAGGCCTGGGCTGTT
GGGCGGTTGGAGATTCAGGTTTTAATCC 
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Appendix Figure 3 (A) Sequence of mutated pmirGLO/AKT2 construct analyzed using 
the chromatogram viewer Geospiza’s FinchTV. (B) Analysis of sequenced mutated 
pmirGLO/AKT2 using NCBI BLAST. Sequence analysis illustrated the successful 
mutation of two miRNA binding sites in the AKT2 sequence, indicated with a black 
box. 
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APPENDIX D: Sequencing analysis of SMAD2 insert and pmirGLO/SMAD2 
constructs 
 
i) Sequencing analysis of SMAD2 insert  
The full sequence of SMAD2 insert was analyzed using the chromatogram viewer 
Geospiza’s Finch TV and compared to sequences in the Human Standard Nucleotide 
BLAST, and the sequence was found to have a match (Identity: 99%). 
Appendix Table 4: Comparative analysis of SMAD2 insert sequence provided by First 
BASE Laboratories against sequence found in Human Standard Nucleotide BLAST. 
Sequence highlighted in grey indicate miRNA binding sites 
First BASE Laboratories sequence: 
CAAAAAGGAGTAAACGCCAGAGCATCAAAGGCCATGTATTTCCTCACAAGAAAAGAAATCTGCAACAATTGGTTTCCT
TTTACTATGAAAAATGTAAATTTCAGATTAAGTTTAACCCCATAAGGACGCATGATTTGTACTTACATATACACATAG
GTTCAGAAGAACTTAGCTATCTAGTTGGCCTCTTCTCTGTTCCATTATAACATCAGTTACCTTAGCTGGATCACTAAG
TGTGAGTCTCACCACCATACTGGTACCTTCAGCTATTACCTGTGTTATAAATCTCATGTTCCATTCAAAGTACTAAAT
GACTGGATGGCACATATCCCAATAAGTATCAGAAATGTTGACAGCCATAGTGCAGCTGAGTTTAGAAGCAACTATGAC
AACATAGGGAAGTAAGGATAAATCACAAGAACACCTAAGGTGGTCAGCTCCTTCTGGTGTGCCTGGGACTTGTTTTGA
GTTTAGCAAAAACTTTACAAGATTAAAAATCAGAGCAAATGAATTTCTTAAGTTCAAGATATGTACTCTCAATGGAGA
ATCGCTTTTGGGCAGTGGTTAAGGCCTCTGATGTGCTACTTATCAGAAAAATCCACATATATACAAAACTCTGCTAAA
AGTTTTGTATCCAGGGAAAGTCCCGCATCCAGGGAAACCCTCAATCCCAGGCACTTTAGGGCAGTAGGCAATTAAGNN
NNANNNA 
 
NCBI cDNA Sequence: 
CTCGAGCAGAACAGACTGGGAAATGCAGTAGACGCCAGAGCATCAAAGGCCATGTATTTCCTCACAAGAAAAGAAA
TCTGCAACAATTGGTTTCCTTTTACTATGAAAAATGTAAATTTCAGATTAAGTTTAACCCCATAAGGACGCATGATTT
GTACTTACATATACACATAGGTTCAGAAGAACTTAGCTATCTAGTTGGCCTCTTCTCTGTTCCATTATAACATCAGTT
ACCTTAGCTGGATCACTAAGTGTGAGTCTCACCACCATACTGGTACCTTCAGCTATTACCTGTGTTATAAATCTCATG
TTCCATTCAAAGTACTAAATGACTGGATGGCACATATCCCAATAAGTATCAGAAATGTTGACAGCCATAGTGCAGCTG
AGTTTAGAAGCAACTATGACAACATAGGGAAGTAAGGATAAATCACAAGAACACCTAAGGTGGTCAGCTCCTTCTGGT
GTGCCTGGGACTTGTTTTGAGTTTAGCAAAAACTTTACAAGATTAAAAATCAGAGCAAATGAATTTCTTAAGTTCAAG
ATATGTACTCTCAATGGAGAATCGCTTTTGGGCAGTGGTTAAGGCCTCTGATGTGCTACTTATCAGAAAAATCCACAT
ATATACAAAACTCTGCTAAAAGTTTTGTATCCAGGGAAAGTCCCGCATCCAGGGAAACCCTCAATCCCAGGCACTTTA
GGGC 
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Appendix Figure 4: (A) Sequence of SMAD2 insert amplified using PCR and analyzed 
using the chromatogram viewer Geospiza’s FinchTV. (B) Analysis of sequenced 
SMAD2 insert using NCBI BLAST. Sequence analysis showed that the SMAD2 
sequence obtained from PCR matched the Homo sapiens SMAD family member 2 
(SMAD2), transcript variant 2. 
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ii) Sequencing analysis of wild-type pmirGLO/SMAD2 constructs 
The full sequence of pmirGLO/SMAD2 constructs was analyzed using the 
chromatogram viewer Geospiza’s Finch TV and compared to sequences in the Human 
Standard Nucleotide BLAST, and the sequence was found to have a match (Identity: 
99%). 
Appendix Table 5: Comparative analysis of pmirGLO/SMAD2 construct sequence 
provided by First BASE Laboratories against sequences found in Human Standard 
Nucleotide BLAST. Sequence highlighted in yellow indicates full sequence of SMAD2 
insert in pmirGLO vector. Sequence highlighted in grey indicate miRNA binding sites 
First BASE Laboratories sequence: 
CCCGGGAAAATTGGGCCGCCGGTTACACCGCCAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAA
GGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTG
TAATTCTAGTTGTTTAAACGAGCTCTAATTGCTAGCTGCCCTAAAGTGCCTGGGATTGAGGGTTTCCCTGGATGCGGG
ACTTTCCCTGGATACAAAACTTTTAGCAGAGTTTTGTATATATGTGGATTTTTCTGATAAGTAGCACATCAGAGGCCT
TAACCACTGCCCAAAAGCGATTCTCCATTGAGAGTACATATCTTGAACTTAAGAAATTCATTTGCTCTGATTTTTAAT
CTTGTAAAGTTTTTGCTAAACTCAAAACAAGTCCCAGGCACACCAGAAGGAGCTGACCACCTTAGGTGTTCTTGTGAT
TTATCCTTACTTCCCTATGTTGTCATAGTTGCTTCTAAACTCAGCTGCACTATGGCTGTCAACATTTCTGATACTTAT
TGGGATATGTGCCATCCAGTCATTTAGTACTTTGAATGGAACATGAGATTTATAACACAGGTAATAGCTGAAGGTACC
AGTATGGCGGTGAGACTCACACTTAGTGATCCAGCTAAGGTAACTGATGTTATAATGGAACAGAGAAGAGGCCAACTA
GATAGCTAAGTTCTTCTGAACCTATGTGTATATGTAAGTACAAATCATGCGTCCTTATGGGGTTAAACTTAATCTGGA
ATTTACATTTTTCATAGTAAAAGGAAACCAATTGTTGCAGATTTCTTTTCTTGTGAGGAAATACATGGCCTTTGATGC
TCTGGCGTCTACTGCATTTCCCAGTCTGTTCTGCTCGAGTCTCGAGAATATGTCGACCTGCAGGCATGCAAGCTGATC
CGGCTGCTAACAAAGCCCGAAAGGAAGCTGAATTGGCTGCTGCCACCGCTGAACAATAACTAGCATAACCCCTTGGGG
CGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGC
TTTATTTGTGAAATTTGGGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAAT
TGCATTCATTTTATGTTTCAGGTTCAGGGGGAAAATGTTGGGAAGGTTTTTTTAAGCAAGTAAAACCCCTCAAAATGG
GGGAAAATCGAATTTTAACAAAAAATTAACGCTTACAATTTTCCGGAGGCGGGATTTTCCCCTTACCCAATTGTGGGG
GGAATTTCAACCGCATAACCGGGATTTGGGCCACCCATGGGCCGGAATAACCCTTGAAAAGAGAAACTTGTTTAGGTA
CCTTCTGAGGCGAAAAAAAACCCTTGTGGAATTG 
NCBI cDNA Sequence: 
AATTGCTAGCTGCCCTAAAGTGCCTGGGATTGAGGGTTTCCCTGGATGCGGGACTTTCCCTGGATACAAAACTTTT
AGCAGAGTTTTGTATATATGTGGATTTTTCTGATAAGTAGCACATCAGAGGCCTTAACCACTGCCCAAAAGCGATTCT
CCATTGAGAGTACATATCTTGAACTTAAGAAATTCATTTGCTCTGATTTTTAATCTTGTAAAGTTTTTGCTAAACTCA
AAACAAGTCCCAGGCACACCAGAAGGAGCTGACCACCTTAGGTGTTCTTGTGATTTATCCTTACTTCCCTATGTTGTC
ATAGTTGCTTCTAAACTCAGCTGCACTATGGCTGTCAACATTTCTGATACTTATTGGGATATGTGCCATCCAGTCATT
TAGTACTTTGAATGGAACATGAGATTTATAACACAGGTAATAGCTGAAGGTACCAGTATGGCGGTGAGACTCACACTT
AGTGATCCAGCTAAGGTAACTGATGTTATAATGGAACAGAGAAGAGGCCAACTAGATAGCTAAGTTCTTCTGAACCTA
TGTGTATATGTAAGTACAAATCATGCGTCCTTATGGGGTTAAACTTAATCTGGAATTTACATTTTTCATAGTAAAAGG
AAACCAATTGTTGCAGATTTCTTTTCTTGTGAGGAAATACATGGCCTTTGATGCTCTGGCGTCTACTGCATTTCCCAG
TCTGTTCTGCTCGAGTCTCGAGAATAT 
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Appendix Figure 5 (A) Sequence of pmirGLO/SMAD2 construct analyzed using the 
chromatogram viewer Geospiza’s FinchTV. (B) Analysis of sequenced 
pmirGLO/SMAD2 using NCBI BLAST. Sequence analysis showed that the sequence of 
SMAD2 insert in pmirGLO vector matched the Homo sapiens SMAD family member 2 
(SMAD2), transcript variant 2. 
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Appendix Figure 5, continued 
iii) Sequencing analysis of mutated pmirGLO/SMAD2 constructs 
The mutated pmirGLO/SMAD2 constructs provided by First BASE Laboratories 
Sdn. Bhd, Malaysia, was analyzed using the chromatogram viewer Geospiza’s Finch 
TV and compared to sequences in the Human Standard Nucleotide BLAST. Results 
indicated that the miRNA binding sites in SMAD2 were successfully mutated. 
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Appendix Table 6: Comparative analysis of mutated pmirGLO/SMAD2 sequence 
provided by First BASE Laboratories against sequences found in Human Standard 
Nucleotide BLAST. Sequence highlighted in yellow indicates full sequence of mutated 
SMAD2 insert in pmirGLO vector. Sequences highlighted in red indicate mutated 
miRNA binding sites. (First site: Mutation of TCTGATA to AGACTAT, Second site: 
Mutation of CACCCC to GAATAA). Sequences highlighted in grey indicate wild-type 
miRNA binding sites. 
First BASE Laboratories sequence: 
CCGGGAAATTGGGCCGCCGGTTACACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAAG
GACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGT
AATTCTAGTTGTTTAAACGAGCTCTAATTGCTAGCTGCCCTAAAGTGCCTGGGATTGAGGGTTTCCCTGGATGCGGGA
CTTTCCCTGGATACAAAACTTTTAGCAGAGTTTTGTATATATGTGGATTTTAGACTATATAGCACATCAGAGGCCTTA
ACCACTGCCCAAAAGCGATTCTCCATTGAGAGTACATATCTTGAACTTAAGAAATTCATTTGCTCTGATTTTTAATCT
TGTAAAGTTTTTGCTAAACTCAAAACAAGTCCCAGGCACACCAGAAGGAGCTGACCACCTTAGGTGTTCTTGTGATTT
ATCCTTACTTCCCTATGTTGTCATAGTTGCTTCTAAACTCAGCTGCACTATGGCTGTCAACATTAGACTATCTTATTG
GGATATGTGCCATCCAGTCATTTAGTACTTTGAATGGAACATGAGATTTATAACACAGGTAATAGCTGAAGGTACCAG
TATGGCGGTGAGACTCACACTTAGTGATCCAGCTAAGGTAACTGATGTTATAATGGAACAGAGAAGAGGCCAACTAGA
TAGCTAAGTTCTTCTGAACCTATGTGTATATGTAAGTACAAATCATGCGTCCTTATGGGGTTAAACTTAATCTGGAAT
TTACATTTTTCATAGTAAAAGGAAACCAATTGTTGCAGATTTCTTTTCTTGTGAGGAAATACATGGCCTTTGATGCTC
TGGCGTCTACTGCATTTCCCAGTCTGTTCTGCTCGAGTCTCGAGAATATGTCGACCTGCAGGCATGCAAGCTGATCCG
GCTGCTAACAAAGCCCGAAAGGAAGCTGAATTGGCTGCTGCCACCGCTGAACAATAACTAGCATAACCCCTTGGGGCG
GCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTT
TATTTGGGAAATTTGGGATGCTATTGCTTTATTTGGAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTG
CATTCATTTTATGTTTCAGGTTCAGGGGAAAAAATTGGGGGAAGGTTTTTTTTAAACCAAGAAAAACCTCCTACAAAG
GGGGGAAAAACCGAATTTTAACAAAAATTTAACGGTTACAATTTCCCGGAAGGGGGATTTTTCCCCTTACCCAACTTG
GGGGGGATATTTTACCCCGGATAACGCGGATTGTGGCCCACCCACTGGGTCCGGAAAAAACCCTCTGAAAGAGGAACA
TTTTTTTATGTCCTTCTGCTGGGGGGAAAAAACACCCCTTGGGGAAGGTGTGGGCCCTATGAGTGGGTGAAACACTCC
GA 
NCBI cDNA Sequence: 
AATTGCTAGCTGCCCTAAAGTGCCTGGGATTGAGGGTTTCCCTGGATGCGGGACTTTCCCTGGATACAAAACTTTT
AGCAGAGTTTTGTATATATGTGGATTTTTCTGATAAGTAGCACATCAGAGGCCTTAACCACTGCCCAAAAGCGATTCT
CCATTGAGAGTACATATCTTGAACTTAAGAAATTCATTTGCTCTGATTTTTAATCTTGTAAAGTTTTTGCTAAACTCA
AAACAAGTCCCAGGCACACCAGAAGGAGCTGACCACCTTAGGTGTTCTTGTGATTTATCCTTACTTCCCTATGTTGTC
ATAGTTGCTTCTAAACTCAGCTGCACTATGGCTGTCAACATTTCTGATACTTATTGGGATATGTGCCATCCAGTCATT
TAGTACTTTGAATGGAACATGAGATTTATAACACAGGTAATAGCTGAAGGTACCAGTATGGCGGTGAGACTCACACTT
AGTGATCCAGCTAAGGTAACTGATGTTATAATGGAACAGAGAAGAGGCCAACTAGATAGCTAAGTTCTTCTGAACCTA
TGTGTATATGTAAGTACAAATCATGCGTCCTTATGGGGTTAAACTTAATCTGGAATTTACATTTTTCATAGTAAAAGG
AAACCAATTGTTGCAGATTTCTTTTCTTGTGAGGAAATACATGGCCTTTGATGCTCTGGCGTCTACTGCATTTCCCAG
TCTGTTCTGCTCGAGTCTCGAGAATAT 
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Appendix Figure 6 (A) Sequence of mutated pmirGLO/SMAD2 construct analyzed 
using the chromatogram viewer Geospiza’s FinchTV. (B) Analysis of sequenced 
mutated pmirGLO/SMAD2 using NCBI BLAST. Sequence analysis illustrated the 
successful mutation of two miRNA binding sites in the SMAD2 sequence, indicated 
with a black box. 
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Appendix Figure 6, continued 
 
 
 
 
 
